Chemoenzymatic Synthesis of Natural Products: Integrating Biocatalysis and Organic Chemistry for Drug Discovery

Abstract

This article comprehensively reviews the burgeoning field of chemoenzymatic synthesis and its transformative impact on natural product research and drug development. By integrating the exceptional selectivity of enzymatic transformations with the versatility of synthetic chemistry, chemoenzymatic strategies enable efficient access to complex molecular architectures that are challenging to produce by traditional means. We explore the foundational principles underpinning this interdisciplinary approach, showcase its application across diverse natural product classes including terpenoids, polyketides, and peptides, and provide practical guidance for troubleshooting and optimizing biocatalytic processes. Furthermore, we present comparative analyses validating the advantages of chemoenzymatic methods over purely chemical or biosynthetic approaches in terms of step-economy, sustainability, and the ability to generate structural analogues for structure-activity relationship studies. This review is tailored for researchers, synthetic chemists, and drug development professionals seeking to leverage these powerful strategies in their work.

The Rise of Chemoenzymatic Synthesis: Principles and Evolutionary Milestones

Chemoenzymatic synthesis is an emerging paradigm in synthetic chemistry that strategically integrates enzymatic transformations with traditional organic synthesis in a multi-step approach to construct complex molecules [1]. Under this hybrid framework, practitioners harness the unparalleled regio- and stereoselectivity of biocatalytic methods while simultaneously leveraging the broad reaction diversity of contemporary synthetic chemistry [1]. This synergy is particularly valuable for streamlining access to bioactive natural products, which often contain intricate chiral centers and complex architectures that are challenging to produce using purely chemical or purely biological means [1].

The rationale for adopting chemoenzymatic strategies stems from recognizing the complementary strengths and limitations of both disciplines. While enzymes offer exquisite selectivity under mild, environmentally benign conditions, they typically catalyze only a small subset of organic transformations [1]. Conversely, synthetic organic chemistry provides powerful bond-forming capabilities but often requires harsh conditions and complex protection/deprotection strategies to achieve similar selectivity profiles [2]. By combining these approaches, chemoenzymatic synthesis enables more efficient synthetic routes with improved synthesis economy, often resulting in reduced step counts, higher overall yields, and superior stereocontrol compared to traditional methods [1].

Core Principles and Strategic Advantages

The theoretical foundation of chemoenzymatic synthesis rests on the strategic placement of enzymatic and chemical steps within a synthetic sequence to maximize their synergistic potential. This involves careful retrosynthetic analysis to identify bond disconnections where enzymatic transformations offer distinct advantages, particularly for forging stereocenters or functionalizing unbiased positions in complex molecular frameworks [3].

Key Strategic Advantages:

• Unparalleled Selectivity: Enzymes provide exquisite stereospecificity and regioselectivity that can be difficult to achieve with chemical catalysts, especially for transformations occurring at unactivated carbon centers or within densely functionalized molecules [1]. For instance, P450 monooxygenases can perform site-selective oxidizations of aliphatic C-H bonds, enabling subsequent skeletal editing through Baeyer-Villiger rearrangements [4].

• Reaction Diversity: The chemical synthesis component provides access to a vast array of non-natural reactions that expand the structural space beyond what is accessible through biosynthesis alone [5]. This includes transformations like oxidative enolate coupling, reductive amination, and various cyclization methods that complement enzymatic capabilities [1].

• Streamlined Synthesis: The hybrid approach often significantly shortens synthetic routes to complex natural products. In multiple documented cases, chemoenzymatic strategies have reduced synthetic steps by 30-50% compared to traditional synthetic approaches while maintaining or improving overall yields [1].

• Sustainability Profile: Enzymatic transformations typically occur under milder conditions with reduced environmental impact, aligning with green chemistry principles [5]. This includes operating in aqueous solutions at ambient temperature and pressure, reducing energy consumption and hazardous waste generation.

Representative Case Studies in Natural Product Synthesis

Recent literature demonstrates the transformative impact of chemoenzymatic approaches in natural product synthesis. The following case studies highlight different strategic applications, with key metrics summarized in Table 1.

Table 1: Key Metrics from Recent Chemoenzymatic Natural Product Syntheses

Natural Product	Key Enzymatic Transformation	Traditional Steps	Chemoenzymatic Steps	Yield Improvement	Key Advantage
Jorunnamycin A	Dual Pictet-Spengler cyclization (SfmC)	15+ steps (prior art)	Significantly reduced [1]	18% from tyrosine [1]	One-step formation of pentacyclic core
Podophyllotoxin	Oxidative cyclization (2-ODD-PH)	6-8 steps	58-95% yield in key step [1]	95% yield in biotransformation [1]	Superior stereocontrol
Kainic Acid	Oxidative cyclization (DsKabC)	6+ steps	2 steps [1]	57% yield on gram-scale [1]	Gram-scale feasibility
Sorbicillinoids	Oxidative dearomatization (Monooxygenase)	Required stoichiometric chiral reagents	Eliminated chiral reagents [1]	Dramatic improvement in synthesis economy [1]	No stoichiometric chiral reagents
Terpene Scaffolds	Head-to-tail cyclization (SHCs)	Multi-step scaffold preparation	Single enzymatic step [3]	>99% ee and de [3]	Decagram scale production

Tetrahydroisoquinoline Alkaloids: Jorunnamycin A and Saframycin A

The tetrahydroisoquinoline (THIQ) alkaloids, including jorunnamycin A and saframycin A, represent a family of tyrosine-derived natural products with potent antitumor activity [1]. A recent chemoenzymatic synthesis utilized a phosphopantetheinylated SfmC, a dual Pictet-Spenglerase, to construct the common pentacyclic core from a tyrosine analog and corresponding aldehydes in a single enzymatic step [1]. Remarkably, this transformation accomplished the formation of two C-C bonds, three C-N bonds, and reduction of a thioester simultaneously [1]. The secondary amine was subsequently methylated chemically using formaldehyde and 2-picoline borane, yielding jorunnamycin A and saframycin A in 18% and 13% overall yield from tyrosine, respectively [1]. This approach constitutes the shortest synthesis of these alkaloids reported to date, demonstrating how enzymatic transformations can dramatically simplify complex molecular assembly.

Aryltetralin Lignans: Podophyllotoxin

Podophyllotoxin, an aryltetralin lignan with potent tubulin depolymerizing activity, has inspired semi-synthetic derivatives used in cancer immunotherapy [1]. Recent chemoenzymatic approaches have leveraged an α-ketoglutarate-dependent dioxygenase (2-ODD-PH) that catalyzes a key oxidative cyclization in the biosynthetic pathway [1]. Two independent research groups developed complementary strategies: one employed a biocatalytic kinetic resolution of racemic hydroxyyatein with 2-ODD-PH, yielding the key intermediate in 39% yield with 95% enantiomeric excess on gram-scale [1]. The other utilized oxidative enolate coupling to synthesize enantiopure yatein, which was transformed to the natural product via biotransformation with 2-ODD-PH in 95% yield on gram-scale [1]. Both approaches provided significant improvements in overall yield and stereocontrol compared to previous synthetic strategies.

Neuropharmacological Agents: Kainic Acid

Kainic acid, a monocyclic compound isolated from marine algae, serves as an important neuropharmacological agent due to its agonism of kainate receptors [1]. Despite its seemingly simple structure, the presence of three contiguous stereocenters presents significant synthetic challenges [1]. A recent chemoenzymatic synthesis employed a homolog of the α-ketoglutarate-dependent dioxygenase DabC, called DsKabC, which catalyzes the oxidative cyclization of "prekainic acid" to kainic acid [1]. The synthesis commenced with a reductive amination between L-glutamic acid and 3-methylcrotonaldehyde to generate the substrate, which was then converted to kainic acid using purified DsKabC in 46% yield on 10 mg scale [1]. By using E. coli expressing DsKabC for direct conversion of crude "prekainic acid," the process was scaled to gram-scale with 57% yield [1]. This two-step sequence represents a dramatic improvement over previous synthetic approaches that required at least six steps.

Fungal Metabolites: Sorbicillinoids

The sorbicillinoids are a family of fungal natural products with promising antiviral activities and intriguing molecular architectures that arise from asymmetric oxidative dearomatization of highly substituted phenols [1]. Significant chemical advances have been made in achieving this transformation, but they typically require stoichiometric chiral hypervalent iodine reagents or chiral Cu(I) salts [1]. Independent research groups demonstrated that an FAD-dependent monooxygenase from sorbicillinol biosynthesis can catalyze highly regioselective oxidative dearomatization of various substituted phenols with exquisite enantioselectivity [1]. The resulting products serve as versatile intermediates for synthesizing diverse sorbicillinoids, including rezishanone C, sorbicatechol A, epoxysorbicillinol, and urea sorbicillinoid, through subsequent chemical transformations such as Diels-Alder cycloadditions and Weitz-Scheffer epoxidations [1]. This biocatalytic oxidation strategy eliminates the need for stoichiometric chiral reagents and dramatically improves synthesis economy.

Terpene Scaffolds via Engineered Cyclases

Terpene synthesis represents a state-of-the-art area where chemoenzymatic approaches have shown particular utility [3]. A recent breakthrough demonstrated the use of engineered squalene-hopene cyclases (SHCs) for the stereocontrolled head-to-tail cyclization of abundant unbiased linear terpenes [3]. By combining engineered SHCs with a practical reaction setup, researchers generated ten distinct chiral terpene scaffolds with exceptional enantiomeric excess (>99% ee) and diastereomeric excess (>99% de) at scales up to decagrams [3]. The enzymatic cyclization overcame limitations of traditional chemical cyclization methods, which often require alternative initiation motifs or strong nucleophiles as terminating groups [3]. The resulting chiral templates were subsequently transformed to valuable (mero)-terpenes using interdisciplinary synthetic methods, including a catalytic ring-contraction of enol-ethers facilitated by cooperative iodine/lipase catalysis [3].

Experimental Methodologies

This section provides detailed protocols for key chemoenzymatic transformations cited in this review, enabling researchers to implement these strategies in their own synthetic campaigns.

Experimental Workflow for Chemoenzymatic Synthesis

The following diagram illustrates the generalized workflow for developing and executing a chemoenzymatic synthesis, integrating both chemical and enzymatic steps while minimizing transitions between reaction paradigms.

Biocatalytic Oxidative Dearomatization Protocol

This procedure details the enzymatic oxidative dearomatization of substituted phenols for sorbicillinoid synthesis, based on methodologies from Gulder and Narayan [1].

Reagents:

• FAD-dependent monooxygenase (cell-free extract or purified enzyme)
• Substrate phenol (e.g., compound 29 from [1])
• NADPH regenerating system (glucose-6-phosphate and glucose-6-phosphate dehydrogenase)
• Coenzyme FAD (50 µM)
• Potassium phosphate buffer (100 mM, pH 7.4)
• Molecular oxygen (air-saturated buffer or gentle bubbling)

Procedure:

• Prepare the reaction mixture containing potassium phosphate buffer (10 mL), substrate phenol (0.5 mmol), FAD (50 µM), and glucose-6-phosphate (10 mM).
• Add glucose-6-phosphate dehydrogenase (5 units) and the monooxygenase (10-50 mg protein depending on specific activity).
• Incubate the reaction at 30°C with gentle shaking (150 rpm) for 4-16 hours.
• Monitor reaction progress by TLC or HPLC until complete consumption of starting material.
• Extract the product with ethyl acetate (3 × 15 mL), combine organic layers, and dry over anhydrous sodium sulfate.
• Concentrate under reduced pressure and purify by flash chromatography (silica gel, hexanes/ethyl acetate gradient) to obtain the dearomatized product (e.g., compound 30).

Key Considerations:

• Maintain adequate aeration for optimal monooxygenase activity
• Enzyme specificity varies - screen multiple homologs for optimal results
• Scale can be increased proportionally with maintained aeration

Chemoenzymatic Synthesis of Podophyllotoxin via 2-ODD-PH

This protocol describes the synthesis of podophyllotoxin using the α-ketoglutarate-dependent dioxygenase 2-ODD-PH, adapted from Fuchs and Renata [1].

Reagents:

• E. coli BL21(DE3) expressing 2-ODD-PH
• Substrate (enantiopure yatein or racemic hydroxyyatein)
• α-Ketoglutaric acid (10 mM final concentration)
• Ascorbic acid (2 mM final concentration)
• Ferrous ammonium sulfate (1 mM final concentration)
• HEPES buffer (50 mM, pH 7.5)
• Cerium(III) chloride (for benzylic oxidation)
• Sodium borohydride (for subsequent reduction)

Procedure:

• Grow E. coli expressing 2-ODD-PH in LB medium with appropriate antibiotics at 37°C to OD600 = 0.6-0.8.
• Induce expression with 0.1 mM IPTG and incubate at 18°C for 16-20 hours.
• Harvest cells by centrifugation (4,000 × g, 20 min) and resuspend in HEPES buffer.
• Prepare biotransformation mixture containing cell suspension (OD600 = 20), substrate (1 mM), α-ketoglutaric acid (10 mM), ascorbic acid (2 mM), and ferrous ammonium sulfate (1 mM).
• Incubate at 30°C with shaking (200 rpm) for 6-12 hours.
• Extract with ethyl acetate (3 × equal volume), dry organic layer over Na2SO4, and concentrate.
• For kinetic resolution approaches, recover both converted and unconverted enantiomers separately.
• For complete synthesis to podophyllotoxin: oxidize the enzymatic product with CrO3 in acetic acid, then reduce with NaBH4 in methanol to afford podophyllotoxin.

Key Considerations:

• Strict control of oxygenation improves reproducibility
• Substrate concentration should be optimized to prevent inhibition
• For gram-scale reactions, use fed-batch substrate addition

Squalene-Hopene Cyclase Catalyzed Terpene Cyclization

This protocol describes the cyclization of unbiased linear terpenes using engineered SHCs, based on the methodology described in [3].

Reagents:

• Engineered SHC variant (whole cells or cell-free extract)
• Linear terpene substrate (e.g., E,E-farnesol, geranyl geraniol)
• Triton X-100 (0.1% w/v)
• Cyclodextrin (optional, for substrate solubilization)
• Potassium phosphate buffer (50 mM, pH 7.0)
• Magnesium chloride (5 mM)

Procedure:

• Prepare SHC-containing cells by growing the production strain in appropriate medium to late log phase.
• Harvest cells by centrifugation and resuspend in potassium phosphate buffer with magnesium chloride to OD600 = 30-50.
• Add Triton X-100 (0.1% w/v) to permeabilize cells.
• Add terpene substrate (1-10 mM) directly or pre-complexed with cyclodextrin for improved solubility.
• Incubate at 30°C with shaking (150 rpm) for 4-24 hours.
• Extract reaction mixture with pentane or hexanes (3 × equal volume).
• Combine organic layers, dry over Na2SO4, and concentrate under reduced pressure.
• Purify cyclized products by flash chromatography or distillation.

Key Considerations:

• Membrane-bound SHCs require detergent for optimal activity with hydrophobic substrates
• Engineered SHC variants show different selectivity profiles - screen for desired product
• Cyclodextrin complexation can improve conversion for poorly soluble substrates

Essential Research Reagent Solutions

Successful implementation of chemoenzymatic synthesis requires access to specialized enzymatic and chemical reagents. Table 2 summarizes key research reagent solutions essential for the field.

Table 2: Essential Research Reagent Solutions for Chemoenzymatic Synthesis

Reagent Category	Specific Examples	Function & Application	Key Considerations
C-C Bond Forming Enzymes	SfmC (Pictet-Spenglerase), Squalene-Hopene Cyclases, DabC homologs	Cyclization and carbon-carbon bond formation in complex scaffold synthesis	Often require co-expression with partner enzymes or phosphopantetheinyl transferases
C-X Bond Forming Enzymes	FAD-dependent Monooxygenases, α-Ketoglutarate-Dependent Dioxygenases, P450 Monooxygenases	Selective oxidation, hydroxylation, and heteroatom incorporation	Cofactor regeneration systems essential for practical implementation
Cofactor Regeneration Systems	NADPH, NADH, ATP	Drive thermodynamically unfavorable enzymatic reactions	In situ regeneration improves atom economy and cost-effectiveness
Enzyme Engineering Tools	Directed evolution kits, Site-saturation mutagenesis	Optimize enzyme activity, stability, and substrate scope	High-throughput screening essential for identifying improved variants
Specialized Substrates	Unbiased terpenes, Phenolic precursors, Amino acid derivatives	Serve as building blocks for enzymatic transformations	May require pre-complexation with cyclodextrins for solubility
Chiral Ligands & Catalysts	Hypervalent iodine reagents, Chiral Cu(I) complexes (for comparison)	Provide stereocontrol in chemical steps complementary to enzymatic steps	Enzymatic approaches often eliminate need for stoichiometric chiral reagents

Computational Tools and Future Directions

The field of chemoenzymatic synthesis is increasingly benefiting from computational tools that facilitate route planning and optimization. Recently, Anand et al. developed minChemBio, a computational synthesis planning tool designed to identify synthetic routes that minimize transitions between biological and chemical reaction paradigms [6]. This approach addresses a significant challenge in chemoenzymatic synthesis: the costly and time-intensive purification steps often required when switching between chemical and biological reactions [6].

The minChemBio algorithm processes extensive reaction databases (1,808,938 chemical reactions from USPTO and 57,541 biological reactions from MetaNetX) to identify efficient pathways that minimize total transitions between reaction types [6]. The tool incorporates dGpredictor to assess thermodynamic favorability, ensuring proposed routes are energetically feasible [6]. In a demonstration, minChemBio identified a more efficient route to 2,5-furandicarboxylic acid from glucose compared to previous approaches that required more expensive starting materials [6].

Future advancements in chemoenzymatic synthesis will likely focus on several key areas:

• Expanding Enzyme Toolkits: Continued discovery and engineering of enzymes for non-natural transformations will broaden the scope of accessible molecular architectures [4].
• Skeletal Editing Strategies: Approaches that enable precise modifications at the level of single atoms or bonds, such as the P450-controlled site-selective ring expansion recently reported, will provide powerful tools for fine-tuning molecular properties [4].
• Therapeutic Oligonucleotide Synthesis: Chemoenzymatic ligation methods are revolutionizing siRNA and sgRNA production, offering advantages in scalability, sustainability, and product quality compared to solid-phase synthesis [7].
• Integration with Synthetic Biology: Combining pathway engineering with targeted chemical modifications will enable production of increasingly complex natural product analogs [5].

Chemoenzymatic synthesis represents a powerful hybrid approach that strategically integrates the selective prowess of enzymatic catalysis with the synthetic flexibility of organic chemistry. As demonstrated by the case studies and methodologies presented herein, this paradigm offers significant advantages for accessing complex natural products and their analogs, including reduced step counts, improved stereocontrol, and enhanced sustainability profiles. The continued development of engineered enzymes, computational planning tools, and innovative synthetic strategies will further establish chemoenzymatic approaches as indispensable tools in natural product research and drug development. As the field advances, the seamless integration of biological and chemical transformations will undoubtedly unlock new possibilities for synthesizing complex molecular architectures with unprecedented efficiency and precision.

The field of organic synthesis has undergone a profound transformation over recent decades, increasingly moving from purely chemical methods toward integrated strategies that harness the power of biological catalysts. Chemoenzymatic synthesis, which strategically combines chemical transformations with enzymatic reactions, has emerged as a powerful paradigm for constructing complex molecules, particularly natural products with therapeutic potential. This approach has evolved from early applications in simple kinetic resolutions to sophisticated retrosynthetic planning that seamlessly integrates biocatalytic steps into synthetic blueprints. The historical development of this field reflects a growing recognition that enzymes offer unparalleled stereoselectivity, regioselectivity, and catalytic efficiency under environmentally benign conditions, often enabling synthetic routes that would be impractical or impossible through traditional chemical methods alone.

The driving force behind this paradigm shift stems from the escalating challenges in natural product synthesis and drug development. Natural products frequently possess complex molecular architectures with multiple stereocenters and sensitive functional groups, presenting significant synthetic hurdles. Furthermore, the pharmaceutical industry faces increasing pressure to develop more sustainable manufacturing processes. Chemoenzymatic strategies address both challenges simultaneously by providing synthetic shortcuts that reduce step counts while offering inherent atom economy and reduced environmental impact. This review examines key technological advances that have shaped modern chemoenzymatic approaches, from foundational kinetic resolution methods to contemporary computational planning tools, with a focus on their application in natural product synthesis for drug discovery.

Fundamental Techniques: Kinetic Resolutions and Beyond

The Principle of Kinetic Resolution

Kinetic resolution (KR) represents one of the earliest and most widely adopted applications of biocatalysis in organic synthesis. This technique exploits the inherent chiral discrimination of enzymes to differentiate between enantiomers in a racemic mixture, allowing one enantiomer to react preferentially while leaving the other essentially untouched. The theoretical foundation of kinetic resolution rests on the difference in reaction rates for the two enantiomers with an enantioselective catalyst, typically expressed through the selectivity factor (s), which represents the ratio of the rate constants for the two enantiomers.

Traditional kinetic resolution faced significant limitations, particularly the inherent 50% maximum yield of any single enantiomer from a racemic starting material. However, modern advances have largely overcome this constraint through dynamic kinetic resolutions (DKR) and related processes where the non-preferred enantiomer is continuously racemized under the reaction conditions, enabling theoretical yields of up to 100%. The strategic importance of kinetic resolution lies in its ability to provide enantioenriched intermediates that serve as building blocks for complex natural product synthesis, particularly for pharmaceuticals where chirality often dictates biological activity.

Advanced Kinetic Resolution in Sulfinyl Chemistry

Recent developments have expanded the scope of kinetic resolution to previously challenging chemical frameworks. A groundbreaking 2025 study demonstrated the first organocatalytic kinetic resolution of sulfinamides through N/O exchange, enabling access to enantioenriched sulfinyl scaffolds [8]. This transformation addresses a significant synthetic challenge, as enantiopure stereogenic-at-sulfur compounds have gained importance in pharmaceuticals due to their unique biological properties, yet their synthesis remained difficult.

The methodology employs squaramide catalysts to achieve high enantioselectivity through a proposed dual activation transition state, wherein both the sulfinamide and alcohol substrates engage with the catalyst via hydrogen-bonding interactions [8]. This system exhibits remarkable substrate generality, accommodating various alcohol types including alkyl, allylic, propargylic, and benzylic alcohols, with selectivity factors (s) reaching up to 143 in optimal cases. The practical utility of this method was demonstrated through the kinetic resolution sulfinylation of bioactive molecules, all affording corresponding products in excellent enantiomeric excess (typically >90% ee) [8].

Table 1: Key Developments in Chemoenzymatic Kinetic Resolution

Development	Key Innovation	Selectivity/Scalability	Application Scope
Organocatalytic KR of sulfinamides [8]	N/O exchange via hydrogen-bonding catalysis	Selectivity factor up to 143	Broad alcohol scope, bioactive molecules
IRED-mediated KR for chiral amines [9]	Imine reductase catalysis	>99% ee, gram-scale	Cinacalcet analog synthesis
KRED optimization for ipatasertib synthesis [9]	Machine learning-aided enzyme engineering	99.7% de (R,R-trans), 100 g/L substrate	API intermediate synthesis

Contemporary Chemoenzymatic Strategies in Natural Product Synthesis

Skeletal Editing of Natural Product Scaffolds

A revolutionary approach that has emerged recently is the chemoenzymatic skeletal editing of natural product scaffolds, which enables precise modifications at the level of single atoms or bonds. A 2025 report detailed a methodology combining P450-controlled site-selective oxidation with subsequent Baeyer-Villiger rearrangement or ketone homologation to achieve ring expansion at aliphatic C─H sites [4]. This strategy represents a significant advancement in the ability to fine-tune molecular structures of complex natural products, potentially altering their biological activity for drug discovery applications.

The power of this approach lies in its synergistic combination of enzymatic and chemical steps. Engineered P450 catalysts provide the regioselectivity necessary to differentiate between similar C─H bonds in complex molecules, while subsequent chemical rearrlements introduce skeletal alterations. This methodology was applied to generate a panel of ring-expanded analogs of various complex natural products, with the skeletal modifications found to drastically alter anticancer activity in some compounds [4]. Such strategies provide medicinal chemists with powerful tools to rapidly access structurally diverse derivatives from natural product starting materials, accelerating structure-activity relationship studies.

Chemoenzymatic Synthesis of Complex Terpenoids and Polyketides

The application of chemoenzymatic strategies to terpenoid and polyketide natural products has yielded particularly impressive results, as these classes often feature complex carbon skeletons with multiple stereocenters. Recent innovations include one-pot multienzyme (OPME) systems that mimic biosynthetic pathways while achieving synthetically useful yields and scales. For instance, the synthesis of nepetalactolone employed a ten-enzyme cascade that established three contiguous stereocenters from geraniol precursor with 93% yield [10]. This system exemplifies several advantages of chemoenzymatic approaches, including the ability to perform both oxidative and reductive transformations in the same pot using shared cofactor regeneration systems.

Similarly impressive, the Renata group has demonstrated gram-scale enzymatic hydroxylations of steroid cores with remarkable regioselectivity, oxidizing a single methylene group despite the presence of 6-7 other oxidizable sites [10]. These transformations achieve both high yields (67-83%) and excellent enantioselectivity, addressing a key challenge in chemical synthesis where such selective oxidations typically require complex protecting group strategies or suffer from poor selectivity.

Table 2: Representative Chemoenzymatic Syntheses of Natural Products

Natural Product	Key Chemoenzymatic Step	Scale/Efficiency	Notable Features
Chrodrimanin C [10]	Enzymatic hydroxylation of 6,6,5 steroid core	Gram-scale, 67-83% yield	Single methylene oxidation despite 6-7 similar sites
Nepetalactolone [10]	10-enzyme OPME cascade	93% yield, ~1 g/L potential production	Sets 3 contiguous stereocenters, combined oxidative/reductive steps
Germacrene D [10]	Multi-enzyme triterpene synthesis	Milligram scale	Modular approach to natural and unnatural terpenoids
Scytalone [10]	Anthrole reductase-mediated ketone reduction	Small scale	Stereoselective reduction in naphthol system

Novel Cyclization Strategies for Complex Peptide Architectures

Perhaps one of the most structurally challenging classes of natural products are the lariat lipopeptides, which feature complex macrocyclic architectures that have historically hampered efficient synthesis and diversification. A groundbreaking 2025 study reported a chemoenzymatic approach that repurposes non-ribosomal peptide cyclases for the synthesis of lariat-shaped macrocycles [11]. This methodology utilizes versatile penicillin-binding protein-type thioesterases (SurE and WolJ) and type-I thioesterases (TycC-TE) to cyclize unprotected, branched peptides bearing multiple nucleophiles in a site-selective manner [11].

The key innovation lies in engineering the substrate shape rather than the enzymes themselves. By incorporating an internal dipeptide unit as a "pseudo-N terminus" and strategically manipulating the stereochemical configuration of potential nucleophiles, the researchers successfully redirected the cyclization specificity of SurE from head-to-tail to head-to-side chain macrocyclization [11]. This approach demonstrates exceptional regiocontrol, with the pseudo-N-terminal residue serving exclusively as the nucleophile despite the presence of other potential nucleophiles in the branched substrate. The methodology was further extended through a tandem cyclization-acylation strategy that enabled one-pot, modular synthesis of lariat-shaped lipopeptides equipped with various acyl groups, with biological screening revealing derivatives with promising antimycobacterial activity (50% growth inhibition at 8-16 µg mL⁻¹) [11].

Retrosynthetic Planning and Computational Tools

The minChemBio Platform for Synthetic Planning

The increasing complexity of chemoenzymatic strategies has created a need for sophisticated computational tools that can facilitate retrosynthetic planning. Recently, researchers developed minChemBio, a computational synthesis planning tool specifically designed to optimize chemoenzymatic routes by minimizing transitions between chemical and biological reaction steps [6]. This addresses a critical practical challenge in chemoenzymatic synthesis, as separation and purification between different reaction types often account for significant time and cost investments.

The minChemBio platform was constructed by curating a massive dataset of 1,808,938 chemical reactions from the USPTO database and 57,541 biological reactions from the MetaNetX database [6]. After rigorous data processing to remove duplicates and incorrectly annotated reactions, the tool implements an algorithm that minimizes biological-to-chemical, chemical-to-biological, and chemical-to-chemical reaction transitions while maintaining synthetic feasibility. The platform incorporates dGpredictor, a tool to assess the thermodynamic favorability of proposed reactions, adding an important dimension to the planning process beyond mere step count minimization [6].

Practical Application and Limitations

The utility of minChemBio was demonstrated through the planning of a chemoenzymatic route to 2,5-furandicarboxylic acid, a bioplastic precursor, from cheap and abundant glucose [6]. Notably, the tool identified routes using starting materials that were more economical than the product, addressing a common limitation of previous computational planning systems that often suggested syntheses requiring more expensive precursors than the target molecule itself. This practical consideration highlights the growing sophistication of retrosynthetic planning tools to incorporate economic factors alongside purely chemical considerations.

Despite these advances, current computational planning tools still face limitations. minChemBio does not currently label major and minor products in reactions, and its performance remains affected by misannotations and data upkeep issues in the underlying databases [6]. Nevertheless, such tools represent a significant step forward in enabling synthetic chemists to more efficiently leverage the growing toolbox of chemoenzymatic transformations for complex natural product synthesis.

Diagram 1: Organocatalytic Kinetic Resolution of Sulfinamides via N/O Exchange. This diagram illustrates the enantioselective pathway where squaramide catalysts enable kinetic resolution through dual activation transition states, yielding both enantioenriched sulfinate esters and recovered sulfinamides with high selectivity [8].

The Scientist's Toolkit: Essential Research Reagents and Materials

Successful implementation of chemoenzymatic strategies requires careful selection of specialized reagents and materials that enable the integration of enzymatic and chemical transformations. The following table summarizes key research reagent solutions essential for the experimental approaches discussed in this review.

Table 3: Essential Research Reagents for Chemoenzymatic Synthesis

Reagent/Material	Function/Application	Key Characteristics	Representative Examples
Engineered Glycosynthases	Chemoenzymatic glycoengineering of mAbs	Mutated ENGases (e.g., Asn/Asp to Ala) that prevent product hydrolysis	Endo-A E173Q/H, Endo-M mutants [12]
Squaramide Organocatalysts	Kinetic resolution via hydrogen-bonding catalysis	Dual activation of sulfinamides and alcohols through H-bonding	Catalyst E, F for sulfinamide KR [8]
P450 Monooxygenases	Site-selective C─H oxidation for skeletal editing	Engineered for divergent regioselectivity	P450-controlled ring expansion [4]
Non-ribosomal Peptide Cyclases	Macrocyclization of unprotected peptides	Broad substrate tolerance, stereospecificity	SurE, WolJ, TycC-TE [11]
One-Pot Multienzyme (OPME) Systems	Cascade biotransformations	Combined oxidative/reductive steps with cofactor regeneration	Nepetalactolone synthesis [10]
Ethylene Glycol (EG) Functionalized Substrates	Simplified enzymatic substrates for cyclization	Diol surrogate for pantetheine leaving group	SurE substrate for lariat peptide synthesis [11]
Cycloxydim	Cycloxydim	Cycloxydim is a selective, systemic herbicide for professional research. It controls grass weeds by inhibiting ACCase. For Research Use Only.	Bench Chemicals
Z-Leu-leu-arg-amc	Z-Leu-leu-arg-amc, MF:C36H49N7O7, MW:691.8 g/mol	Chemical Reagent	Bench Chemicals

Experimental Protocols for Key Methodologies

Protocol: Organocatalytic Kinetic Resolution of Sulfinamides

This protocol describes the kinetic resolution of racemic N-Boc-sulfinamides through N/O exchange with alcohols, adapted from the 2025 Nature Communications report [8].

Materials:

• Racemic N-Boc-sulfinamide substrate (e.g., rac-1d, 0.1 mmol)
• Squaramide catalyst E or F (10 mol%)
• Anhydrous alcohol (1.0 mmol as nucleophile and solvent)
• Anhydrous dichloromethane (DCM)
• Molecular sieves (4 Ã…)

Procedure:

• Activate molecular sieves by flame-drying under vacuum.
• In an argon-filled glove box, combine sulfinamide substrate (0.1 mmol), squaramide catalyst (0.01 mmol), and 4 Ã… molecular sieves (50 mg) in a reaction vial.
• Add anhydrous alcohol (1.0 mmol) as both nucleophile and solvent.
• Seal the vial and stir the reaction at room temperature (23°C) for 48 hours.
• Monitor reaction progress by TLC or LC-MS until approximately 45-50% conversion is achieved.
• Concentrate the reaction mixture under reduced pressure.
• Purify by flash column chromatography (hexanes/ethyl acetate) to separate the sulfinate ester product and recovered sulfinamide.
• Determine enantiomeric excess by chiral HPLC or SFC analysis.

Notes:

• The optimal conversion for maximum enantiopurity is substrate-dependent but typically ranges from 40-50%.
• Catalyst E typically affords (S)-sulfinate esters and (R)-sulfinamides, while catalyst F provides the opposite enantiomers.
• The method demonstrates broad scope with linear, allylic, propargylic, and benzylic alcohols.

Protocol: SurE-Catalyzed Lariat Peptide Cyclization

This protocol describes the enzymatic macrocyclization of branched, EG-functionalized peptide substrates to form lariat-shaped lipopeptides, adapted from the 2025 Nature Chemistry report [11].

Materials:

• Branched peptide substrate with C-terminal EG ester (e.g., compound 4, 0.05 mmol)
• SurE macrocyclase (5 mol%)
• HEPES buffer (100 mM, pH 7.5)
• DMSO (for substrate solubilization)

Procedure:

• Express and purify SurE macrocyclase according to published procedures [11].
• Prepare the branched peptide substrate using standard Fmoc-SPPS with EG-functionalized resin and orthogonal Dde protection for lysine side chain modification.
• Prepare a stock solution of the peptide substrate in DMSO (10 mM concentration).
• In a reaction vial, combine HEPES buffer (100 mM, pH 7.5, 1 mL) with SurE enzyme (final concentration 5 mol% relative to substrate).
• Add the peptide substrate from DMSO stock (final concentration 0.5 mM, maintaining DMSO concentration ≤5% v/v).
• Incubate the reaction at 30°C with gentle shaking for 3 hours.
• Monitor reaction completion by LC-MS.
• Quench the reaction by adding an equal volume of acetonitrile.
• Purify the cyclic lariat peptide by preparative HPLC.
• Confirm cyclic structure by MS/MS analysis.

Notes:

• The pseudo-N-terminal nucleophile must be l-configured for efficient cyclization.
• SurE exhibits excellent regioselectivity when the native N-terminus is d-configured, exclusively forming the lariat cyclic product.
• The reaction typically proceeds quantitatively under optimized conditions.

Diagram 2: Computational Retrosynthetic Planning with minChemBio. This workflow illustrates how the minChemBio platform utilizes curated reaction databases and transition minimization algorithms to design efficient chemoenzymatic routes from simple starting materials to valuable target molecules [6].

The historical trajectory of chemoenzymatic synthesis reveals a field that has matured from specialized applications in kinetic resolution to a comprehensive synthetic paradigm capable of addressing some of the most complex challenges in natural product synthesis. The integration of enzymatic and chemical transformations has progressively blurred the traditional boundaries between biosynthesis and organic synthesis, giving rise to hybrid approaches that leverage the strengths of both disciplines. As the field advances, several emerging trends suggest future directions, including the increased use of artificial intelligence for enzyme engineering and pathway design, the development of more sophisticated one-pot multi-step cascades, and the application of chemoenzymatic strategies to novel therapeutic modalities beyond traditional small molecules.

The ongoing refinement of computational planning tools like minChemBio represents a crucial step toward mainstream adoption of chemoenzymatic approaches in both academic and industrial settings. As these tools incorporate more sophisticated considerations of enzyme compatibility, reaction conditions, and scalability, they will increasingly enable synthetic chemists to design efficient chemoenzymatic routes for complex natural products and pharmaceutical targets. Furthermore, the continued discovery and engineering of enzymes with novel catalytic activities promises to expand the synthetic toolbox available for retrosynthetic planning. Collectively, these advances solidify chemoenzymatic synthesis as an indispensable strategy in modern organic synthesis, particularly for the construction of structurally complex natural products with therapeutic potential.

The field of organic synthesis is increasingly moving beyond the question "Can we make it?" to focus on "How well can we make it?"—emphasizing efficiency, economy, and modularity [13]. Within this evolving landscape, chemoenzymatic synthesis has emerged as a powerful strategy that integrates the precision of biological catalysts with the flexibility of synthetic methodology. This approach leverages enzymes as potent, selective catalysts alongside traditional synthetic transformations to streamline the synthesis of complex natural products and pharmaceutical targets [13] [14]. The complementary nature of these disciplines enables synthetic chemists to overcome challenges that remain formidable when using either methodology alone.

Natural products have long served as inspiration for synthetic chemists, providing valuable blueprints for pharmaceutical development [13]. Similarly, the enzymes that constitute biosynthetic pathways to these molecules offer equally intriguing opportunities for synthetic applications [13]. Recent advances in genomics, bioinformatics, and molecular biology have provided chemists with unprecedented tools for biosynthetic analysis and enzyme engineering, creating new opportunities for enzyme applications in total synthesis [13]. As Nature's catalysts, enzymes demonstrate exceptional regio-, chemo-, and enantioselectivity across diverse substrates and reactions—many of which are difficult or impossible to replicate conventionally [13]. The integration of enzymatic and synthetic chemistry represents a frontier in synthetic methodology that combines sustainability with precision [14].

Fundamental Principles of Enzyme Catalysis

Enzymatic Selectivity and Transition State Stabilization

Enzymes achieve extraordinary rate accelerations through strong stabilizing interactions between the protein and reaction transition states [15]. The defining property of enzymatic catalysts is their specificity for binding the transition state with significantly higher affinity than the substrate [15]. This fundamental principle enables enzymes to provide immense rate accelerations while maintaining precise control over reaction outcome. For example, orotidine 5′-monophosphate decarboxylase (OMPDC) demonstrates a remarkable 31 kcal/mol stabilization of the transition state compared to only 8 kcal/mol stabilization of the ground-state complex [15].

The architectural features that enable this specificity provide key insights for harnessing enzymatic power in synthesis. Many enzymes exist in flexible, entropically rich ground states that convert to stiff, catalytically active Michaelis complexes upon substrate binding [15]. This conformational transition reduces the substrate-binding energy expressed at the Michaelis complex while enabling full expression of large transition-state binding energies [15]. The utilization of substrate-binding energy to drive these conformational changes represents a sophisticated evolutionary adaptation that enables both specificity and catalytic power.

Structural Dynamics in Enzyme Function

The coexistence of protein flexibility and stiffness represents complementary properties essential for extraordinary catalytic efficiency [15]. While catalytic events occur at stiff protein active sites, enzymes frequently evolve with flexible structures in their unliganded forms that undergo large ligand-driven conformational changes to active, stiff forms [15]. This paradigm reconciles the historic "lock-and-key" and "induced-fit" models of enzyme catalysis [15].

Experimental evidence indicates that phosphodianion-binding energy of phosphate monoester substrates drives conversion of their protein catalysts from flexible ground states to stiff, catalytically active Michaelis complexes [15]. This mechanism extends to multiple enzyme systems, including triosephosphate isomerase (TIM) and glycerol phosphate dehydrogenase (GPDH) [15]. The existence of flexible ground states provides a mechanism for utilizing ligand-binding energy to mold catalysts into active forms, reducing expressed substrate-binding energy while enabling full expression of large transition-state binding energies [15].

Table 1: Key Enzymes in Chemoenzymatic Synthesis and Their Functions

Enzyme	Reaction Catalyzed	Selectivity Features	Applications in Synthesis
Transaminases	Chiral amine synthesis	Enantioselective	Sitagliptin intermediate [14]
Lipases	Kinetic resolution	Enantioselective	Tetrazomine synthesis [13]
Purine Nucleoside Phosphorylases	Glycosidic bond formation	Regio- and stereoselective	Islatravir synthesis [14]
Triosephosphate Isomerase (TIM)	Proton transfer	Dianion activation	Fundamental studies [15]
OMP Decarboxylase	Decarboxylation	Transition state stabilization	Fundamental studies [15]

Strategic Frameworks for Chemoenzymatic Synthesis

Classification of Chemoenzymatic Approaches

The integration of biocatalysis with chemical synthesis follows several conceptual frameworks, which can be categorized into four primary approaches based on the role of enzymes in the synthetic design [13]:

• Providing enantioenriched starting materials or intermediates: Enzymes play a supporting role, typically performing kinetic resolutions or desymmetrizations to generate chiral compounds without influencing the broader synthetic design.
• Enabling evaluation of biosynthetic hypotheses: Chemically or chemoenzymatically synthesized intermediates probe subsequent biosynthetic transformations, facilitating characterization of putative or poorly-understood enzymes.
• Motivating retrosynthetic disconnections with known enzymatic reactions: Enzymatic reactions serve as inspiration for synthetic designs, influencing the broader retrosynthetic strategy through deliberate incorporation of enzymatic transformations.
• Motivating retrosynthetic disconnections by filling methodological gaps: Retrosynthetic disconnections are proposed prior to identifying suitable enzymes, leveraging enzyme discovery and engineering to perform roles inaccessible to chemical methodology.

These approaches represent a spectrum of integration depth, from using enzymes as practical tools to resolution to fully embedding biocatalytic logic into retrosynthetic planning.

Approach 1: Providing Enantioenriched Intermediates

In this approach, enzymes perform supporting roles in multi-step syntheses, typically through kinetic resolution to generate chiral compounds. The synthetic logic remains largely unchanged, with the enzyme providing access to enantiopure materials from racemic precursors. A representative example comes from the synthesis of tetrazomine, which features an unusual 3-hydroxypipecolic acid motif [13]. The Williams group implemented a chemoenzymatic synthesis of chiral pipecolic acid derivative starting from picolinic acid [13]. Exhaustive hydrogenation furnished racemic cis-3-hydroxypipecolic acid, which was protected and esterified before treatment with lipase PS and vinyl acetate in diisopropyl ether achieved kinetic resolution to provide nearly quantitative yield (46%) of the enantiopure material [13]. Despite its seemingly trivial role, the biocatalytic resolution proved instrumental in assigning the correct configuration of the natural product [13].

This approach leverages the inherent chiral environment of enzyme active sites, which typically favor one enantiomer over the other, leading to preferential consumption of the "matched" isomer [13]. While kinetic resolution theoretically limits yields to 50%, this drawback is mitigated by the availability and lower cost of racemic materials compared to chiral alternatives [13]. Furthermore, enzymes can also catalyze desymmetrization of meso compounds, bypassing the 50% yield limitation [13].

Approach 3: Enzymatic Reactions Driving Retrosynthetic Design

In contrast to the supporting role described in Approach 1, enzymatic reactions can serve as central inspiration for synthetic designs. As the biocatalytic toolbox expands, more syntheses incorporate enzymatic disconnections as simplifying transforms that influence the broader synthetic strategy [13]. This represents a deeper integration of biocatalysis into synthetic planning, resulting in retrosynthetic analyses orthogonal to those relying solely on chemical transformations.

Industrial applications demonstrate the power of this approach. In the synthesis of islatravir, purine nucleoside phosphorylase and phosphopentomutase were evolved to catalyze the regio- and stereoselective installation of an unnatural purine moiety on chemically or enzymatically synthesized unprotected, unnatural deoxyribose analogs [14]. This enzymatic transformation enabled a more efficient overall process than possible with purely synthetic methodology [14]. Similarly, the evolution and implementation of a transaminase to selectively catalyze formation of the chiral amine in sitagliptin from chemically derived pro-sitagliptin represents a landmark achievement in this approach [14].

Computational Framework for Hybrid Synthesis Planning

Integrated Retrosynthetic Search Algorithm

The identification of synthetic routes combining enzymatic and synthetic steps has traditionally been a manual, intuition-driven process [14]. Recent advances in computer-aided synthesis planning (CASP) have enabled the development of algorithms that balance exploration of enzymatic and synthetic transformations to identify hybrid synthesis plans [14]. This approach extends the space of retrosynthetic moves by thousands of uniquely enzymatic one-step transformations, discovering routes to molecules for which purely synthetic or enzymatic searches find none [14].

The hybrid search algorithm employs two neural network models for retrosynthesis—one covering 7,984 enzymatic transformations and another covering 163,723 synthetic transformations [14]. This integrated approach prioritizes possible retrosynthetic steps in a way that balances exploration of both enzymatic and synthetic steps, identifying shorter pathways where enzymatic steps replace multiple synthetic steps [14]. Application to pharmaceutical targets such as (-)-Δ9-tetrahydrocannabinol (THC, dronabinol) and R,R-formoterol (arformoterol) demonstrates how this strategy facilitates replacement of metal catalysis, high step counts, or costly enantiomeric resolution with more efficient hybrid proposals [14].

Table 2: Comparison of Enzymatic and Synthetic Reaction Databases for CASP

Database Feature	Enzymatic Database (BKMS)	Synthetic Database (Reaxys)
Total Reactions	~37,000	>10,000,000
Unique Templates	7,984	163,723
Data Sources	BRENDA, KEGG, Metacyc, SABIO-RK	Reaxys
Template Precedent	~80% of templates have only one precedent	Templates typically have multiple precedents
Transformation Coverage	Highly specific, biologically relevant	Broad, diverse chemical space

Unique Value of Enzymatic Transformations

Analysis of enzymatic and synthetic reaction databases reveals that enzymatic transformations expand accessible chemical space beyond synthetic methodology alone [14]. Although the synthetic organic chemistry toolkit encompasses far more transformations than known enzymatic chemistry, enzymes catalyze numerous unique reactions not captured by synthetic reaction templates [14]. The hybrid search algorithm identifies 4,169 unique enzymatic templates beyond those captured by synthetic chemistry, demonstrating the value of integrating both approaches [14].

The template-based approach maintains a link between retrosynthetic suggestions and precedent reactions from the database, making model suggestions interpretable and actionable as starting points for enzyme selection and optimization [14]. This connection to experimental precedent is crucial for practical implementation of proposed synthetic routes.

Diagram 1: Hybrid retrosynthetic search algorithm integrating enzymatic and synthetic transformation models. The algorithm balances exploration of both enzymatic (green) and synthetic (blue) steps to identify viable hybrid synthesis routes.

Experimental Implementation and Optimization

Chemoenzymatic Reaction Optimization

Successful implementation of chemoenzymatic synthesis requires optimization of reaction conditions to maximize efficiency and cost-effectiveness. A representative example comes from the chemoenzymatic synthesis of milk thistle flavonolignan glucuronides, where systematic optimization enhanced yield while reducing resource requirements [16]. This process evaluated multiple parameters including enzyme source, enzyme concentration, and cofactor concentration relative to substrate [16].

Optimized conditions used at least one-fourth the amount of microsomal protein and UDP-glucuronic acid (UDPGA) cofactor compared to typical conditions employing human-derived subcellular fractions, providing substantial cost savings [16]. The optimization protocol examined enzyme source (bovine liver microsomes versus S9 fraction), enzyme concentration (1, 0.5, and 0.25 mg/ml for bovine liver microsomes), and UDPGA concentration relative to flavonolignan concentration (10-fold and 2-fold molar excess) [16]. This systematic approach enabled large-scale synthesis (40 mg starting material) that generated multiple glucuronide metabolites in quantities sufficient for characterization and biological testing [16].

The Scientist's Toolkit: Essential Research Reagents

Table 3: Essential Research Reagents for Chemoenzymatic Synthesis

Reagent/Resource	Function/Purpose	Application Example
Bovine Liver Microsomes (BLMs)	Cost-effective enzyme source for glucuronidation	Milk thistle flavonolignan glucuronidation [16]
UDP-Glucuronic Acid (UDPGA)	Cofactor for glucuronosyltransferases	Flavonolignan glucuronidation [16]
Lipase PS	Enantioselective kinetic resolution	Tetrazomine pipecolic acid resolution [13]
Alamethicin	Pore-forming peptide for membrane disruption	Activation of microsomal enzymes [16]
Transaminases	Chiral amine synthesis	Sitagliptin intermediate production [14]
Purine Nucleoside Phosphorylases	Glycosidic bond formation	Islatravir synthesis [14]
1,4-Dimethoxybenzene-D10	1,4-Dimethoxybenzene-D10, MF:C8H10O2, MW:148.22 g/mol	Chemical Reagent
NITD-349	NITD-349, MF:C17H20F2N2O, MW:306.35 g/mol	Chemical Reagent

Case Studies in Advanced Chemoenzymatic Synthesis

Pharmaceutical Target Synthesis

The synthesis of complex pharmaceutical targets exemplifies the power of chemoenzymatic approaches. The application of hybrid synthesis planning to (-)-Δ9-tetrahydrocannabinol (THC, dronabinol) and R,R-formoterol (arformoterol) demonstrates how enzymatic steps can replace metal catalysis, reduce step counts, or eliminate costly enantiomeric resolution [14]. In these cases, the integrated computational approach identified hybrid routes that would have remained undiscovered using only synthetic or enzymatic reactions in isolation [14].

Another compelling example comes from the synthesis of islatravir, where enzymatic transformations provided superior regioselectivity compared to synthetic methods [14]. The implementation of evolved purine nucleoside phosphorylase and phosphopentomutase enzymes catalyzed regio- and stereoselective installation of an unnatural purine moiety on unprotected, unnatural deoxyribose analogs [14]. This biocatalytic strategy enabled a more efficient process overall than possible with purely synthetic methodology [14].

Natural Product Synthesis

The synthesis of tetrazomine illustrates the strategic application of enzymatic resolution to access challenging stereocenters [13]. The target molecule features an unusual 3-hydroxypipecolic acid motif with initially unassigned stereochemistry [13]. The chemoenzymatic approach provided enantiopure material for structure confirmation while delivering key intermediates for the total synthesis. The Williams group employed lipase PS-mediated kinetic resolution of racemic cis-3-hydroxypipecolic acid derivative, achieving nearly quantitative yield (46%) of enantiopure material that was advanced to the final natural product [13].

Diagram 2: Chemoenzymatic synthesis of tetrazomine pipecolic acid fragment. The enzymatic resolution with Lipase PS provides the key enantiopure intermediate from racemic starting material.

The continued advancement of chemoenzymatic synthesis depends on addressing several challenges and opportunities. Current synthetic enzyme design remains limited by incomplete knowledge of enzymatic machinery, suggesting that advances in natural enzyme characterization will unlock new design strategies [17]. Computational techniques that access relevant time and length scales for enzyme activity represent a key research area within the catalysis community [17]. Particularly promising is the development of ensemble-based approaches to synthetic enzyme design that move beyond the outdated "single structure" picture to account for structural dynamics and dynamic allostery [17].

The integration of enzymatic and synthetic chemistry represents more than a methodological convenience—it embodies a strategic approach to synthesis that leverages the unique strengths of both disciplines. Enzymes provide unparalleled selectivity and sustainable reaction conditions, while synthetic methodology offers breadth of transformation and operational simplicity. The future of chemoenzymatic synthesis will be shaped by advances in several areas: (1) continued expansion of the enzymatic reaction toolkit through discovery and engineering; (2) development of more sophisticated computational tools for hybrid pathway design; and (3) improved understanding of enzyme dynamics and allostery to inform design strategies [17] [14]. As these advances mature, the seamless integration of enzymatic and synthetic steps will increasingly become standard practice in complex molecule synthesis.

The combination of state-of-the-art chemical and biocatalytic methodology positions practitioners of chemoenzymatic synthesis to implement advances in both fields toward concise synthesis of complex natural products and pharmaceutical targets [13]. By leveraging the unique potential of biocatalytic transformations to streamline synthetic sequences, this hybrid approach represents a powerful strategy for addressing the evolving challenges of synthetic efficiency, economy, and modularity [13]. As the field progresses, the continued integration of enzymatic selectivity with synthetic flexibility will undoubtedly yield new innovations in complex molecule synthesis.

Four Conceptual Frameworks for Enzyme Integration in Multi-step Synthesis

The field of organic synthesis is increasingly focused on efficiency, economy, and modularity, moving beyond the fundamental question of whether a molecule can be made to how well it can be made [13]. Within this context, chemoenzymatic synthesis—the integration of enzymatic and chemical synthetic steps—has emerged as a powerful strategy for the concise synthesis of complex natural products. Enzymes, as Nature's catalysts, offer unparalleled regio-, chemo-, and enantioselectivity across a wide range of transformations, many of which are challenging to replicate with traditional synthetic chemistry alone [13]. Recent breakthroughs in genomics, bioinformatics, and molecular biology, particularly directed evolution, have provided synthetic chemists with an unprecedented ability to utilize and tailor enzymes for synthetic campaigns [13] [5].

This whitepaper outlines four primary conceptual frameworks for integrating biocatalysis into multi-step synthesis, providing researchers and drug development professionals with a structured guide for strategic planning. These frameworks are not mutually exclusive but represent distinct philosophical approaches to leveraging the unique capabilities of enzymes within a synthetic sequence.

The Four Conceptual Frameworks

The integration of enzymes into synthetic design can be categorized into four main approaches, distinguished by the role of the enzyme and its influence on the overarching retrosynthetic logic.

Approach 1: To Provide Enantioenriched Starting Materials or Intermediates

In this approach, enzymes play a supporting role, typically performing kinetic resolutions or desymmetrizations to generate chiral, enantioenriched compounds from racemic or achiral precursors [13]. The critical distinction of this approach is that the enzymatic step does not influence the broader synthetic design; the overall logic of the route remains unchanged, with the enzyme serving as a highly selective tool to set stereochemistry.

Mechanism: Enzymes are ideal for kinetic resolution due to the chiral environment of their active sites, which favors binding and transformation of one enantiomer over the other. Lipases and acylases have been widely used for this purpose [13]. While kinetic resolution has a maximum theoretical yield of 50%, desymmetrization of meso compounds can overcome this limitation.

Experimental Protocol: Kinetic Resolution of a Pipecolic Acid Derivative

• Objective: Obtain enantiopure Fmoc-protected 3-hydroxypipecolic acid ester, a key intermediate in the synthesis of tetrazomine [13].
• Materials: Racemic Fmoc-3-hydroxypipecolic acid ester, Lipase PS (from Burkholderia cepacia), vinyl acetate, diisopropyl ether.
• Procedure:
  • Dissolve the racemic substrate (e.g., compound 17 from the synthesis) in dry diisopropyl ether.
  • Add lipase PS and vinyl acetate.
  • Stir the reaction mixture at room temperature for 3.5 days.
  • Monitor reaction progress by TLC or chiral HPLC.
  • Upon completion, filter the mixture to remove the enzyme.
  • Concentrate the filtrate under reduced pressure.
  • Purify the product (e.g., enantiopure acetate 18) using flash chromatography.
• Key Parameters: The choice of solvent and acyl donor (e.g., vinyl acetate) is crucial for high enzyme activity and conversion. The reaction time must be optimized to achieve high enantiomeric excess (e.g., 98:2 er reported) [13].

Approach 2: To Enable the Evaluation of Biosynthetic Hypotheses

This approach employs chemical or chemoenzymatic synthesis to access biosynthetic intermediates, which are then used to probe the function of putative biosynthetic enzymes in vitro. This provides a direct, chemical-biology-based alternative to genetic knockout experiments for elucidating biosynthetic pathways [13].

Mechanism: Putative biosynthetic intermediates are synthesized and incubated with purified enzymes or enzyme cocktails. The products are then analyzed to confirm the enzymatic activity and characterize the transformation, thereby validating or refuting a biosynthetic hypothesis.

Experimental Protocol: In Vitro Reconstitution of a Biosynthetic Pathway

• Objective: Characterize the function of a putative cytochrome P450 enzyme in a biosynthetic pathway.
• Materials: Chemically synthesized putative substrate, purified P450 enzyme, NADPH cytochrome P450 reductase, NADPH cofactor, reaction buffer.
• Procedure:
  • Prepare a reaction buffer (e.g., 50 mM Tris-HCl, pH 7.5).
  • Add the synthesized substrate to the buffer, ensuring good solubility (may require a co-solvent like DMSO, kept at low concentration).
  • Add the purified P450 enzyme and its cognate reductase.
  • Initiate the reaction by adding NADPH.
  • Incubate at a defined temperature (e.g., 30°C) with shaking.
  • Quench the reaction at various time points by adding an organic solvent (e.g., acetonitrile).
  • Analyze the quenched samples using LC-MS to detect product formation.
  • Isolate and characterize the product(s) using NMR spectroscopy to determine structure.
• Key Parameters: The stoichiometry between the P450 and its reductase is critical for optimal activity [18]. Control reactions without the enzyme or without NADPH are essential.

Approach 3: To Motivate Retrosynthetic Disconnections with Known Enzymatic Reactions

Here, known enzymatic reactions serve as direct inspiration for synthetic design. The deliberate incorporation of a specific enzymatic transformation acts as a simplifying "T-goal" in retrosynthetic analysis, fundamentally shaping the route in a way that is orthogonal to purely chemical logic [13].

Mechanism: This strategy leverages the unique selectivity of enzymes to make strategic bond disconnections that would be non-trivial with synthetic chemistry. Examples include using terpene cyclases to construct complex carbocyclic cores in one step [18] or P450 enzymes for site-selective C–H oxidation [4].

Experimental Protocol: Chemoenzymatic Skeletal Editing via Ring Expansion

• Objective: Perform site-selective ring expansion of a natural product scaffold via a chemoenzymatic cascade [4].
• Materials: Natural product substrate, engineered P450 enzyme (whole cells or purified enzyme), NADPH regeneration system, m-CPBA or diazomethane for subsequent chemical steps.
• Procedure:
  • P450-Mediated Oxidation: Incubate the substrate with an engineered P450 catalyst to achieve site-selective oxidation of an aliphatic C–H bond to a ketone.
  • Workup: Extract the ketone intermediate.
  • Skeletal Editing:
    • Path A (Baeyer-Villiger): Treat the ketone with m-CPBA to insert an oxygen atom, forming a ring-expanded lactone.
    • Path B (Homologation): React the ketone with diazomethane to form a homologated, ring-expanded product.
  • Purification: Isolate the final skeletally edited analog using preparative HPLC.
• Key Parameters: The selectivity of the ring expansion is dictated by the initial, enzyme-controlled site of oxidation. Engineering the P450 is often necessary to achieve divergent regioselectivity on complex scaffolds [4].

Approach 4: To Motivate Retrosynthetic Disconnections by Filling Gaps in Current Methodology

This forward-looking approach involves proposing a retrosynthetic disconnection for which no suitable catalyst currently exists. Advances in genetic technology and directed evolution are then harnessed to discover or engineer an enzyme to perform this "gap-filling" role, which may be traditionally occupied by or entirely inaccessible to chemical methodology [13].

Mechanism: The initial disconnection is chosen based on synthetic logic, potentially without a specific biocatalyst in mind. Researchers then screen metagenomic libraries or employ directed evolution campaigns to create "new-to-nature" biocatalysts that can achieve the desired transformation with high selectivity.

Experimental Protocol: Directed Evolution of a "New-to-Nature" Biocatalyst

• Objective: Engineer an enzyme to catalyze a non-natural reaction essential to a proposed synthetic route.
• Materials: Gene library of the parent enzyme, expression host (e.g., E. coli), chemical substrate for the desired reaction, high-throughput screening assay.
• Procedure:
  • Gene Library Construction: Introduce random mutations into the gene of the parent enzyme using error-prone PCR or other gene diversification methods.
  • Expression and Screening: Express the mutant library in a microbial host. Culture clones in microtiter plates and lyse cells to release enzymes.
  • Activity Screening: Add the target substrate to each well and use a high-throughput assay (e.g., colorimetric, fluorescence, or mass spectrometry-based) to identify active clones.
  • Hit Validation: Sequence positive hits and characterize the improved enzymes.
  • Iterative Evolution: Use the best hit from one round as the template for the next round of evolution, potentially focusing on different regions of the enzyme, until the desired activity and selectivity are achieved.
• Key Parameters: The design of a rapid and reliable screening assay is the most critical factor for success. The substrate scope and stability of the evolved enzyme must be characterized before integration into a multi-step synthesis.

Quantitative Comparison of the Frameworks

The table below summarizes the key characteristics, advantages, and challenges associated with each framework.

Table 1: Comparative Analysis of the Four Frameworks for Enzyme Integration

Framework	Influence on Synthetic Design	Key Enzyme Function	Technical Complexity	Relative Step Count Impact
1. Provide Enantioenriched Intermediates	Minimal (Supporting role)	Kinetic resolution, desymmetrization	Low	Neutral
2. Evaluate Biosynthetic Hypotheses	Retrospective (Hypothesis-driven)	Pathway validation, intermediate transformation	Medium	Variable
3. Motivate Disconnections with Known Enzymes	High (Directs T-goal)	Core bond formation, selective functionalization	Medium to High	Reductive
4. Motivate Disconnections by Filling Gaps	Transformative (Creates new methodology)	"New-to-nature" catalysis	Very High	Potentially Highly Reductive

The Scientist's Toolkit: Essential Research Reagents and Materials

Successful implementation of these frameworks relies on a suite of specialized reagents and materials.

Table 2: Key Research Reagent Solutions for Chemoenzymatic Synthesis

Reagent / Material	Function	Example Applications
Lipases & Esterases (e.g., Lipase PS)	Kinetic resolution of racemic alcohols/acids via enantioselective hydrolysis or acylation.	Synthesis of enantiopure pipecolic acid derivatives [13].
Engineered P450 Monooxygenases	Site- and stereoselective oxidation of unactivated C-H bonds.	Skeletal editing via late-stage ring expansion [4].
Terpene Cyclases (e.g., Pentalenene Synthase)	One-step enzymatic cyclization of linear precursors to complex polycyclic cores.	Construction of the guaia-6,10(14)-diene scaffold in englerin A synthesis [18].
Metal-Organic Frameworks (MOFs)	Nanocarriers for enzyme co-immobilization, enhancing stability and enabling cascade reactions.	Compartmentalization of multi-enzyme systems to minimize diffusion limitations [19].
Organic-Inorganic Hybrid Nanoflowers (HNFs)	Self-assembled immobilization matrices that boost enzymatic activity and stability.	Co-immobilization of cellulases for cellulose-to-glucose conversion [20].
Directed Evolution Kits	Platforms for gene mutagenesis and high-throughput screening to engineer enzyme function.	Creating bespoke biocatalysts for gaps in synthetic methodology (Approach 4) [13] [5].
Saquayamycin B1	Saquayamycin B1, MF:C31H32O12, MW:596.6 g/mol	Chemical Reagent
CARM1-IN-1 hydrochloride	CARM1-IN-1 hydrochloride, CAS:2070018-31-2, MF:C26H22Br2ClNO3, MW:591.7 g/mol	Chemical Reagent

Strategic Workflow and Computational Planning

The decision-making process for integrating enzymes into synthesis can be guided by computational tools and a structured workflow. Emerging computational synthesis planning tools, such as those described by [14] and minChemBio [6], are now designed to balance the exploration of enzymatic and synthetic reaction spaces, suggesting hybrid routes that minimize costly transitions between chemical and biological steps.

The following diagram illustrates a strategic workflow for selecting and implementing the appropriate framework, from target analysis to experimental execution.

Framework Selection Workflow

The strategic integration of enzymes into multi-step synthesis, as delineated by the four frameworks presented, provides a powerful and evolving toolbox for the concise and efficient construction of complex molecules. The choice of framework depends on the synthetic challenge: from the tactical resolution of enantiomers (Framework 1) to the hypothesis-driven interrogation of biosynthesis (Framework 2), and further to the strategic use of enzymes to define retrosynthetic logic (Framework 3) or to create entirely new catalytic solutions (Framework 4). As advances in enzyme engineering, immobilization technologies, and computational planning continue to lower the barriers to implementation, these chemoenzymatic strategies are poised to become central methodologies in natural product research and pharmaceutical development, enabling the synthesis of novel analogs with tailored biological activities [4] [18].

The integration of enzymatic transformations into synthetic organic chemistry has fundamentally expanded the toolbox available for the construction of complex molecules. Chemoenzymatic strategies, which combine the precision of biocatalysis with the flexibility of synthetic chemistry, have emerged as particularly powerful approaches for the synthesis and diversification of natural products and pharmaceutical agents [9]. These strategies leverage the exceptional chemo-, regio-, and stereoselectivity of enzymes to perform transformations that are challenging to achieve using traditional chemical methods, often under mild, environmentally benign conditions [9]. Within this framework, oxidoreductases, transferases, and lyases represent three fundamental enzyme classes that enable key bond-forming and functional group interconversion steps. This review provides an in-depth examination of recent advances in applying these enzyme classes to natural product synthesis, with particular emphasis on experimental protocols, reagent solutions, and emerging technological synergies such as machine learning-guided enzyme discovery that are shaping the future of chemoenzymatic synthesis.

Oxidoreductases in Synthesis

Functional Scope and Mechanistic Principles

Oxidoreductases (EC 1) catalyze electron transfer reactions, playing indispensable roles in functional group interconversions and selective C-H activation. According to the Enzyme Commission classification system, this diverse class encompasses oxidases, dehydrogenases, reductases, oxygenases, and peroxidases [21]. Their significance in synthetic chemistry stems from their ability to perform highly selective oxidation and reduction reactions under mild conditions, often with cofactor recycling systems enabling practical synthetic applications.

The industrial relevance of oxidoreductases continues to grow, with them constituting the second largest revenue generator in the global enzymes market after hydrolases [21]. Their value is particularly evident in asymmetric synthesis, where they facilitate the production of chiral building blocks with exceptional enantioselectivity. For instance, ketoreductases (KREDs) have been successfully employed in the synthesis of ipatasertib, a potent protein kinase B inhibitor, where an engineered variant demonstrated a 64-fold increase in apparent kcat and high diastereoselectivity (99.7% de) [9].

Table 1: Major Oxidoreductase Categories and Their Synthetic Applications

Category	EC Subclass	Characteristic Reaction	Synthetic Application	Example Enzymes
Oxidases	EC 1.1-1.3	Direct transfer of hydrogen to oxygen, producing water or Hâ‚‚Oâ‚‚	Polymer synthesis, biosensors	Laccases, Monoamine oxidases
Dehydrogenases	EC 1.4	Hydride transfer to acceptor substrates	Asymmetric synthesis of chiral alcohols and amines	Alcohol dehydrogenase, Glutamate dehydrogenase
Oxygenases	EC 1.13-1.14	Incorporation of oxygen into substrates	Late-stage functionalization, ring expansion	Cytochrome P450s, α-Ketoglutarate-dependent enzymes
Reductases	EC 1.4-1.8	Reduction of substrates using reduced cofactors	Ketone reduction, reductive amination	Imine reductases, Enoate reductases

Experimental Protocol: P450-Mediated Skeletal Editing via Ring Expansion

A recent innovative application of oxidoreductases in natural product diversification involves P450-controlled site-selective ring expansion through a chemoenzymatic skeletal editing strategy [4]. This methodology enables precise modification of molecular frameworks at the level of single atoms or bonds, offering powerful opportunities for fine-tuning the biological activity of natural product scaffolds.

Required Materials:

• Engineered P450 enzyme catalyst (divergent regioselectivity variants)
• Natural product substrate (aliphatic C-H containing scaffold)
• Cofactor regeneration system (NADPH/GDH/glucose or equivalent)
• Appropriate reaction buffer (typically phosphate or Tris, pH 7-8)
• Oxygen source (atmospheric Oâ‚‚ or controlled oxygenation)
• Post-oxidation rearrangement reagents (e.g., for Baeyer-Villiger conditions)

Procedure:

• Enzyme Preparation: Express and purify engineered P450 variants exhibiting divergent regioselectivity toward the target natural product scaffold.
• Biocatalytic Oxidation: Incubate the natural product substrate (0.1-1.0 mM) with the selected P450 catalyst (1-5 mol%) in appropriate buffer containing NADPH-regenerating system at 25-30°C for 4-16 hours with mild agitation.
• Reaction Monitoring: Track reaction progression via LC-MS/TLC until complete consumption of starting material or conversion plateau.
• Product Isolation: Extract oxidized intermediate with ethyl acetate or dichloromethane, dry over anhydrous Naâ‚‚SOâ‚„, and concentrate under reduced pressure.
• Skeletal Editing: Subject the P450-generated ketone intermediate to either Baeyer-Villiger rearrangement (using mCPBA or enzymatic BV monooxygenases) or ketone homologation conditions to effect ring expansion.
• Characterization: Purify the ring-expanded final product via flash chromatography or preparative HPLC and characterize by NMR, HRMS, and X-ray crystallography.

This chemoenzymatic approach has been successfully applied to generate panels of ring-expanded analogs of various complex natural products, with the skeletal modifications frequently resulting in significantly altered biological activities, including enhanced anticancer properties [4].

α-Ketoglutarate-Dependent Enzymes and Predictive Tools

The α-ketoglutarate (α-KG)/Fe(II)-dependent enzymes represent a particularly valuable subclass of oxidoreductases for C-H functionalization, leveraging a common radical intermediate to achieve diverse transformations including hydroxylation, desaturation, halogenation, and skeletal rearrangements [22]. Their practical advantage stems from uniform reaction conditions driven by the oxidation of the small-molecule co-substrate α-KG, unlike other oxidative enzymes that require partner reductases [22].

Recent efforts have addressed the historical challenge of predicting enzyme-substrate compatibility through the development of CATNIP (Compatibility Assessment Tool for Natural Product-Inspired Pairs), a machine learning-based tool trained on high-throughput experimentation data [22]. This tool predicts compatible α-KG/Fe(II)-dependent enzymes for given substrates or ranks potential substrates for specific enzyme sequences, significantly derisking biocatalytic route planning.

Diagram 1: Workflow for predictive biocatalytic reaction discovery. The process integrates high-throughput experimental data with machine learning to enable compatibility prediction between substrates and enzymes.

Transferases in Synthesis

Functional Scope and Classification

Transferases (EC 2) catalyze the movement of functional groups from a donor molecule to an acceptor molecule, enabling key transformations in natural product diversification and conjugate modification [23]. The systematic naming of transferases follows the "donor:acceptor grouptransferase" convention, though common names are frequently used in practice [23]. This enzyme class exhibits remarkable diversity, with over 450 unique enzymes categorized into ten major subclasses based on the specific functional group transferred [23].

Table 2: Transferase Subclasses and Representative Functions

EC Number	Subclass	Group Transferred	Synthetic Application	Example Enzymes
EC 2.1	Single-carbon transferases	Methyl, formyl, carboxy, carbamoyl groups	Natural product diversification, epigenetic modulation	Methyltransferases, Formyltransferases
EC 2.2	Aldehyde and ketone transferases	Aldehyde or ketone groups	Carbohydrate synthesis, pentose phosphate pathway	Transketolases, Transaldolases
EC 2.3	Acyl transferases	Acyl groups	Peptide bond formation, macrocyclization	Peptidyl transferases, Acyltransferases
EC 2.4	Glycosyl transferases	Glycosyl, hexosyl, pentosyl groups	Glycodiversification, solubility enhancement	Glycosyltransferases, Lactose synthase
EC 2.5	Alkyl and aryl transferases	Alkyl or aryl groups (excluding methyl)	Amino acid synthesis, natural product modification	Cysteine synthase
EC 2.6	Nitrogenous transferases	Nitrogen-containing groups	Amino acid metabolism, chiral amine synthesis	Transaminases, Oximinotransferases
EC 2.7	Phosphorus transferases	Phosphorus-containing groups	Nucleotide synthesis, signal transduction	Phosphotransferases, Kinases, Polymerases

Methyltransferases: Functions and Applications

Among transferases, methyltransferases (MTs) have garnered significant attention for their potential in providing clean, green alkylation strategies as alternatives to traditional toxic methylation reagents [24]. These enzymes utilize S-adenosylmethionine (SAM) as an electrophilic methyl donor, enabling chemo-, regio-, and stereospecific methylation of hydroxyl and amino groups, thiols, and reactive carbon atoms [24]. The biological significance of methylation spans cell signaling, membrane component synthesis, and expression regulation of proteins and nucleic acids [24].

Structural analyses have revealed that SAM-dependent MTs coalesce into five major classes with distinct topological features [24]:

• Class I MTs feature a Rossmann-like fold with an alternating α/β sequence and represent the largest group.
• Class II MTs specialize in reactivating oxidized cobalamin and exhibit a horseshoe-like topology.
• Class III MTs are dimeric enzymes that primarily target tetrapyrroles.
• Class IV MTs (SPOUT superfamily) modify tRNAs and rRNAs and feature a characteristic knot topology.
• Class V MTs (SET domains) methylate histone lysines and possess a complex structure with twisted β-sheets.

Experimental Protocol: Chemoenzymatic Glycosylation Using Glycosyltransferases

Glycosyltransferases represent a particularly valuable subclass of transferases for natural product modification, enabling the attachment of sugar moieties to aglycone scaffolds with exquisite regio- and stereocontrol. The following protocol outlines a representative glycosylation procedure for enhancing the water solubility and stability of polyphenolic natural products [25].

Required Materials:

• Glycosyltransferase enzyme (plant or microbial source)
• Polyphenol aglycone substrate (flavonoid, catechin, etc.)
• Sugar donor (UDP-glucose, TDP-glucose, etc.)
• Appropriate reaction buffer (Tris or phosphate, typically pH 7-8)
• Cofactor regeneration system (if required)
• Organic solvents for extraction (ethyl acetate, methanol)
• Analytical standards for product characterization

Procedure:

• Reaction Setup: Prepare a reaction mixture containing the polyphenol aglycone (1-10 mM) and sugar donor (1.2-2.0 equiv) in appropriate buffer.
• Enzyme Addition: Add glycosyltransferase enzyme (0.1-5 mg/mL) to initiate the reaction.
• Incubation: Maintain the reaction at 25-37°C with gentle agitation for 2-24 hours, monitoring progress by TLC or HPLC.
• Cofactor Regeneration: For reactions requiring cofactor regeneration, include necessary components (e.g., pyrophosphatase with sucrose synthase system for UDP-glucose regeneration).
• Reaction Termination: Quench the reaction by heat inactivation (5 min at 95°C) or addition of organic solvent.
• Product Isolation: Remove precipitated protein by centrifugation or filtration, then extract the glycosylated product with appropriate organic solvent.
• Purification: Purify the product using column chromatography or preparative HPLC.
• Characterization: Confirm structure and regiochemistry by NMR, MS, and comparison with authentic standards when available.

This glycosylation strategy has been successfully applied to compounds like green tea catechins, where enzymatic conjugation enhanced superoxide anion scavenging activity and improved thermal stability and solubility [25]. Similarly, cellulase from Trichoderma viride has been employed for trans-glucosylation of (+)-catechin and (-)-epigallocatechin gallate, producing derivatives with improved functional properties as food additives [25].

Lyases in Synthesis

Functional Scope and Synthetic Utility

Lyases (EC 4) catalyze the cleavage of various chemical bonds by means other than hydrolysis or oxidation, often forming new double bonds or ring structures. While comprehensive search results specific to lyases were limited in the current query, their synthetic importance in natural product synthesis warrants inclusion. These enzymes are particularly valuable for C-C bond formation through addition or elimination mechanisms, enabling stereocontrolled assembly of molecular frameworks.

In chemoenzymatic synthesis, lyases have been employed for:

• Hydrocyanation reactions for chiral nitrile synthesis
• Aldol additions for controlled C-C bond formation
• Decarboxylation for generating reactive enolate intermediates
• Ring-forming reactions for carbocycle and heterocycle construction

The integration of lyase-catalyzed steps with traditional synthetic transformations provides powerful strategies for streamlining natural product synthesis, often eliminating protecting group manipulations and enabling direct access to stereochemically complex intermediates.

Research Reagent Solutions for Enzymatic Transformations

Successful implementation of enzymatic transformations requires access to specialized reagents and materials. The following table summarizes key solutions for researchers developing chemoenzymatic synthesis methodologies.

Table 3: Essential Research Reagents for Enzymatic Transformations

Reagent Category	Specific Examples	Function/Purpose	Application Notes
Oxidoreductase Cofactors	NAD(P)H, NAD(P)+, FAD, FMN	Electron donor/acceptor in redox reactions	Typically used with regeneration systems (e.g., GDH/glucose for NADPH)
Methyltransferase Cofactors	S-adenosylmethionine (SAM)	Methyl group donor	Often requires in situ regeneration due to cost and instability
Glycosyl Donors	UDP-glucose, TDP-glucose, UDP-galactose	Sugar donors for glycosyltransferases	Regeneration systems (sucrose synthase) improve efficiency
Acyl Donors	Acetyl-CoA, Malonyl-CoA	Acyl group donors for acyltransferases	CoA derivatives often generated enzymatically
Reaction Stabilizers	Dithiothreitol (DTT), β-mercaptoethanol	Thiol protectants for enzyme stability	Critical for oxygen-sensitive enzymes (e.g., Fe(II)/α-KG dependent)
Engineered Enzyme Panels	P450 variants, α-KG-dependent enzyme library	Providing diverse selectivity and activity	Enable reaction optimization and substrate scope expansion
Extremophilic Enzymes	Thermophilic laccases, Halophilic dehydrogenases	Enhanced stability under process conditions	Suitable for non-aqueous media and elevated temperatures

Emerging Trends and Future Perspectives

The field of chemoenzymatic synthesis continues to evolve rapidly, driven by advances in enzyme discovery, protein engineering, and process integration. Several emerging trends are particularly noteworthy for their potential to expand the applications of oxidoreductases, transferases, and lyases in natural product synthesis.

Machine Learning-Guided Enzyme Discovery and Engineering

The application of machine learning algorithms to enzyme discovery and engineering represents a paradigm shift in biocatalyst development. Tools like CATNIP demonstrate how high-throughput experimental data can train predictive models for enzyme-substrate compatibility, potentially overcoming the traditional bottleneck of identifying suitable biocatalysts for specific transformations [22]. Similarly, machine learning-aided enzyme engineering has enabled the design of smaller, more focused mutant libraries, significantly reducing screening efforts while identifying variants with dramatically improved catalytic properties, as exemplified by the 64-fold kcat improvement achieved for a ketoreductase used in ipatasertib synthesis [9].

Integration of Novel Enzymatic Cascades

The development of multi-enzyme cascades represents another frontier in chemoenzymatic synthesis. By combining multiple enzymatic transformations in single reaction vessels, these systems minimize intermediate isolation, improve overall efficiency, and enable the construction of complex molecular architectures. Recent innovations include the repurposing of head-to-tail non-ribosomal peptide cyclases for lariat peptide synthesis, where engineering substrate shape rather than the enzyme itself enabled access to previously inaccessible topological architectures [11]. Such approaches demonstrate the power of combining chemical synthesis (for substrate preparation) with enzymatic catalysis (for selective transformation) to access diverse molecular scaffolds.

Diagram 2: Chemoenzymatic synthesis of lariat lipopeptides. The pathway illustrates the conversion of linear peptide substrates to complex lariat structures through enzymatic cyclization and subsequent functionalization.

Chemoenzymatic Strategies for Natural Product Diversification

The combination of enzymatic and chemical transformations enables sophisticated skeletal editing approaches for natural product diversification. As demonstrated by P450-mediated ring expansion strategies, this hybrid methodology enables precise modification of molecular frameworks that would be challenging to achieve through either enzymatic or chemical methods alone [4]. Such approaches are particularly valuable for structure-activity relationship studies during drug discovery, where subtle structural modifications can dramatically alter biological activity.

The continued discovery and engineering of enzymes from extremophilic microorganisms also addresses key limitations in process compatibility, providing biocatalysts that maintain activity and stability under the demanding conditions often required for industrial applications [21]. These extremophilic enzymes, particularly oxidoreductases from thermophilic, halophilic, and acidophilic organisms, offer enhanced robustness toward organic solvents, extreme pH, and elevated temperatures, significantly expanding the operational window for biocatalytic transformations.

Oxidoreductases, transferases, and lyases constitute powerful catalytic tools for modern natural product synthesis, enabling transformations with unparalleled selectivity under environmentally benign conditions. Their integration into chemoenzymatic strategies, complemented by advances in enzyme engineering, cascade design, and machine learning-guided discovery, continues to expand the synthetic toolbox available to researchers. As these technologies mature, chemoenzymatic approaches are poised to play an increasingly central role in the synthesis and diversification of complex molecular architectures, particularly in pharmaceutical and fine chemical industries where selectivity and sustainability are paramount. The ongoing characterization of novel enzymatic activities and development of sophisticated reaction systems promises to further blur the traditional boundaries between enzymatic and chemical synthesis, heralding a new era of integrated strategies for complex molecule construction.

The field of biocatalysis has undergone a profound transformation, evolving from the use of native enzymes for specific metabolic reactions to the engineering of sophisticated catalysts capable of performing abiological, "new-to-nature" transformations. This expansion of the biocatalytic toolbox is fundamentally reshaping chemoenzymatic strategies for the synthesis of complex natural products, which remain an indispensable source of drug leads and therapeutic agents. By combining the unparalleled selectivity of enzymatic catalysis with the broad reactivity of synthetic chemistry, researchers can now devise more efficient, sustainable, and innovative routes to structurally intricate molecules [18] [26]. This guide details the core concepts, methodologies, and practical applications driving this advancement, providing a technical resource for scientists engaged in natural product and pharmaceutical research.

From Natural Machinery to Engineered Catalysts

The Foundation: Native Enzymes in Synthesis

Native enzymes, employed for their inherent catalytic activities, provide a powerful starting point for chemoenzymatic synthesis. Their high selectivity—enantioselectivity, regioselectivity, and chemoselectivity—often enables direct solutions to complex challenges in natural product construction.

A quintessential example is the use of terpene cyclases in constructing the core architectures of terpenoid natural products. These enzymes catalyze the cyclization of linear, achiral isoprenoid diphosphates into complex polycyclic scaffolds with multiple stereocenters in a single step [18]. For instance, in the chemoenzymatic synthesis of the antimalarial drug artemisinin, an engineered amorphadiene synthase in S. cerevisiae cyclizes farnesyl diphosphate to form amorpha-4,11-diene. This key enzymatic step establishes the core sesquiterpene skeleton, which is subsequently functionalized by a cytochrome P450 (CYP71AV1) to yield artemisinic acid, the advanced precursor to artemisinin [18]. Similarly, the synthesis of the potent cytotoxin englerin A leverages a fungal sesquiterpene cyclase (FgJ02895) to produce guaia-6,10(14)-diene from farnesyl diphosphate on a gram scale, showcasing the practical utility of enzymatic cyclization [18].

Table 1: Representative Native Enzymes and Their Applications in Natural Product Synthesis

Enzyme Class	Natural Function	Application Example	Key Advantage
Terpene Cyclase [18]	Cyclization of linear isoprenoids	Construction of artemisinin and englerin A core	Step-economical formation of complex carbocycles
Cytochrome P450 [18]	C-H bond oxidation	Late-stage oxidation of artemisinin precursor	Regio- and stereoselective C-H functionalization
α-Ketoglutarate-dependent NHI Enzyme [27]	C-H hydroxylation, halogenation, desaturation	Diversification of unnatural substrates	Functionalization of strong C-H bonds
Flavin-Dependent Halogenase [26]	Regioselective halogenation	Site-selective arene chlorination/bromination	Provides handles for cross-coupling chemistry

Expanding the Repertoire: Engineering 'New-to-Nature' Reactions

The true frontier of biocatalysis lies in engineering enzymes to catalyze reactions not found in their natural repertoire. This is achieved by leveraging innate catalytic promiscuity and using advanced protein engineering tools to enhance and redirect enzyme function.

The engineering of cytochrome P450 enzymes for abiological nitrene transfer and carbene transfer reactions is a landmark achievement. This work was inspired by biomimetic studies with synthetic iron-porphyrin complexes [28]. Starting from trace promiscuous activities, directed evolution has produced engineered P450 variants that now perform highly stereoselective intramolecular C-H aminations and intermolecular cyclopropanations with thousands of turnovers [28]. In a striking example of new reactivity, hemoproteins have been engineered to catalyze the formation of bicyclobutanes from alkynes, a transformation not observed with chemocatalytic methods [28].

Another innovative approach involves repurposing flavin-dependent enzymes for photoredox catalysis. By exploiting the innate photochemistry of the flavin cofactor, enzymes such as ene-reductases have been transformed into asymmetric radical reactors. Visible light excitation of the flavin generates a radical species from alkyl halides, and the chiral enzyme environment controls the subsequent radical addition or hydrogen atom transfer steps, enabling asymmetric transformations that are challenging for small-molecule catalysis [28].

Table 2: Engineered 'New-to-Nature' Reactions and Their Catalytic Systems

Reaction Type	Engineered Enzyme/System	Key Application	Notable Feature
Nitrene Transfer [28]	Cytochrome P450 variants	Intramolecular C-H amination	High enantioselectivity; inspired by biomimetic catalysts
Carbene Transfer [28]	Engineered Hemoproteins	Cyclopropanation, Bicyclobutane formation	Access to strained carbocycles not accessible chemically
Asymmetric Photoredox [28]	Flavin-dependent 'Ene'-Reductases	Radical hydroalkylation of olefins	Combines photochemistry with enzymatic stereocontrol
Non-Canonical C-H Activation [27]	α-KG/Fe(II)-dependent enzymes	Functionalization of complex intermediates	Predictable compatibility via tools like CATNIP

Methodologies for Developing and Implementing Advanced Biocatalysts

Experimental Protocol: Directed Evolution for Abiological Activity

Directed evolution remains a cornerstone methodology for enhancing enzyme performance and instilling new functions. The following protocol outlines a standard workflow for evolving an enzyme for a new-to-nature reaction, such as a C-H amination catalyst [28].

• Gene Library Generation: Create genetic diversity through error-prone PCR or site-saturation mutagenesis targeting the enzyme's active site and surrounding residues.
• Host Transformation and Expression: Clone the mutant library into an appropriate expression vector and transform into a bacterial host (e.g., E. coli).
• High-Throughput Screening (HTS):
  • Culture transformed colonies in deep-well plates.
  • Induce enzyme expression.
  • Lyse cells or prepare crude lysates.
  • Assay activity by adding the unnatural substrate (e.g., a sulfonyl azide for nitrene transfer) and detecting product formation. Readouts can include UV/Vis spectroscopy, fluorescence, or LC-MS.
• Hit Identification and Sequencing: Select the most active variants from the primary screen and sequence their genes to identify beneficial mutations.
• Iteration: Use the best hit as a template for subsequent rounds of mutagenesis and screening until the desired activity and selectivity are achieved.

Experimental Protocol: Integrated Chemoenzymatic One-Pot Reaction

Integrating biocatalysis with chemocatalysis in a single pot can streamline synthesis and improve efficiency. This protocol describes a one-pot cascade combining flavin-dependent halogenase (Fl-Hal) catalysis with palladium-catalyzed cross-coupling [26].

• Reaction Setup:
  • Buffer/Solvent System: Use an aqueous or biphasic solvent system compatible with both catalysts. For Fl-Hal and Pd-catalyzed coupling, a phosphate buffer (e.g., 50 mM, pH 7.5) is suitable.
  • Substrates: Add the arene substrate (e.g., tryptophan), sodium bromide/chloride, and co-substrates (e.g., α-ketoglutarate for some NHI enzymes).
• Biocatalytic Halogenation:
  • Add the flavin-dependent halogenase (whole cells or purified enzyme), along with its cofactor regeneration system (e.g., glucose dehydrogenase for NADH regeneration).
  • Incubate the mixture with shaking at 25-30°C for 6-24 hours to generate the regioselectively halogenated intermediate.
• Transition-Metal Catalysis:
  • Directly to the same pot, add the palladium catalyst (e.g., Pd(PPh₃)â‚„), the coupling partner (e.g., phenylboronic acid for a Suzuki reaction), and a base (e.g., Kâ‚‚CO₃).
  • Seal the vessel and heat to 50-80°C for 12-24 hours to effect the cross-coupling.
• Work-up and Analysis:
  • Quench the reaction and extract the product with an organic solvent (e.g., ethyl acetate).
  • Purify the crude material by flash chromatography and characterize the final biaryl product using NMR and mass spectrometry.

Computational and Machine Learning Tools

The integration of computational methods is accelerating biocatalyst development. Machine learning (ML) models are now used to predict the compatibility between enzyme sequences and small-molecule substrates, derisking the implementation of biocatalytic steps [27]. Tools like CATNIP (Compatibility Assessment Tool for Natural and Invented Products) can suggest suitable α-ketoglutarate/Fe(II)-dependent enzymes for a given substrate or rank potential substrates for a given enzyme sequence [27]. Furthermore, automated in vivo enzyme engineering platforms are emerging, which combine ML-guided library design, hypermutation systems, and growth-coupled selection in integrated, robotic workflows to rapidly optimize biocatalysts [29].

Diagram 1: Enzyme Engineering Workflow

The Scientist's Toolkit: Essential Research Reagent Solutions

Successful implementation of advanced biocatalysis requires a suite of specialized reagents and tools. The following table details key components of the modern biocatalytic toolkit.

Table 3: Key Research Reagent Solutions for Advanced Biocatalysis

Reagent / Material	Function / Application	Example Use Case
Immobilized Lipases (e.g., Eversa Transform) [30]	Hydrolysis and esterification under mild conditions.	Sustainable production of epoxidized monoalkyl esters from waste oils.
Engineered Transaminases (TAs) [26]	Synthesis of chiral amines from ketones.	Integrated with metal catalysis for one-pot synthesis of enantiopure biaryl amines.
Flavin-Dependent Halogenases (Fl-Hal) [26]	Regioselective C-H halogenation of arenes.	Provides halide handles for subsequent Pd-catalyzed cross-coupling.
Alcohol Dehydrogenases (ADHs) [26]	Stereoselective reduction of ketones to alcohols.	Used in tandem with metal-catalyzed isomerization or cross-coupling.
α-Ketoglutarate (α-KG) / Fe(II) [27]	Cofactor system for NHI-dependent enzymes.	Fuels a wide range of oxidative biocatalysis, from hydroxylation to rearrangement.
Hypermutation Plasmid Systems [29]	Accelerated in vivo directed evolution.	Continuous evolution of enzymes via growth-coupled selection in automated biofoundries.
CATNIP Prediction Tool [27]	In silico enzyme-substrate compatibility prediction.	Derisks biocatalytic step planning for α-KG/Fe(II)-dependent enzymes.
Z-Phe-Tyr(tBu)-diazomethylketone	Z-Phe-Tyr(tBu)-diazomethylketone, CAS:86-03-3, MF:C31H34N4O5, MW:542.6 g/mol	Chemical Reagent
18-Deoxyherboxidiene	18-Deoxyherboxidiene, MF:C25H42O5, MW:422.6 g/mol	Chemical Reagent

The biocatalytic toolbox has expanded beyond recognition, from a collection of natural catalysts to a dynamic and engineerable platform that includes powerful 'new-to-nature' reactions. This evolution, driven by directed evolution, protein design, and machine learning, is intrinsically linked to progress in chemoenzymatic synthesis. The strategic combination of enzymatic and chemical catalysis provides a robust framework for constructing complex natural products with unprecedented efficiency and selectivity. As computational and automated methods continue to mature, the scope and impact of biocatalysis in drug discovery and sustainable chemical synthesis are poised for even greater growth.

Implementing Chemoenzymatic Strategies: Techniques and Case Studies Across Natural Product Classes

Terpene cyclases (TCs) are nature's master architects, catalyzing the most complex carbocyclization reactions known to biochemistry that transform simple linear prenyl diphosphates into intricate molecular scaffolds with remarkable stereochemical precision. This whitepaper examines the strategic integration of terpene cyclases within chemoenzymatic frameworks for natural product synthesis, focusing on mechanistic insights, structural biology advances, and practical experimental methodologies. We detail how these enzymes create structural diversity through conserved reaction mechanisms and highlight emerging applications in pharmaceutical development. The integration of structural biology, computational design, and synthetic biology approaches provides unprecedented opportunities to harness terpene cyclases for producing bioactive terpenoids with pharmaceutical relevance, offering sustainable alternatives to traditional plant extraction and chemical synthesis.

Terpenoids represent the most structurally diverse class of natural products, with over 80,000 identified structures possessing wide-ranging biological activities and industrial applications [31]. These compounds derive their structural variety from enzymatic modifications of simple isoprenoid precursors, with terpene cyclases serving as the pivotal enzymes that catalyze the formation of complex carbocyclic skeletons from acyclic substrates [32]. The cyclization mechanisms employed by these enzymes represent fascinating biochemical transformations that involve generation of reactive carbocation intermediates followed by precisely orchestrated cyclization, rearrangement, and termination steps [33].

Within chemoenzymatic strategies for natural product synthesis, terpene cyclases provide the foundational architecture upon which subsequent functionalization reactions build molecular complexity. Their ability to generate multiple carbon-carbon bonds and stereocenters in a single enzymatic step makes them invaluable tools for synthetic biology and drug discovery platforms [34]. Recent advances in structural biology, particularly cryo-electron microscopy, have revolutionized our understanding of terpene cyclase structure-function relationships, enabling more rational engineering approaches for producing novel terpenoid scaffolds with tailored pharmaceutical properties [35].

Fundamental Biochemistry of Terpene Cyclases

Classification and Reaction Mechanisms

Terpene cyclases are categorized based on their structural folds and reaction mechanisms, with two primary classes governing the initial activation of the isoprenoid substrate:

• Class I terpene cyclases typically utilize an aspartate-rich DDXXD motif to coordinate magnesium ions that facilitate substrate ionization by stabilizing the diphosphate leaving group [36]. This ionization generates an initial carbocation that initiates the cyclization cascade.
• Class II terpene cyclases employ a DXDD motif that protonates the terminal carbon-carbon double bond of the substrate to create a carbocation intermediate [35]. This mechanism is characteristic of bifunctional cyclases that catalyze both substrate synthesis and cyclization.

Following initial carbocation formation, both classes of terpene cyclases guide the subsequent cyclization through precise control of the reaction trajectory within the enzyme active site. The cyclization cascade proceeds through a series of carbocation intermediates that undergo structural rearrangements, hydride shifts, and cyclizations until termination occurs via proton elimination or nucleophile capture [33].

Table 1: Classification of Terpene Cyclases Based on Structure and Mechanism

Classification	Catalytic Motif	Activation Mechanism	Representative Enzymes
Class I	DDXXD	Ionization of diphosphate group via Mg²⁺ coordination	5-epi-aristolochene synthase (TEAS), epi-cedrol synthase (AECS)
Class II	DXDD	Protonation of terminal double bond	Copalyl diphosphate synthase (PvCPS), labdadienyl diphosphate synthase
Bifunctional	Both Class I & II motifs	Sequential prenyl transfer and cyclization	Fungal diterpene synthases with prenyltransferase and cyclase domains

Structural Features and Active Site Architecture

The three-dimensional structures of terpene cyclases reveal conserved folds that create specialized active site chambers tailored to guide reactive carbocation intermediates through specific reaction trajectories. Plant terpene cyclases typically feature α-helical domains that form the active site cavity, with the size and shape of this cavity determining product specificity [36]. The interior surfaces of these active sites are lined with aromatic residues and carbohydrate moieties that stabilize carbocation intermediates through cation-π interactions and provide structural scaffolding for the hydrophobic isoprenoid chain.

Recent cryo-EM structural analysis of a bifunctional class II terpene cyclase from Penicillium verruculosum (PvCPS) at 2.9 Ã… resolution has provided unprecedented insights into fungal terpene cyclase architecture [35]. This structure reveals a catalytic dyad mechanism for the final deprotonation step in labdane diterpene formation, with notable differences from bacterial and plant homologs. Comparative structural analysis indicates that while the residues guiding formation of the bicyclic labdane core remain conserved across kingdoms, the specific catalytic residues mediating terminal reaction steps have diverged through evolution.

Metabolic Context and Precursor Supply

Terpene cyclases operate within broader metabolic networks that supply the essential isoprenoid precursors. Understanding this metabolic context is crucial for optimizing terpenoid production in engineered systems.

Figure 1: Terpenoid Biosynthesis Pathways Showing Terpene Cyclase Context. The MEP (methylerythritol phosphate) and MVA (mevalonate) pathways generate universal precursors IPP and DMAPP, which are converted to linear prenyl diphosphates that serve as substrates for terpene cyclases. [32] [33]

Biosynthetic Pathways to Isoprenoid Precursors

Two distinct metabolic pathways supply the essential five-carbon building blocks for all terpenoids:

• The Mevalonate (MVA) Pathway: Primarily operating in the cytoplasm and endoplasmic reticulum of eukaryotes, this pathway converts three molecules of acetyl-CoA to isopentenyl diphosphate (IPP) through a series of six enzymatic steps. A key regulatory point is the conversion of HMG-CoA to mevalonate, catalyzed by HMG-CoA reductase (HMGR), which consumes two NADPH molecules [32] [33].

• The Methylerythritol Phosphate (MEP) Pathway: Located in plastids, this pathway utilizes pyruvate and glyceraldehyde-3-phosphate (GAP) to produce IPP and its isomer DMAPP through seven enzymatic steps. The first committed step catalyzed by DXS (1-deoxy-D-xylulose-5-phosphate synthase) represents a major flux-control point [33].

Following their synthesis, IPP and DMAPP undergo sequential condensation by isoprenyl diphosphate synthases (IDSs) to produce the direct substrates for terpene cyclases: geranyl diphosphate (GPP, C10), farnesyl diphosphate (FPP, C15), and geranylgeranyl diphosphate (GGPP, C20) [33]. The structural diversity of terpenoids begins at this stage, with variations in enzyme architecture and alternative catalytic mechanisms generating unconventional terpene scaffolds.

Experimental Approaches for Terpene Cyclase Characterization

Enzyme Kinetic Analysis and Product Identification

Comprehensive characterization of terpene cyclase activity requires integrated experimental approaches to elucidate kinetic parameters and identify cyclization products.

Table 2: Experimental Methods for Terpene Cyclase Analysis

Method Category	Specific Techniques	Key Information Obtained	Technical Considerations
Kinetic Analysis	Steady-state kinetics, Pre-steady-state kinetics, Isotope labeling	Catalytic efficiency (kcat/Km), Reaction mechanism, Intermediate identification	Use of radiolabeled ([¹⁴C] or [³H]) or stable isotope ([¹³C]) substrates for tracing
Product Profiling	Argentation TLC (arg-TLC), Radiometric GC (r-GC)	Separation of terpenoid products based on unsaturation, Quantitative product distribution	Argentation TLC separates by number of double bonds; GC provides quantitative data
Structural Identification	GC-MS, NMR spectroscopy	Definitive product structure elucidation, Stereochemical assignment	Combined approach: GC-MS for initial identification, NMR for complete structural elucidation
Site-Directed Mutagenesis	Alanine scanning, Active site tailoring	Identification of catalytic residues, Mechanism elucidation, Product specificity engineering	Based on sequence alignments and structural data to target variable positions

Protocol 1: Steady-State Kinetic Analysis of Terpene Cyclases

• Enzyme Preparation: Express and purify recombinant terpene cyclase using affinity chromatography. Confirm purity via SDS-PAGE and concentration via Bradford assay.

• Reaction Setup: In a 1 mL reaction volume, combine:

  • 50 mM appropriate buffer (pH optimum for enzyme)
  • 5-10 mM MgClâ‚‚ or other required cofactors
  • 0.1-100 μM [¹⁴C]-labeled prenyl diphosphate substrate
  • 0.1-100 nM purified enzyme

• Reaction Execution:

  • Incubate at optimal temperature (typically 30°C)
  • Terminate reactions at timed intervals (30 s to 30 min) with 100 μL 1M HCl or EDTA
  • Extract products with organic solvents (pentane:ethyl acetate, 1:1)

• Product Analysis:

  • Separate products by argentation TLC or radiometric GC
  • Quantify product formation using radiometric detection
  • Calculate kinetic parameters (K_m, V_max, k_cat) from initial velocity data

Protocol 2: Structural Characterization of Terpene Cyclase Products

• Large-Scale Enzyme Reactions:

  • Scale up reaction volume to 50-100 mL
  • Use unlabeled substrate at concentrations near K_m
  • Incubate for 2-24 hours with enzyme monitoring by TLC

• Product Extraction:

  • Extract repeatedly with pentane:ethyl acetate (1:1)
  • Combine organic layers and dry over anhydrous Naâ‚‚SOâ‚„
  • Concentrate under reduced pressure

• Purification:

  • Purify crude extract by flash chromatography
  • Further purify individual compounds by preparative TLC or HPLC

• Structural Elucidation:

  • Analyze by GC-MS with appropriate terpenoid databases
  • Conduct NMR analysis (¹H, ¹³C, COSY, HSQC, HMBC) for complete structural assignment
  • Compare spectroscopic data with known terpenoid standards

Structural Biology Approaches

Protocol 3: Crystallization and Structure Determination of Terpene Cyclases

• Protein Production for Crystallography:

  • Express selenomethionine-labeled protein in appropriate host
  • Purify using immobilized metal affinity chromatography (IMAC)
  • Further purify by size exclusion chromatography

• Crystallization Screening:

  • Use robotic screening with commercial sparse matrix screens
  • Optimize initial hits using grid screening around initial conditions
  • Consider microseeding and additive screening for difficult targets

• Data Collection and Structure Solution:

  • Collect X-ray diffraction data at synchrotron sources
  • Solve structure using molecular replacement or experimental phasing
  • For cryo-EM: collect data on vitrified samples, perform 2D/3D classification, and refine atomic model

Recent structural insights from cryo-EM analysis of PvCPS have revealed conserved residues that guide the formation of the bicyclic labdane core but divergent catalytic dyads that mediate the final deprotonation step of catalysis [35]. This structural information provides critical guidance for protein engineering campaigns aimed at generating diverse bicyclic diterpene scaffolds.

Chemoenzymatic Applications in Natural Product Synthesis

Strategic Integration with Chemical Synthesis

Terpene cyclases serve as powerful tools in chemoenzymatic synthesis by providing complex molecular scaffolds that can be further functionalized through chemical or enzymatic methods. A prominent example is the chemoenzymatic skeletal editing approach, which combines P450-mediated site-selective oxidation with subsequent Baeyer-Villiger rearrangement or ketone homologation to achieve ring expansion at aliphatic C-H sites [4]. This strategy enables the production of skeletally diverse natural product analogs that would be challenging to access through traditional synthetic approaches alone.

The strategic value of terpene cyclases in chemoenzymatic synthesis includes:

• Scaffold Diversification: Generating multiple structurally distinct terpenoid cores from common precursors
• Stereochemical Control: Establishing complex stereocenters with high fidelity
• Late-Stage Functionalization: Providing advanced intermediates for subsequent chemical modification
• Skeletal Editing: Enabling strategic atomic-level modifications to natural product frameworks

Metabolic Engineering for Terpenoid Production

The construction of microbial cell factories for terpenoid production represents a key application of terpene cyclase engineering. Recent work with Pichia pastoris as a host organism has demonstrated the development of a "plug-and-play" cell factory for universal terpenoid production by enhancing expression of the MVA pathway and reducing branch pathway diversion [37]. This platform has successfully produced various terpenoids including β-elemene, β-farnesene, (+)-valencene, and (−)-α-bisabolol.

Metabolomic analysis of engineered strains has revealed that increased key protein copy numbers enhances arginine synthesis and other metabolic pathways, highlighting the complex regulatory networks that constrain rational metabolic engineering and providing important clues for further strain optimization [37].

Figure 2: Experimental Workflow for Developing Terpene Cyclase-Based Production Platforms. This integrated approach combines host engineering, pathway optimization, and product diversification strategies to achieve efficient terpenoid production. [32] [34] [37]

The Scientist's Toolkit: Essential Research Reagents and Materials

Table 3: Essential Research Reagents for Terpene Cyclase Studies

Reagent Category	Specific Examples	Function/Application	Technical Notes
Enzyme Expression Systems	E. coli BL21(DE3), Pichia pastoris, Baculovirus system	Heterologous terpene cyclase production	P. pastoris advantages: eukaryotic processing, high density cultivation
Chromatography Materials	Ni-NTA resin, GST affinity tags, Size exclusion matrices	Protein purification	Include protease inhibitors during purification; test enzymatic activity promptly
Substrates & Cofactors	GPP, FPP, GGPP, MgCl₂, MnCl₂, K⁺ ions	Cyclase activity assays	Commercially available or synthesized enzymatically; stability varies - store at -80°C
Analytical Standards	Authentic terpenoid standards, Deuterated solvents	Product identification and quantification	Critical for GC-MS and NMR comparison; internal standards for quantification
Molecular Biology Reagents	Site-directed mutagenesis kits, Cloning vectors, Sequencing primers	Enzyme engineering and construct generation	Design mutations based on structural data and sequence alignments
Chromatography Standards	Squalene, β-amyrin, Cholesterol, Radiolabeled substrates	Metabolic flux analysis, Pathway tracing	Use [¹⁴C]- or [³H]-labeled for sensitive detection in complex mixtures
N,N-dibutyl-2-chloropyridin-4-amine	N,N-dibutyl-2-chloropyridin-4-amine, CAS:1602008-01-4, MF:C13H21ClN2, MW:240.77 g/mol	Chemical Reagent	Bench Chemicals
1,3,5-Tribromobenzene-d3	1,3,5-Tribromobenzene-d3, MF:C6H3Br3, MW:317.82 g/mol	Chemical Reagent	Bench Chemicals

Future Perspectives and Research Directions

The field of terpene cyclase research continues to evolve rapidly, with several emerging trends shaping future investigations:

• Computational Design and AI Integration: The application of artificial intelligence and machine learning for predicting terpene cyclase functions and engineering novel catalytic activities represents a frontier in the field [32]. These approaches can leverage the growing database of terpene cyclase sequences and structures to identify patterns governing product specificity.

• Substrate Channeling in Bifunctional Enzymes: Recent investigations into bifunctional class II terpene synthases have revealed preferential substrate transit from the prenyltransferase to the cyclase domain, consistent with a model in which transient domain association facilitates substrate channeling due to active-site proximity [35]. Understanding and engineering this substrate channeling could significantly enhance terpenoid production yields.

• CRISPR-Cas9 Mediated Genome Editing: The implementation of advanced genome editing tools in terpenoid-producing hosts enables precise metabolic engineering and pathway optimization [34]. This technology allows for multiplexed gene integration and regulatory element engineering to balance metabolic flux.

• Chemoenzymatic Skeletal Editing: The combination of P450-mediated oxidation with subsequent chemical rearrangement enables strategic skeletal editing of terpenoid natural products [4]. This approach provides powerful tools for fine-tuning the structure and biological activity of organic molecules for drug discovery applications.

As structural biology techniques continue to advance, particularly in cryo-EM methodology, our understanding of terpene cyclase architecture and mechanism will deepen, enabling more sophisticated engineering approaches. The integration of terpene cyclases into broader chemoenzymatic synthesis platforms holds exceptional promise for expanding the chemical space accessible to medicinal chemistry and drug discovery efforts.

The biosynthesis of polyketides and macrolides represents one of nature's most sophisticated feats of synthetic chemistry, performed by enzymatic assembly lines known as polyketide synthases (PKSs). These modular systems catalyze the step-wise condensation of simple carboxylic acid precursors into structurally complex bioactive molecules with impressive pharmacological activities, including antibiotics, anticancer agents, and immunosuppressants [38] [39]. The field of polyketide and macrolide engineering leverages this natural biosynthetic machinery through chemoenzymatic strategies, combining the selectivity of enzymatic catalysis with the versatility of chemical synthesis to generate novel compounds with tailored properties [30] [40]. This approach has emerged as a powerful alternative to total synthesis, overcoming limitations in producing complex natural products and their analogs through traditional chemical methods alone [39]. The modular logic of PKSs, where discrete enzymatic domains correspond to specific chemical transformations, provides a programmable framework for engineering novel biosynthetic pathways [38] [41]. Within the broader context of chemoenzymatic strategies for natural product synthesis, PKS engineering stands out for its potential to access structurally diverse libraries of complex molecules that would be challenging to produce by conventional synthetic organic chemistry.

Architectural Foundations of Modular Polyketide Synthases

Basic Module Organization and Catalytic Domains

Modular type I polyketide synthases are multimodular enzymes in which each module is responsible for one round of polyketide chain elongation and functional group modification [38] [39]. The core catalytic domains present in a typical elongation module include:

• Ketosynthase (KS): Catalyzes decarboxylative Claisen condensation between the growing polyketide chain and an extender unit, forming a new carbon-carbon bond [38] [41].
• Acyltransferase (AT): Selects and loads the appropriate acyl-CoA extender unit (e.g., malonyl-CoA, methylmalonyl-CoA) onto the ACP [38] [41].
• Acyl Carrier Protein (ACP): Carries the growing polyketide chain via a phosphopantetheine prosthetic group, shuttling intermediates between catalytic domains [38].

Additionally, modules may contain varying combinations of processing domains:

• Ketoreductase (KR): Reduces the β-keto group to a hydroxyl group [41].
• Dehydratase (DH): Eliminates water from the β-hydroxy group to form an enoyl group [41].
• Enoylreductase (ER): Reduces the enoyl group to a fully saturated methylene group [41].

The sequential action of modules in the PKS assembly line determines the final structure of the polyketide product, with the colinearity between module order and biochemical transformations enabling predictive biosynthetic engineering [38].

Structural Mechanisms for Vectorial Biosynthesis

A defining feature of assembly-line PKSs is their implementation of vectorial biosynthesis, ensuring that the growing polyketide chain is channeled along a uniquely defined sequence of modules, with each module used only once in the catalytic cycle [38]. This process involves three core reactions within each module's catalytic cycle, as illustrated in Figure 1:

• Transacylation: The AT domain catalyzes a thiol-to-thioester exchange that transfers an extender unit from acyl-CoA to the ACP domain [38].
• Elongation: The KS domain performs the signature decarboxylative Clisen-like condensation that extends the polyketide chain through C–C bond formation – the principal exergonic step in the cycle [38].
• Translocation: Distinct thiol-to-thioester exchanges transfer the growing chain between modules – from the upstream ACP to the current KS (entry translocation), and from the current ACP to the downstream KS (exit translocation) [38].

Figure 1: Catalytic cycle of a prototypical PKS module, illustrating the core reactions of transacylation, elongation, and translocation that enable vectorial biosynthesis.

This vectorial biosynthetic mechanism fundamentally distinguishes assembly-line PKSs from iterative systems like fatty acid synthases, where the same KS-ACP pair is reused through multiple elongation cycles [38]. The structural basis for this directional channeling remains an active area of investigation, with protein-protein interactions and docking domains playing crucial roles in coordinating the sequential handoff of intermediates between modules [38] [41].

Engineering Strategies for Pathway Diversification

Module Boundary Design and Engineering Success Rates

The definition of module boundaries has proven critical for successful PKS engineering. Traditional engineering approaches using the boundary immediately upstream of KS domains often resulted in nonfunctional chimeric synthases [41]. Recent advances implementing an updated module boundary downstream of KS domains have significantly improved success rates, preserving the evolutionary relationship between KS domains and their upstream processing domains [41]. This updated boundary maintains the coordination between KS gatekeeping and the functional groups introduced by processing enzymes, enhancing compatibility between engineered modules [41].

Combinatorial engineering experiments systematically testing this updated boundary reveal both the promise and challenges of modular redesign. A comprehensive study constructing all possible triketide, tetraketide, and pentaketide synthases from the pikromycin PKS demonstrated declining but appreciable success rates with increasing synthase complexity [41]:

Table 1: Success rates for PKS engineering using updated module boundaries

Synthase Type	Number Constructed	Functional Synthases	Success Rate	Principal Impediments
Triketide	5	3	60%	KS gatekeeping
Tetraketide	25	8	32%	KS gatekeeping, module-skipping
Pentaketide	125	8	6.4%	KS gatekeeping, module-skipping

This data highlights KS gatekeeping – where KS domains exhibit selectivity for their natural substrates – and module-skipping – where intermediates bypass intended modules – as the primary obstacles to successful pathway engineering [41]. The higher success rates for shorter synthases suggest that minimizing the number of engineered interfaces improves functional outcomes.

Domain Swapping and Module Exchange

Domain swapping represents a fundamental engineering strategy for altering polyketide structure through the exchange of catalytic domains with different specificities [39]. AT domain swapping has been particularly successful for modifying extender unit incorporation, directly influencing side-chain chemistry at specific positions in the polyketide backbone [39]. Similarly, exchanging reductive loop domains (KR, DH, ER) enables programmed alteration of the β-carbon functional groups [39].

Module exchange, where entire modules are swapped between PKS systems, offers a more comprehensive approach to structural diversification [39]. This strategy benefits from preserving pre-optimized interactions between domains within natural modules while introducing substantial structural variation [39]. Successful implementation often requires careful consideration of docking domains – specialized terminal sequences that mediate interpolypeptide interactions between modules [41]. Engineering orthogonal docking domains, such as those from the spinosyn synthase, can improve proper assembly of hybrid PKS systems [41].

Table 2: Key engineering strategies for PKS pathway diversification

Engineering Strategy	Target	Structural Outcome	Success Factors
AT Domain Swapping	Extender unit specificity	Altered side chains at specific positions	Broad substrate specificity of AT domains
Reductive Loop Engineering	β-carbon functionalization	Modified hydroxyl, enoyl, or methylene groups	Compatibility with ACP domain
Module Exchange	Multiple structural features	Combined alterations from donor module	Updated module boundaries; compatible docking domains
Directed Evolution	Thioesterase domain	Enhanced macrocyclization of unnatural substrates	Screening for improved total turnover numbers [42]

Figure 2 illustrates a generalized workflow for combinatorial PKS engineering, incorporating modern design principles such as the updated module boundary and orthogonal docking domains:

Figure 2: Workflow for combinatorial PKS engineering using a BioBricks-like assembly approach with updated module boundaries.

Experimental Methodologies and Protocols

Combinatorial PKS Assembly and Screening

The construction of hybrid PKS pathways employs modular DNA assembly techniques inspired by synthetic biology. A BioBricks-like platform enables the sequential ligation of DNA fragments encoding updated PKS modules between the first and last modules of a parent pathway (e.g., pikromycin P1 and P7 modules) [41]. Key methodological considerations include:

• Vector Design: Cloning plasmids contain synthetic DNA encoding T7 promoter/terminator sequences, lac operators, ribosomal binding sites, and orthogonal docking domains from heterologous PKS systems (e.g., spinosyn SpnB/SpnC, SpnC/SpnD, SpnD/SpnE) [41].
• Module Engineering: DNA encoding individual modules is PCR-amplified and inserted between restriction sites (e.g., SpeI/BmtI for N-terminal portions, MfeI/XbaI for C-terminal portions) that preserve conserved residues at junction points [41].
• Host System: Engineered E. coli strains (e.g., K207-3) metabolically optimized for PKS polypeptide activation and methylmalonyl-CoA extender unit supply serve as heterologous expression hosts [41].
• Product Analysis: Culture extracts are analyzed by high-resolution LC/MS, with anticipated products identified through exact mass determination (±5 ppm) and MS/MS fragmentation patterns compared to authentic standards [41].

This platform has been successfully applied to construct 5 triketide, 25 tetraketide, and 125 pentaketide synthases, enabling systematic evaluation of engineering principles [41].

Directed Evolution of Thioesterase Domains for Macrocyclization

Thioesterase (TE) domains function as critical gatekeepers in PKS pathways, catalyzing the release and macrocyclization of full-length polyketide chains [42]. Directed evolution campaigns can enhance TE activity toward unnatural substrates, overcoming natural substrate specificity limitations:

• Library Generation: Create mutant TE libraries through site-saturation mutagenesis targeting residues proximal and distal to the active site [42]. The parent construct is typically a PikAIII-TE fusion protein containing an initial beneficial mutation (e.g., S148C) [42].
• Screening Methodology: Employ high-throughput mass spectrometry to identify variants with enhanced macrocyclization activity toward unnatural substrates (e.g., amide hexaketide 1) [42]. Primary screening assesses conversion rates, followed by secondary screening measuring total turnover numbers (TTNs) and initial reaction rates [42].
• Evaluation Metrics: Isolated yield of macrocycle product provides the key metric for evolutionary progress. Beneficial mutations from sequential rounds are combined into composite variants [42].
• Structural Analysis: Characterized beneficial mutations (e.g., L3F, F14L, A129G) often map to regions affecting substrate binding pocket flexibility rather than direct active site contacts, suggesting allosteric mechanisms for enhanced substrate accommodation [42].

This approach has yielded TE variants with 6-fold improved isolated yields of hybrid macrolactone/lactam products compared to parent enzymes, significantly expanding the scope of accessible polyketide architectures [42].

The Scientist's Toolkit: Essential Research Reagents

Successful implementation of polyketide and macrolide engineering requires specialized genetic tools, enzymatic components, and analytical resources. The following table catalogues essential research reagents referenced in recent studies:

Table 3: Key research reagents for polyketide and macrolide engineering

Reagent / Tool	Type	Function in Engineering	Example Application
Pikromycin PKS Modules	Genetic Parts	Source of well-characterized domains for engineering	Combinatorial pathway construction [41]
Spinosyn Docking Domains	Protein Interaction Motifs	Mediate orthogonal interpolypeptide interactions	Chimeric PKS assembly [41]
E. coli K207-3	Engineered Host	Heterologous expression with native PKS activation and extender unit supply	Metabolic engineering of polyketide production [41]
Pik TE S148C Mutant	Engineered Enzyme	Initial template for directed evolution	Macrocyclization of unnatural amide-containing substrates [42]
Malonyl/Acetyl-transferase (MAT) Domain	Promiscuous Enzyme	Regioselective modification of polyketide scaffolds	Reprogramming substituents via domain swapping [40]
FtmOx1	Biocatalyst	Enzymatic C-H peroxidation	Chemoenzymatic synthesis of endoperoxide natural products [43]
squarunkin A	squarunkin A, MF:C25H32F3N5O4, MW:523.5 g/mol	Chemical Reagent	Bench Chemicals
SI-2 hydrochloride	SI-2 hydrochloride, MF:C15H16ClN5, MW:301.77 g/mol	Chemical Reagent	Bench Chemicals

The engineering of modular polyketide synthases for macrolide synthesis represents a maturing frontier in chemoenzymatic natural product synthesis. While substantial progress has been made in understanding PKS architecture and developing engineering strategies, significant challenges remain in achieving predictable control over polyketide structure. The field continues to grapple with KS gatekeeping, module-skipping, and incompatible domain-domain interactions that limit the success rates of engineered pathways, particularly as the complexity of synthetic systems increases [41]. Future advances will likely depend on deeper structural insights into the molecular mechanisms of intermodular communication and intermediate channeling along the assembly line [38].

Integration of computational design and machine learning approaches with experimental screening holds particular promise for navigating the vast sequence-function landscape of PKS engineering [40]. Similarly, the application of directed evolution to overcome bottlenecks in downstream processing, such as TE-mediated macrocyclization of unnatural substrates, demonstrates how traditional enzyme engineering approaches can expand the boundaries of chemoenzymatic synthesis [42]. As these tools mature, the vision of programmable biosynthesis for generating diverse polyketide libraries with tailored pharmacological properties moves closer to realization, offering powerful new avenues for drug discovery and development in the context of natural product-based therapeutics.

The synthesis of alkaloids, a large class of nitrogen-containing natural products with profound pharmacological activities, presents a continuous challenge in organic chemistry. Traditional chemical synthesis often relies on harsh conditions, expensive catalysts, and complex protection-deprotection strategies. Within the context of chemoenzymatic strategies for natural product synthesis, two enzyme classes have emerged as powerful tools for constructing the core scaffolds of these molecules: Pictet-Spenglerases and Imine Reductases [9] [44]. These biocatalysts facilitate key bond-forming reactions with exceptional stereoselectivity under mild, environmentally benign conditions, aligning with the principles of green chemistry and sustainable pharmaceutical development [9]. This whitepaper provides an in-depth technical examination of these enzymes, detailing their mechanisms, experimental applications, and implementation protocols for researchers and drug development professionals.

Pictet-Spenglerases: Enzymatic Catalysts for C-C Bond Formation

Pictet-Spenglerases (P-Sases) catalyze the stereoselective condensation between a β-arylethylamine and a carbonyl compound to form tetrahydroisoquinoline (THIQ) or tetrahydro-β-carboline (THBC) scaffolds, which are privileged structures in numerous alkaloids and pharmaceuticals [45] [44]. The classical chemical Pictet-Spengler reaction requires acidic conditions and often results in racemic mixtures, whereas enzymatic versions achieve high stereocontrol [45].

Mechanism and Key Enzymes

The enzymatic reaction proceeds through an imine intermediate formed from the amine and carbonyl, followed by an electrophilic aromatic substitution cyclization. A key enzyme in this class is norcoclaurine synthase (NCS) from Thalictrum flavum (TfNCS), which catalyzes the stereoselective Pictet-Spengler reaction of dopamine with chiral aldehydes [9]. Quantum chemical calculations have elucidated the mechanism of TfNCS, revealing the rate-limiting step and key residues responsible for its high stereospecificity [9]. The enzyme activates the reaction through an enzyme-bound iminium ion and stabilizes the transition state, enabling precise stereochemical outcomes that are difficult to achieve with chemical catalysts.

Experimental Protocol: Biocatalytic Pictet-Spengler Cyclization

Objective: To synthesize (S)-norcoclaurine from dopamine and 4-hydroxyphenylacetaldehyde using TfNCS [9].

• Reaction Setup:
  • Prepare a 50 mL reaction mixture containing 50 mM potassium phosphate buffer (pH 7.0).
  • Add 10 mM dopamine hydrochloride and 12 mM 4-hydroxyphenylacetaldehyde.
  • Initiate the reaction by adding 0.1 mg/mL of purified TfNCS.
• Reaction Conditions:
  • Incubate at 30°C with gentle shaking (150 rpm) for 4-6 hours.
  • Monitor reaction completion by HPLC or LC-MS.
• Work-up and Isolation:
  • Terminate the reaction by adding 1 mL of 1 M HCl.
  • Extract the product with ethyl acetate (3 x 50 mL).
  • Combine organic layers, dry over anhydrous sodium sulfate, and concentrate under reduced pressure.
  • Purify the crude product by flash chromatography (silica gel, dichloromethane/methanol gradient) to obtain (S)-norcoclaurine.
• Analysis:
  • Determine enantiomeric excess by chiral HPLC (Chiralpak AD-H column, n-hexane/isopropanol/diethylamine as mobile phase).
  • Confirm structure by (^1)H NMR, (^{13})C NMR, and high-resolution mass spectrometry.

Table 1: Performance Metrics of Engineered Pictet-Spenglerases

Enzyme Source/Variant	Reaction	Key Mutations	Conversion (%)	Stereoselectivity (ee/de%)
Wild-type TfNCS [9]	Dopamine + aldehyde	N/A	>90 (model)	>99% ee (model)
Engineered ThAOS [9] [46]	C-C bond formation with expanded substrates	Structure-guided	High (Qualitative)	High (Qualitative)

Diagram 1: Catalytic Mechanism of Norcoclaurine Synthase (NCS). The enzyme (TfNCS) binds the imine intermediate to form an enzyme-stabilized iminium ion, facilitating the stereoselective cyclization via a rate-limiting transition state to yield the enantiopure tetrahydroisoquinoline product.

Imine Reductases: Precision Catalysts for Chiral Amine Synthesis

Imine Reductases (IREDs) catalyze the NADPH-dependent reduction of imine bonds to form chiral amines, which are pivotal structural elements in over 40% of pharmaceutical agents [9]. These biocatalysts offer a sustainable alternative to metal-catalyzed asymmetric reductive amination, operating under mild conditions with exceptional stereoselectivity.

Mechanism and Enzyme Engineering

IREDs typically function via a ping-pong bi-bi mechanism, where NADPH cofactor binds first, followed by the imine substrate. The hydride from NADPH is transferred to the imine carbon, resulting in the formation of a chiral amine product. A key challenge has been the limited substrate scope of native IREDs, particularly for bulky amine substrates [9]. To address this, advanced screening methods like Increasing-Molecule-Volume Screening have been developed to identify IRED variants with expanded active sites. For instance, the identified IR-G02 IRED exhibits a broad substrate range and has been utilized to synthesize over 135 secondary and tertiary amines [9].

Experimental Protocol: IRED-Catalyzed Synthesis of an API Intermediate

Objective: Gram-scale kinetic resolution synthesis of a Cinacalcet analogue using an imine reductase [9].

• Reaction Setup:
  • Prepare a 100 mL reaction mixture in 100 mM Tris-HCl buffer (pH 7.0).
  • Add 20 mM racemic amine substrate and 100 mM sodium formate.
  • Add 1 mM NADP+ as cofactor.
  • Add 5 mg/mL of purified IR-G02 IRED and 1 U/mL formate dehydrogenase (FDH) for cofactor regeneration.
• Reaction Conditions:
  • Incubate at 30°C with orbital shaking at 200 rpm for 24 hours.
  • Maintain pH at 7.0 using an automated pH controller.
• Work-up and Isolation:
  • Quench the reaction by adding 5 M NaOH until pH >10 is reached.
  • Extract the product with tert-butyl methyl ether (3 x 100 mL).
  • Dry the combined organic layers over anhydrous MgSO4 and concentrate in vacuo.
  • Purify the residue by preparative HPLC to obtain the desired enantiomer.
• Analysis:
  • Determine conversion and enantiomeric excess by chiral HPLC.
  • Typical performance: >99% ee at 48% conversion (kinetic resolution).

Table 2: Performance Metrics of Engineered Imine Reductases (IREDs)

Enzyme / ID	Substrate Scope	Engineering Strategy	Conversion / Yield	Stereoselectivity	Application
IR-G02 IRED [9]	>135 secondary/tertiary amines	Increasing-Molecule-Volume Screening	48% (Gram-Scale)	>99% ee	Cinacalcet analog
Engineved KRed [9] [46]	Ipatasertib ketone precursor	Mutational scanning & ML	≥98% Conv.	99.7% de (R,R-trans)	Ipatasertib (API)

Integrated Chemoenzymatic Cascades in Alkaloid Synthesis

The combination of Pictet-Spenglerases and Imine Reductases in multi-enzymatic cascades represents the cutting edge of chemoenzymatic synthesis, enabling the construction of complex alkaloids from simple precursors in a single reaction vessel [9] [47]. This approach minimizes intermediate isolation, reduces waste, and improves overall atom economy.

Experimental Protocol: One-Pot Cascade for Tetrahydro-β-Carboline Synthesis

Objective: One-pot synthesis of a chiral tetrahydro-β-carboline from tryptamine and an aldehyde using a Pictet-Spenglerase/IRED cascade.

• Reaction Setup:
  • Prepare a 50 mL mixture in 100 mM phosphate buffer (pH 7.5).
  • Add 10 mM tryptamine, 15 mM aldehyde, and 100 mM sodium formate.
  • Add 0.05 mg/mL of a suitable Pictet-Spenglerase.
  • Add 0.1 mg/mL of an IRED and 1 U/mL FDH.
  • Include 0.5 mM NADP+ as cofactor.
• Reaction Conditions:
  • Incubate at 30°C for 12-16 hours with shaking.
• Monitoring and Isolation:
  • Monitor reaction progress by TLC or LC-MS.
  • Quench with saturated NaHCO3 solution and extract with ethyl acetate.
  • Purify the product via flash chromatography.

Diagram 2: One-Pot Chemoenzymatic Cascade. The pathway integrates a Pictet-Spenglerase for cyclization and an Imine Reductase (IRED) for chiral amine formation, with *in situ cofactor regeneration by Formate Dehydrogenase (FDH).*

The Scientist's Toolkit: Essential Reagents and Materials

Successful implementation of biocatalytic strategies requires specific reagents and materials. The following table details key components for setting up reactions with Pictet-Spenglerases and Imine Reductases.

Table 3: Research Reagent Solutions for Biocatalytic Alkaloid Synthesis

Reagent / Material	Specifications / Example Sources	Function in Experimental Setup
Imine Reductases (IREDs)	IR-G02 variant (specific toward bulky amines) [9]; Commercially available IREDs (e.g., from Codexis)	Catalyzes the NADPH-dependent, stereoselective reduction of cyclic imines to chiral amines.
Pictet-Spenglerases	Norcoclaurine Synthase (TfNCS) [9]; Recombinant enzymes expressed in E. coli.	Catalyzes the stereoselective C-C bond formation between β-arylethylamines and aldehydes.
Nicotinamide Cofactors	NADP+, sodium salt, ≥95% (HPLC); NADPH, tetrasodium salt, ≥97% (HPLC)	Essential redox cofactor for IREDs; NADP+ is used in reaction schemes with a regeneration system.
Cofactor Regeneration System	Formate Dehydrogenase (FDH) from C. boidinii; Sodium Formate	Regenerates NADPH from NADP+ using formate as a cheap, clean sacrificial substrate, driving reaction to completion.
Engineered Ketoreductase (KRed)	Engineved variant from S. salmonicolor (10 mutations) [9] [46]	Reduces ketone precursor in chemoenzymatic API synthesis (e.g., for Ipatasertib) with high diastereoselectivity.
Reaction Buffers	Potassium Phosphate (50-100 mM, pH 7.0-7.5); Tris-HCl Buffer (50-100 mM, pH 7.0-8.0)	Provides optimal pH environment and ionic strength for maintaining enzyme stability and activity.
CB2R-IN-1	CB2R-IN-1, MF:C23H27F3N4O6S3, MW:608.7 g/mol	Chemical Reagent
GENZ-882706	GENZ-882706, MF:C26H25N5O3, MW:455.5 g/mol	Chemical Reagent

Pictet-Spenglerases and Imine Reductases have revolutionized the approach to alkaloid synthesis, enabling efficient, stereocontrolled construction of complex molecular architectures under sustainable conditions. The integration of these biocatalysts into cascades, combined with advanced enzyme engineering and computational design, represents a paradigm shift in natural product synthesis and pharmaceutical development. As protein engineering and bioinformatics continue to advance, the scope and efficiency of these enzymes will expand further, solidifying their role as indispensable tools in the synthetic chemist's repertoire.

Non-ribosomal peptide synthetases (NRPSs) are multi-modular enzymatic assembly lines responsible for the production of a vast array of complex peptide natural products in bacteria, fungi, and other organisms [48] [49]. Unlike ribosomally synthesized peptides, NRPSs operate independently of messenger RNA, enabling the incorporation of a diverse range of over 500 different monomeric building blocks, including D-amino acids, fatty acids, hydroxy acids, and N-methylated amino acids [49]. This structural diversity results in peptides with an extremely broad spectrum of biological activities and pharmacological properties, making them invaluable as toxins, siderophores, pigments, antibiotics, cytostatics, and immunosuppressants [49]. The architectural logic of NRPSs follows an assembly-line biosynthesis, where each module is responsible for the incorporation of one monomeric building block into the growing peptide chain [48]. A minimal elongation module consists of three core domains: an adenylation (A) domain for substrate selection and activation, a peptidyl carrier protein (PCP) domain for substrate shuttling, and a condensation (C) domain for peptide bond formation [48] [50]. Understanding the structure, function, and mechanistic details of these enzymatic assembly lines provides the foundation for harnessing their biosynthetic potential through chemoenzymatic strategies.

NRPS Domain Architecture and Catalytic Mechanisms

Core Domains and Their Functions

The biosynthesis of non-ribosomal peptides is orchestrated by the coordinated activity of multiple catalytic domains organized into modules. The order and specificity of these domains determine the sequence and structure of the final peptide product.

Table 1: Core Catalytic Domains in Non-Ribosomal Peptide Synthetases

Domain	Abbreviation	Core Function	Essential Features
Adenylation	A	Selects and activates amino acid substrates using ATP	Contains 10 conserved sequences (A1-A10); determines substrate specificity
Peptidyl Carrier Protein	PCP	Shuttles substrates and intermediates between catalytic domains	Contains conserved serine for 4'-phosphopantetheine attachment
Condensation	C	Catalyzes peptide bond formation between donor and acceptor substrates	Contains conserved HHxxxDG catalytic motif
Thioesterase	TE	Releases full-length peptide from NRPS assembly line; often catalyzes cyclization	α/β-hydrolase fold; catalyzes hydrolysis or macrocyclization

The initiation of non-ribosomal peptide synthesis begins with the starting module, which typically contains an adenylation (A) domain, a peptidyl carrier protein (PCP) domain, and optionally, formylation (F) or N-methylation (NMT) domains [49]. Subsequent elongation modules incorporate additional residues into the growing peptide chain, with each elongation cycle consisting of substrate loading, condensation, and optional modification steps such as epimerization (E) [49]. The process concludes in the termination module, where a thioesterase (TE) or reductase (R) domain catalyzes the release of the completed peptide, often with concurrent macrocyclization or reduction to aldehydes or alcohols [48] [49].

Figure 1: NRPS Assembly Line Architecture showing the coordinated function of catalytic domains across initiation, elongation, and termination modules in non-ribosomal peptide synthesis.

Structural Basis of Substrate Selection and Activation

The adenylation domain serves as the gateway for substrate entry into the NRPS pathway. These approximately 500-residue domains belong to the adenylate-forming enzyme superfamily, which also includes acyl-CoA synthetases and firefly luciferase [48]. NRPS adenylation domains employ a Bi Uni Uni Bi ping-pong mechanism involving two half-reactions [48]. In the first step, the A domain recognizes its cognate amino acid and activates it with ATP to form an aminoacyl-adenylate intermediate, releasing inorganic pyrophosphate. A significant conformational change then occurs through a domain alternation strategy, where the C-terminal subdomain rotates approximately 140° to reorganize the active site for the second half-reaction [48]. This transition repositions the aminoacyl-adenylate to enable nucleophilic attack by the thiol of the 4'-phosphopantetheine (PPant) cofactor of the adjacent PCP domain, resulting in a covalent aminoacyl-thioester [48].

Structural studies of adenylation domains, beginning with PheA from gramicidin synthetase, have revealed the molecular basis of substrate specificity [48]. The active site contains key consensus sequences designated A1 through A10 that impart both structural and substrate-stabilizing roles [48]. The A domain primarily determines which amino acid is incorporated at each position, with approximately 10 signature residues controlling substrate specificity [49]. This understanding has enabled computational redesign of A-domain specificity, expanding the toolbox for NRPS engineering [49].

The peptidyl carrier protein domain serves as the mobile arm that shuttles substrates and intermediates between catalytic sites. These small domains (70-90 amino acids) adopt a characteristic four-α-helical bundle fold [48]. A conserved serine residue located at the start of helix α2 serves as the attachment site for the 4'-phosphopantetheine cofactor, which is derived from coenzyme A and installed by phosphopantetheinyl transferases (PPTases) [48]. This post-translational modification converts the inactive "apo" form to the active "holo" state, enabling covalent substrate binding via a thioester linkage [48]. NMR studies have revealed that PCP domains exhibit significant conformational dynamics, sampling multiple states that facilitate interactions with different catalytic partners [48].

Peptide Bond Formation by Condensation Domains

Condensation domains catalyze the central chemical reaction of NRPSs: peptide bond formation. These domains typically accept two PCP-bound substrates and catalyze nucleophilic attack of the α-amino group from the downstream "acceptor" aminoacyl-PCP on the upstream "donor" peptidyl-PCP thioester [50]. Crystal structures of C domains, beginning with VibH from the vibriobactin system, revealed that they comprise a pseudo-dimer of the chloramphenicol acetyl transferase (CAT) fold, with key catalytic residues forming a conserved HHxxxDG motif located at the interface between the two subdomains [50].

Recent structural insights into C domain function have come from the 2.2 Ã… resolution structure of the PCP2-C3 didomain from the fuscachelin NRPS of Thermobifida fusca (PDB ID: 7KVW) [50]. This structure captures a catalytic snapshot of a C domain in complex with an aminoacyl-PCP acceptor substrate, revealing that the interface between the PCP and C domains is dominated by hydrophobic interactions involving residues V2534, L2515, L2518, F2508, and F2538 of the PCP domain and A2907, V2908, V2584, L2580, and W2579 of the C domain [50]. The structure also identified an arginine gating mechanism (R2906) that controls access of acceptor substrates to the active site, preventing unloaded PCP domains from entering [50]. Contrary to earlier hypotheses, C domains do not appear to contain a distinct "A domain-like" side chain selectivity pocket; instead, residues within the active site motif serve to tune acceptor substrate selectivity [50].

Cyclization and Termination Strategies

Thioesterase-Domain Catalyzed Macrocyclization

The termination of non-ribosomal peptide synthesis is typically catalyzed by thioesterase domains, which release the full-length peptide from the NRPS assembly line. Most TEs belong to the α/β-hydrolase fold family and employ a classic catalytic triad (Ser-His-Asp) to catalyze substrate hydrolysis or macrocyclization [48]. In the cyclization mechanism, the active site serine attacks the thioester linkage between the completed peptide and the final PCP domain, forming an acyl-enzyme intermediate [11]. This intermediate is then nucleophilically attacked by an internal functional group within the peptide substrate (e.g., hydroxyl, amine, or thiol side chain), resulting in macrocyclic product formation [11].

Structural studies of thioesterase domains, including the SrfA-C thioesterase from surfactin biosynthesis (PDB ID: 1JMK) and the fengycin biosynthesis thioesterase (PDB ID: 2CB9), have provided insights into the cyclization machinery [48]. These structures reveal a canonical α/β-hydrolase fold with a capacious substrate-binding pocket that accommodates the peptidyl substrate and positions the nucleophile for intramolecular attack [48]. The TE domain's ability to control cyclization regio- and stereoselectivity makes it particularly valuable for chemoenzymatic applications.

Emerging Classes of Non-Ribosomal Peptide Cyclases

Beyond canonical thioesterases, recent research has identified additional enzyme families capable of catalyzing peptide cyclization. Penicillin-binding protein-type thioesterases represent an emerging class of NRPS cyclases with significant biocatalytic potential [51]. Unlike classical α/β-hydrolase TEs, PBP-type TEs exhibit broad substrate tolerance for both sequence and length, making them particularly attractive for synthetic applications [11] [51]. The most notable representative is SurE, a macrocyclase from surugamide biosynthesis that demonstrates remarkable promiscuity toward non-native substrates [11].

Another important cyclase is TycC thioesterase, which catalyzes head-to-tail cyclization of the decapeptide precursor in tyrocidine biosynthesis [11]. TycC-TE has been shown to tolerate substantial substrate variations, including diverse sequences and lengths, making it a valuable tool for chemoenzymatic synthesis [11]. The structural basis for this promiscuity likely stems from conformational flexibility in the substrate-binding pockets of these cyclases, allowing accommodation of non-native substrates.

Table 2: Major Classes of Non-Ribosomal Peptide Cyclases

Cyclase Class	Representative Examples	Catalytic Mechanism	Structural Features	Applications
Type I Thioesterases (α/β-hydrolase)	SrfA-C TE, TycC TE	Ser-His-Asp catalytic triad; acyl-enzyme intermediate	Canonical α/β-hydrolase fold; capacious substrate pocket	Macrocyclization of linear peptidyl substrates; often shows strict regioselectivity
Penicillin-Binding Protein-type TEs	SurE, WolJ	Nucleophile-assisted catalysis; likely involves tyrosine residue	PBP fold distinct from α/β-hydrolases; more open active site	Broad substrate tolerance; synthesis of diverse macrocyclic scaffolds
Reductase Domains	RNRP, AusA	NADPH-dependent reduction to aldehydes or alcohols	Rossmann fold for NADPH binding; reductive release	Production of linear peptides with C-terminal modified ends

Chemoenzymatic Synthesis of Lariat Lipopeptides

Recent advances have demonstrated the repurposing of NRPS cyclases for the synthesis of structurally complex lariat lipopeptides—important antimicrobial agents characterized by a carboxy-terminal macrocyclic "head" group and a long acyl chain appended to an amino-terminal "tail" [11]. The conventional chemical synthesis of these architectures faces significant challenges, including the need for orthogonal protecting groups and dilute conditions to suppress intermolecular coupling [11].

A breakthrough chemoenzymatic approach has enabled efficient access to lariat-shaped macrocycles using versatile NRP cyclases [11]. This strategy involves engineering branched peptide substrates containing multiple nucleophiles, including a native amino terminus and a pseudo-amino terminus, which are then site-selectively cyclized using NRPS cyclases [11]. Key to this approach was the discovery that PBP-type TEs like SurE exhibit relaxed specificity toward the N-terminal nucleophile but strictly recognize its stereochemical configuration, accepting only L-configured residues as nucleophiles [11].

In a representative experiment, researchers designed a branched octapeptide substrate based on the surugamide B sequence but incorporating an internal dipeptide unit as a 'pseudo-N terminus,' where L-Ile was attached to the side chain of L-Lys via an isopeptide bond [11]. When incubated with SurE, this substrate was converted into both canonical head-to-tail cyclic peptides and lariat-shaped cyclic peptides in comparable amounts (60% and 40%, respectively) [11]. By replacing the native N-terminal L-Ile with D-Val to suppress head-to-tail cyclization, the researchers achieved quantitative formation of the lariat-shaped cyclic peptide through exclusive cyclization via the pseudo-N-terminal L-Ile [11].

Figure 2: Chemoenzymatic Strategy for Lariat Peptide Synthesis using engineered substrates and NRPS cyclases to achieve regioselective macrocyclization.

Experimental Approaches for NRPS Structural and Mechanistic Studies

Structural Biology Techniques

Elucidating the three-dimensional architecture of NRPS enzymes has been crucial for understanding their catalytic mechanisms and conformational dynamics. X-ray crystallography has provided the majority of high-resolution structural information, with landmark structures including the SrfA-C termination module (Cond-Aden-PCP-TE) at 3.0 Ã… resolution (PDB ID: 2VSQ) and the EntF (PCP-TE) didomain [48]. These structures have revealed the spatial organization of catalytic domains and identified key interfacial regions that mediate domain-domain communication.

More recently, the structure of the PCP2-C3 didomain from the fuscachelin NRPS was solved at 2.2 Ã… resolution using single-wavelength anomalous dispersion (SAD) with xenon-derivatized crystals [50]. This structure provided unprecedented insights into acceptor substrate binding and the gating mechanism that controls access to the C domain active site [50]. Technical challenges in NRPS structural biology include the inherent flexibility of these multi-domain proteins and the dynamic nature of carrier domain interactions with catalytic partners.

Mechanism-Based Inhibitors and Trapped Intermediates

A powerful strategy for capturing transient NRPS complexes involves the use of mechanism-based inhibitors that trap interactions between catalytic and carrier protein domains [48]. For example, the structures of EntE-B (Aden-PCP) and PA1221 (Aden-PCP) complexes were determined using covalent inhibitors that mimic the aminoacyl-adenylate transition state, stabilizing normally transient domain interactions [48]. These approaches have been particularly valuable for visualizing the structural rearrangements that occur during the domain alternation of adenylation domains and the PCP docking interactions with partner domains.

Cross-linking strategies have also been employed to stabilize dynamic complexes for structural studies. By introducing covalent links between interacting domains, researchers have been able to capture meta-stable states along the catalytic pathway that would otherwise be too transient for conventional structural biology approaches [50].

Molecular Dynamics Simulations

Computational approaches, particularly molecular dynamics simulations, have provided complementary insights into NRPS function that extend beyond static crystal structures. MD simulations have been used to study the conformational landscape of carrier domains, the dynamics of domain alternation in adenylation domains, and the structural basis of substrate specificity in condensation domains [11].

In studies of SurE-catalyzed lariat peptide formation, MD simulations of covalent docking models revealed that L-configured nucleophiles are retained in the nucleophile binding site during 50 ns simulations, with an average distance of 4.5 Ã… between the nucleophilic amine and the electrophilic carbonyl carbon [11]. In contrast, D-configured nucleophiles exhibited greater positional variability and larger distances to the reaction center (>10 Ã…), explaining the observed stereospecificity of PBP-type TEs [11].

Research Reagent Solutions for NRPS Studies

Table 3: Essential Research Reagents for Non-Ribosomal Peptide Synthetase Investigations

Reagent/Category	Specific Examples	Function/Application	Technical Notes
Stable Acyl-CoA Analogues	Aminoacyl-/peptidyl-CoA	Mimic PCP-bound substrates for structural and kinetic studies	Bypass need for active holo-PCP; enable precise biochemical characterization
Mechanism-Based Inhibitors	Aminoacyl-sulfamoyl adenylates	Trap A-PCP domain interactions for structural studies	Covalently stabilize transient complexes; enable crystallization
Phosphopantetheinyl Transferases	Sfp from B. subtilis	Convert apo-PCP to holo-PCP for functional assays	Essential for in vitro reconstitution of NRPS activity; broad substrate specificity
Carrier Protein Domains	TycC PCP (PDB: 1DNY), BlmI (PDB: 4I4D)	Study PCP-catalytic domain interactions	NMR and crystallography studies reveal conformational dynamics
Crystallization Tags	Fusion proteins (MBP, GST)	Improve crystallization of individual domains	Enhance solubility and crystal contacts; particularly useful for PCP domains
Non-hydrolyzable Substrate Analogues	Aminophosphonate phosphonamidates	Probe condensation domain mechanism	Mimic tetrahedral intermediate in peptide bond formation
Thioesterase Substrates	PEG-functionalized peptides	Chemoenzymatic synthesis of macrocyclic peptides	Simplify substrate synthesis; enable high-yield cyclization

Non-ribosomal peptide synthetases and cyclases represent nature's sophisticated solution to complex peptide synthesis, employing an assembly-line logic that continues to inspire chemoenzymatic strategies for natural product synthesis. The structural insights gained from NRPS domains and multi-domain complexes have illuminated the molecular mechanisms underlying substrate selection, peptide bond formation, and product release [48] [50]. Meanwhile, the discovery and characterization of diverse peptide cyclases, including classical thioesterases and emerging PBP-type TEs, have expanded the toolbox for chemoenzymatic synthesis of complex peptide architectures [11] [51].

The strategic repurposing of NRPS cyclases for the synthesis of challenging molecular scaffolds, such as lariat lipopeptides, demonstrates the power of combining chemical synthesis with enzymatic catalysis [11]. This approach leverages the promiscuity and regio- and stereoselectivity of natural cyclases while avoiding the synthetic challenges associated with conventional macrocyclization methods. Future directions in this field will likely focus on expanding the repertoire of biocatalysts through genome mining, optimizing enzyme properties through engineering, and developing integrated platforms that combine synthetic chemistry with enzymatic transformations.

As structural characterization techniques continue to advance, providing ever more detailed snapshots of these dynamic molecular machines, our ability to understand, predict, and engineer NRPS function will correspondingly improve. This synergistic integration of structural biology, mechanism-based inhibitor studies, computational simulations, and chemoenzymatic synthesis promises to unlock new opportunities for accessing diverse peptide natural products and their analogs through efficient, sustainable synthetic strategies.

The integration of radical-based transformations with enzymatic catalysis represents a paradigm shift in synthetic organic chemistry, enabling previously inaccessible disconnections and streamlining the synthesis of complex molecules. This chemoenzymatic approach harnesses the unparalleled selectivity and mild reaction conditions of biocatalysts alongside the unique reactivity and functional group tolerance of single-electron processes. Within the broader context of chemoenzymatic strategies for natural product synthesis, this hybrid methodology has demonstrated particular efficacy for constructing stereochemically dense and highly oxidized terpenoids, alkaloids, and other pharmaceutically relevant scaffolds. This technical guide examines the fundamental principles, methodological frameworks, and practical implementation of radical-chemoenzymatic cascades, providing researchers with comprehensive experimental protocols and critical analytical tools for deploying these strategies in drug development and natural product research.

Retrosynthetic strategy is inherently constrained by the transformations available at the time of its conception. The recent emergence of new technologies in both radical chemistry and biocatalysis has created opportunities for unconventional disconnections that were previously inconceivable [52]. Radical-based retrosynthetic disconnections have gained significant traction due to the unique chemoselectivity and functional group compatibility of radical species, while biocatalytic retrosynthesis has flourished through the exceptional selectivity of enzymatic transformations and advances in protein engineering [52] [18]. Despite their individual advantages, these approaches have largely evolved independently until recently.

The strategic merger of these domains represents a powerful frontier in synthetic chemistry, particularly for the synthesis of complex natural products with therapeutic potential. This hybrid approach leverages the one-electron logic of radical chemistry to complement traditional polar disconnections, while simultaneously harnessing the region- and stereoselectivity of enzymatic catalysis [53]. The efficiency gains are particularly evident in the synthesis of oxidized meroterpenoids, where researchers have developed routes of 7-12 steps from commercial materials to access eight distinct natural products from two common molecular scaffolds [52].

This technical guide examines the foundational principles and practical implementation of integrated radical-chemoenzymatic strategies, with a specific focus on their application within natural product synthesis research. By providing detailed experimental frameworks and analytical tools, this work aims to equip researchers with the methodologies necessary to advance drug development through more efficient and sustainable synthetic paradigms.

Conceptual Foundations and Strategic Approaches

The integration of radical and biocatalytic logic in synthetic chemistry enables two primary strategic approaches, each with distinct advantages and implementation considerations.

Classification of Integrated Strategies

• Enzymatic Cyclization Followed by Radical Functionalization: This approach utilizes terpene cyclases to construct complex carbocyclic skeletons from linear precursors in a single step, capitalizing on the enzymatic machinery evolved for this specific purpose. The cyclized products then serve as platforms for radical-based functionalization, including C-H functionalization, cross-coupling, and fragment assembly [18]. This strategy is particularly valuable for accessing terpenoid architectures that would require numerous steps using traditional synthetic approaches alone.

• Radical-Based Skeleton Assembly with Enzymatic Tailoring: This alternative methodology employs radical-based C-C bond formations to generate core structural frameworks, which are subsequently functionalized through enzymatic transformations, particularly oxidations, to install requisite functional groups with precise stereocontrol [18]. The radical steps often leverage modern activation modes including photoredox catalysis, electrochemical methods, and metal-catalyzed hydrogen atom transfer processes.

Synergistic Advantages in Natural Product Synthesis

The combination of radical and biocatalytic strategies addresses fundamental challenges in natural product synthesis. Enzymatic transformations provide unparalleled regio- and stereoselectivity for C-H functionalization and other challenging transformations under mild conditions, while radical chemistry offers complementary bond-forming capabilities with exceptional functional group tolerance [52] [18]. This synergy is particularly evident in the synthesis of highly oxidized terpenoids, where traditional chemical methods often struggle with selective oxidation at non-activated positions.

The merger of these approaches also enables novel cascade processes that improve synthetic efficiency. By combining multiple catalytic cycles in a single reaction vessel, chemoenzymatic cascades minimize intermediate isolation, reduce operating time and cost, decrease waste generation, and mitigate issues associated with handling unstable intermediates [54]. Furthermore, the synergistic combination of multiple catalysts can produce unique reactivities and improved outcomes unattainable through sequential application of individual catalysts.

Experimental Methodologies and Protocols

This section provides detailed experimental procedures for implementing key radical-chemoenzymatic transformations, with a focus on practical considerations and technical optimization.

Biocatalytic Hydroxylation of Terpene Scaffolds

Objective: Site-selective C3-hydroxylation of sclareolide and sclareol to generate advanced intermediates for meroterpenoid synthesis [52].

Materials:

• Sclareolide or sclareol (commercially available)
• E. coli cells co-expressing P450BM3 variant (BM3 MERO1) and thermostabilised phosphate dehydrogenase (Opt13)
• pET22b(+) and pRSF vectors for protein expression
• NADP+ cofactor
• Potassium phosphate buffer (pH 7.4)
• D-glucose (for cofactor regeneration)

Procedure:

• Culture Preparation: Inoculate E. coli BL21(DE3) cells harboring both pET22b(+)-BM3 MERO1 and pRSF-Opt13 plasmids in LB medium with appropriate antibiotics. Grow at 37°C until OD600 reaches 0.6-0.8.
• Protein Expression: Induce protein expression with 0.1 mM IPTG and incubate at 25°C for 20 hours with shaking at 180 rpm.
• Cell Harvesting: Pellet cells by centrifugation (4,000 × g, 20 minutes, 4°C) and resuspend in potassium phosphate buffer (100 mM, pH 7.4).
• Reaction Setup: Prepare reaction mixture containing:
  • Cell lysate (20-30 mg/mL total protein)
  • Substrate (sclareolide or sclareol, 1-5 mM from DMSO stock, final DMSO <2%)
  • NADP+ (1 mM)
  • D-glucose (10 mM)
  • In potassium phosphate buffer (100 mM, pH 7.4)
• Biocatalytic Reaction: Incubate at 30°C with shaking at 200 rpm for 6-24 hours.
• Product Extraction: Extract reaction mixture with ethyl acetate (3 × equal volume), combine organic layers, and concentrate under reduced pressure.
• Purification: Purify products by flash chromatography (silica gel, hexane/ethyl acetate gradient).

Analytical Data:

• 3-(OH)-Sclareolide: >95% conversion from sclareolide, approximately 5000 total turnover number (TTN) [52].
• No detectable C2-hydroxylated byproduct.
• Conversion monitored by TLC, GC-MS, or HPLC.

Critical Parameters:

• Maintain substrate concentration below 5 mM to prevent enzyme inhibition.
• Control DMSO concentration (<2% v/v) to maintain enzyme activity.
• Optimal protein expression requires precise control of induction conditions.

Ene-Reductase Catalyzed Construction of C(sp³)-S Stereocenters

Objective: Enantioselective synthesis of chiral sulfides via ene-reductase catalyzed conjugate reduction of prochiral vinyl sulfides [55].

Materials:

• Prochiral vinyl sulfide substrate (e.g., dimethyl 2-(phenylthio)fumarate)
• Ene-reductase (ENE-101, cell-free extract)
• Glucose dehydrogenase (GDH-101, GDH-5, or GDH-8)
• NADP+ or NAD+ cofactor
• D-glucose
• KPBS buffer (pH 7.0)
• DMSO (for substrate solubilization)

Procedure:

• Reaction Setup: Prepare reaction mixture containing:
  • KPBS buffer (pH 7.0)/DMSO (19:1 v/v)
  • Vinyl sulfide substrate (5-20 mM)
  • ENE-101 cell-free extract (10-20 mg/mL total protein)
  • Glucose dehydrogenase (1 mg/mL)
  • NADP+ or NAD+ (1 mM)
  • D-glucose (50 mM)
• Biocatalytic Reduction: Incubate at 30°C with shaking (200 rpm) for 24 hours.
• Reaction Monitoring: Monitor conversion by TLC or HPLC.
• Product Isolation: Extract with ethyl acetate (3 × volumes), dry over Naâ‚‚SOâ‚„, and concentrate.
• Purification: Purify by flash chromatography (silica gel, hexane/ethyl acetate).

Analytical Data:

• Dimethyl 2-(phenylthio)succinate: >99% conversion, >99% ee [55].
• Isolated yield: 91-95%.
• Stereoconvergent reaction from Z/E mixtures (4.1:1) affords 97% ee.

Critical Parameters:

• Maintain reaction temperature at 30°C; elevated temperatures (37°C) reduce enantioselectivity.
• ENE-101 accepts both NADP+ and NAD+ without affecting conversion or enantioselectivity.
• Z-isomers generally show higher reactivity than E-isomers.

Radical-Based Functionalization of Enzymatically Derived Intermediates

Objective: Implementation of hydrogen atom transfer (HAT) and radical C-C bond formation on terpene scaffolds generated through enzymatic cyclization [18].

Materials:

• Enzymatically derived terpene scaffold (e.g., guaia-6,10(14)-diene from engineered yeast)
• HAT catalyst (e.g., Fe-based complex)
• Hydrogen source (e.g., silanes or thiols)
• Photoredox catalyst (if photochemical activation required)
• Anhydrous solvent (acetonitrile or DCM)

Procedure:

• Substrate Preparation: Obtain terpene scaffold through enzymatic cyclization (e.g., using engineered S. cerevisiae producing 0.8 g/L in fed-batch fermentation) [18].
• Reaction Setup: Prepare solution in anhydrous solvent containing:
  • Terpene substrate (0.1-0.5 M)
  • HAT catalyst (5-10 mol%)
  • Hydrogen source (1.5-2.0 equivalents)
• Radical Reaction: Stir under nitrogen atmosphere at room temperature or elevated temperature as required.
• For photoredox variants: Add photoredox catalyst (1-2 mol%) and irradiate with blue LEDs (450 nm) while stirring.
• Reaction Monitoring: Monitor by TLC or GC-MS until completion.
• Workup and Purification: Concentrate under reduced pressure and purify by flash chromatography.

Analytical Data:

• Guaia-6,10(14)-diene to diene 9: Efficient isomerization via HAT catalysis [18].
• Subsequent dihydroxylation and epoxidation afford englerin A core structure.

Critical Parameters:

• Maintain anhydrous conditions for radical reactions.
• Optimize catalyst loading based on substrate reactivity.
• Control irradiation intensity and duration for photoredox reactions.

Data Presentation and Analysis

Quantitative Analysis of Enzyme Variants

Table 1: Performance Metrics of Engineered P450BM3 Variants for Sclareolide Hydroxylation [52]

Variant	Mutations from WT	Conversion (%)	TTN	C2-OH Byproduct	Key Features
BM3 MERO1	4 AA substitutions from II-H8	>95%	~5000	Not detected	Optimal activity for sclareolide
BM3 MERO2	Includes T235A, R471A	<95%	Lower than MERO1	Not reported	Enhanced solvent tolerance but reduced activity
BM3 MERO3	Reversion of C47R, I94K	Comparable to MERO1	Comparable to MERO1	Not detected	Thermostabilizing mutations not necessary

Table 2: Substrate Scope of Ene-Reductase Catalyzed Vinyl Sulfide Reduction [55]

Substrate	Configuration	Conversion (%)	Yield (%)	ee (%)	Product Configuration
1aa	Z	>99	91-95	>99	S
1aa	E	>99	91-95	88	S
1aa	Z/E mixture (4.1:1)	>99	91-95	97	S
1ab-ah	Z or E	50-96	50-96	72->99	S
1ai-al	Z	83->99	36-86	79->99	S
1an-ar	Z	>99	90-95	94->99	S
1an-ar	E	20-45	NR	50-66	R

The Researcher's Toolkit: Essential Reagents and Materials

Table 3: Key Research Reagent Solutions for Radical-Chemoenzymatic Cascades

Reagent/Catalyst	Function	Application Examples	Key Considerations
P450BM3 Variants (BM3 MERO1)	Site-selective C-H hydroxylation	Sclareolide C3-hydroxylation	Requires NADPH recycling system; optimal at <5 mM substrate
Ene-Reductase (ENE-101)	Enantioselective alkene reduction	Vinyl sulfide to chiral sulfide	Compatible with NAD+ or NADP+; optimal at 30°C
Glucose Dehydrogenase (GDH variants)	Cofactor regeneration (NADPH → NADP+)	All NADPH-dependent biotransformations	Compatible with multiple enzyme systems
Terpene Cyclases (e.g., STC5, FgJ02895)	Cyclization of linear isoprenoids	Guaia-6,10(14)-diene production from FPP	Often requires metabolic engineering for precursor supply
HAT Catalysts	Hydrogen atom transfer for C-H functionalization	Olefin isomerization in englerin A synthesis	Enables site-selective functionalization
Photoredox Catalysts	Single-electron transfer under light irradiation	Radical generation under mild conditions	Compatible with many enzyme classes
Transition Metal Catalysts	Cross-coupling, hydrogenation	Combining with enzymes in cascades	Potential metal poisoning of enzymes requires compartmentalization
Dabigatran-13C6	Dabigatran-13C6 Stable Isotope	Dabigatran-13C6 is a 13C-labeled internal standard for precise LC-MS/MS quantification of dabigatran in plasma. For Research Use Only. Not for human or veterinary use.	Bench Chemicals
Carbaryl-D3	Carbaryl-D3 Stable Isotope - 1312339-14-2	Carbaryl-D3 (methyl-d3), CAS 1312339-14-2. A high-purity internal standard for research. For Research Use Only. Not for human or veterinary use.	Bench Chemicals

Workflow Visualization and Strategic Planning

Integrated Radical-Chemoenzymatic Cascade Framework

Diagram 1: Integrated radical-chemoenzymatic cascade framework showing the sequential and convergent modules for natural product synthesis.

Strategic Disconnection Planning for Meroterpenoids

Diagram 2: Strategic disconnection planning for meroterpenoid synthesis showing convergent routes from industrial feedstocks via biocatalytic hydroxylation and radical diversification.

The integration of radical chemistry with biocatalytic transformations represents a significant advancement in synthetic methodology, particularly for the efficient construction of complex natural products. This hybrid approach transcends the limitations of traditional synthetic paradigms by combining the precise selectivity of enzymatic catalysis with the versatile bond-forming capabilities of radical-based reactions. The experimental protocols and strategic frameworks presented in this technical guide provide researchers with practical tools for implementing these methodologies in drug development and natural product research.

Future developments in this field will likely focus on enhancing compatibility between radical and enzymatic systems, particularly through compartmentalization strategies and protein engineering to create enzyme variants with improved tolerance to non-natural reaction conditions. Additionally, the continued expansion of synthetic electrosynthesis and photobiocatalysis will open new avenues for sustainable reaction design. As these methodologies mature, radical-chemoenzymatic cascades are poised to become indispensable tools for synthesizing increasingly complex molecular architectures with greater efficiency and reduced environmental impact.

One-pot multi-enzyme (OPME) systems represent a powerful chemoenzymatic strategy that integrates multiple enzyme-catalyzed reactions within a single reaction vessel, eliminating the need for intermediate isolation and purification steps. This approach has revolutionized the synthesis of complex biomolecules, particularly in the realm of natural product synthesis and glycobiology. By harnessing the exquisite selectivity of enzymatic catalysis while avoiding laborious purification processes, OPME systems significantly enhance synthetic efficiency, reduce waste generation, and improve overall reaction economics [56]. The fundamental principle underlying OPME technology involves the coordinated operation of multiple enzymes that catalyze sequential transformations, where the product of one enzymatic reaction serves as the substrate for the next in a cascade manner.

The development of OPME systems has been particularly transformative for synthesizing carbohydrates and glycoconjugates, which play crucial roles in biological recognition processes but present significant synthetic challenges due to their structural complexity. Traditional chemical synthesis of these compounds often requires extensive protecting group manipulations and lengthy synthetic routes. In contrast, OPME systems leverage the inherent regio- and stereo-selectivity of enzymes to construct complex glycan structures with remarkable precision [57]. The versatility of these systems is further enhanced by the substrate promiscuity exhibited by many bacterial enzymes, allowing for the incorporation of non-natural functionalities and the synthesis of structural analogs for structure-activity relationship studies [56].

Core Principles and Strategic Advantages

Fundamental Operational Mechanisms

OPME systems function based on synchronized enzymatic cascades where reaction equilibrium is driven toward product formation through careful optimization of reaction conditions compatible with all integrated enzymes. A key operational principle involves in situ generation of unstable intermediates, particularly high-energy sugar nucleotide donors such as UDP-glucose, GDP-fucose, and CMP-sialic acid, which are continuously produced from inexpensive monosaccharide precursors and consumed by glycosyltransferases to form desired glycan structures [56]. This approach avoids the accumulation of these costly and unstable intermediates, enhancing process efficiency and economy.

The successful implementation of OPME systems relies on several critical factors: (1) identification of enzymes with compatible operating conditions (pH, temperature, buffer composition); (2) balancing enzyme ratios to ensure optimal flux through the cascade; (3) careful selection of enzyme candidates with adequate substrate promiscuity to accept modified substrates; and (4) potential inclusion of auxiliary enzymes to regenerate cofactors or remove inhibitory byproducts [56] [58]. Bacterial enzymes are particularly favored in OPME applications due to their robustness, ease of production in E. coli expression systems, and generally broader substrate specificity compared to their mammalian counterparts [56].

Strategic Advantages in Synthesis

The implementation of OPME systems offers substantial advantages over traditional synthetic approaches:

• Elimination of Intermediate Isolation: By avoiding multiple purification steps, OPME systems significantly reduce processing time, material losses, and solvent waste generation. This streamlined approach can cut synthetic timelines from several days to just 4-18 hours for many sialoside syntheses [58].

• Enhanced Reaction Efficiency: The continuous consumption of intermediates drives reaction equilibria toward product formation, often resulting in higher overall yields. The direct channeling of intermediates between enzymes can also potentially protect labile intermediates from degradation.

• Access to Diverse Structural Analogs: The substrate promiscuity of many enzymes utilized in OPME systems enables the synthesis of naturally occurring structures and non-natural analogs from appropriately modified precursors. This flexibility is particularly valuable for drug discovery applications where structure-activity relationships must be explored [56] [59].

• Superior Stereocontrol: Enzymatic catalysis provides inherent stereo- and regio-selectivity, eliminating the need for protecting groups that are typically required in purely chemical synthetic approaches. This allows for direct synthesis of complex chiral molecules with precise stereochemical outcomes.

Representative OPME Systems and Applications

OPME Systems for Sugar Nucleotide and Glycan Synthesis

Researchers have developed various OPME configurations for synthesizing major glycan epitopes found in mammalian glycomes. The table below summarizes representative OPME systems for synthesizing sugar nucleotides and oligosaccharides:

Table 1: Representative OPME Systems for Sugar Nucleotide and Oligosaccharide Synthesis

System ID	Target Product	Key Enzymes Involved	Precursors	Application Examples
SA1a	UDP-GlcNAc	BiNahK, AGX1, Pyrophosphatase	GlcNAc, ATP, UTP	Synthesis of N-glycan precursors [56]
SA1b	UDP-GalNAc	BiNahK, AGX1, Pyrophosphatase	GalNAc, ATP, UTP	Synthesis of O-GalNAc glycans (Tn antigen) [56]
SA2	UDP-Gal	GalK, AGX1, Pyrophosphatase	Gal, ATP, UTP	T-antigen synthesis [56]
SA4	UDP-GlcA	UDP-Glc DH, UDP-Sugar PP	UDP-Glc, NAD+	Glycosaminoglycan synthesis [56]
SA5	GDP-Man	BiNahK, AGM1, Pyrophosphatase	Man, ATP, GTP	C-mannosylation [56]
OPME3	Gal-containing	GalK, AGX1, PPase, GalT	Gal, ATP, UTP, acceptor	Lacto-series glycans [56]
OPME5	GlcA-containing	UDP-Glc DH, UDP-Sugar PP, GlcAT	UDP-Glc, NAD+, acceptor	Glycosaminoglycan oligosaccharides [56]

These systems exemplify the modularity of OPME approaches, where enzyme combinations can be strategically selected based on the target product structure. The salvage pathway enzymes employed in these systems typically require fewer enzymatic steps compared to de novo pathways, simplifying the overall reaction design [56].

OPME Synthesis of Sialosides

Sialic acid-containing glycoconjugates play critical roles in cellular recognition processes, and their synthesis has been greatly facilitated by OPME approaches. A well-established one-pot three-enzyme (OP3E) system for sialoside synthesis incorporates: (1) a sialic acid aldolase (e.g., from E. coli K-12) that condenses N-acetylmannosamine (ManNAc) with pyruvate to form sialic acid; (2) a CMP-sialic acid synthetase (e.g., from N. meningitidis, NmCSS) that activates sialic acid using cytidine triphosphate (CTP); and (3) a sialyltransferase (e.g., from P. multocida, PmST1, for α2,3-linkages or P. damsela, Pd2,6ST, for α2,6-linkages) that transfers sialic acid to acceptor glycans [58].

Table 2: Key Enzymes for OPME Sialoside Synthesis

Enzyme	Source	Function	Specific Activity	Key Features
Sialic Acid Aldolase	E. coli K-12	Condenses ManNAc with pyruvate to form sialic acid	1.1 U/mg	Tolerates C5- and C7-C9 modified ManNAc analogs [58]
CMP-Sialic Acid Synthetase (CSS)	N. meningitidis	Activates sialic acid to form CMP-sialic acid using CTP	290 U/mg	Flexible toward sialic acid modifications [58]
α2,3-Sialyltransferase (PmST1)	P. multocida	Transfers sialic acid to Gal-containing acceptors	60 U/mg	Multifunctional; also has sialidase activity at higher pH [58]
α2,6-Sialyltransferase (Pd2,6ST)	P. damsela	Forms α2,6-sialyl linkages	35 U/mg	Specific for α2,6-linkage formation [58]

This versatile system has been successfully applied to synthesize sialosides containing natural sialic acid forms (Neu5Ac, Neu5Gc, KDN) and non-natural analogs with modifications at C5, C7, C8, or C9 positions, demonstrating remarkable substrate flexibility [58]. The methodology has been extended to modify cell surface glycans and label glycoconjugates with isotopes, chromophores, or fluorophores for biological studies [58].

OPME Synthesis of MUC1 Glycopeptide Antigens

The application of OPME systems to glycopeptide synthesis is exemplified by the efficient chemoenzymatic synthesis of tumor-associated MUC1 glycopeptide antigens. Researchers have employed OPME approaches to convert Tn-MUC1 glycopeptides (GalNAcα-Ser/Thr) to STn-MUC1 (Neu5Acα2-6GalNAcα-Ser/Thr) and ST-MUC1 (Neu5Acα2-3Galβ1-3GalNAcα-Ser/Thr) structures containing naturally occurring and non-natural sialic acids [59].

For STn-MUC1 synthesis, a one-pot three-enzyme system was utilized, containing a sialyltransferase (Photobacterium damselae or Photobacterium sp. α2,6-sialyltransferase), E. coli sialic acid aldolase (EcNanA), and N. meningitidis CMP-sialic acid synthetase (NmCSS). This system efficiently converted chemically synthesized Tn-MUC1 glycopeptide (APG(GalNAcα)STAPPA) to STn-MUC1 glycopeptides with quantitative consumption of the starting material when supplemented with extra CTP and following flash C18 cartridge purification to remove inhibitory CMP [59].

Similarly, T-MUC1 glycopeptide was synthesized using a cloned Campylobacter jejuni β1-3-galactosyltransferase mutant (CjCgtBΔ30-His6), which exhibited unusual activity in transferring one or more galactose residues to Tn-MUC1. Subsequent sialylation using Pasteurella multocida α2-3-sialyltransferase 3 (PmST3) with NmCSS and EcNanA in one pot efficiently produced ST-MUC1 glycopeptides containing Neu5Ac, Neu5Gc, or C5/C9-modified sialic acids [59]. These synthetic glycopeptides serve as valuable candidates for cancer vaccine development.

Experimental Protocols

General OPME Reaction Setup and Optimization

Establishing a robust OPME system requires careful consideration of several parameters to ensure optimal cascade efficiency:

• Enzyme Selection and Screening: Prioritize bacterial enzymes for their robustness and broader substrate tolerance. Conduct small-scale analytical reactions (100-200 µL) to assess enzyme compatibility and substrate conversion before scaling up [58].

• Reaction Buffer Optimization: Identify a compromise buffer system that maintains adequate activity for all enzymes. Common buffers include Tris-HCl (10-50 mM, pH 7.5-8.5) or HEPES (20-100 mM, pH 7.0-7.5) with MgClâ‚‚ (5-20 mM) as a common cofactor for kinases and nucleotidyltransferases [58].

• Cofactor and Energy Source Supplementation: Include ATP (2-10 mM) for kinases, corresponding NTPs (UTP, GTP, CTP; 2-10 mM) for nucleotidyltransferases, and NAD⁺ (1-5 mM) for dehydrogenases when required. An inorganic pyrophosphatase (0.1-1 U/mL) can be added to drive reactions toward sugar nucleotide formation by consuming inhibitory pyrophosphate [56].

• Temperature and Time Profiling: Most OPME reactions proceed efficiently at 30-37°C with reaction times ranging from 4-18 hours for sialosides [58] to 24-48 hours for more complex cascades. Monitor reaction progress by TLC, HPLC, or MS.

Protocol: One-Pot Three-Enzyme Synthesis of α2,3-Linked Sialoside

This protocol details the synthesis of Neu5Acα2-3LacβProN₃ from ManNAc and lactose-derived acceptor [58]:

Table 3: Reaction Setup for α2,3-Linked Sialoside Synthesis

Component	Final Concentration	Volume/Amount	Notes
Tris-HCl buffer (pH 8.5)	50 mM	4.5 mL	Pre-warmed to 37°C
MgCl₂	10 mM	10 µL of 1 M stock	Essential cofactor
ManNAc	40 mM	15.8 mg	Sialic acid precursor
Sodium pyruvate	100 mM	33 mg	Aldol condensation substrate
CTP	20 mM	28.5 mg	Energy donor for activation
LacβProN₃ acceptor	20 mM	~34 mg	Acceptor concentration may vary
E. coli sialic acid aldolase	1.1 U/mg, 2 mg	2.2 U	Specific activity: 1.1 U/mg
N. meningitidis CSS (NmCSS)	290 U/mg, 0.1 mg	29 U	Specific activity: 290 U/mg
P. multocida sialyltransferase (PmST1)	60 U/mg, 0.5 mg	30 U	Specific activity: 60 U/mg
Total Volume	5 mL	Adjust with Hâ‚‚O

Procedure:

• Prepare the reaction mixture by sequentially adding Tris-HCl buffer, MgClâ‚‚, ManNAc, sodium pyruvate, CTP, and LacβProN₃ acceptor to a 15-mL conical tube.
• Add the enzymes in the following order: sialic acid aldolase, CMP-sialic acid synthetase, and sialyltransferase.
• Incubate the reaction mixture at 37°C for 12-16 hours with gentle shaking (150-200 rpm).
• Monitor reaction progress by TLC (n-PrOH/CH₃COâ‚‚H/Hâ‚‚O, 4:3:2, v/v) or MALDI-TOF MS.
• Terminate the reaction by heating at 100°C for 3 minutes or through purification.
• Purify the product using Bio-Gel P-2 gel filtration chromatography, followed by C18 reverse-phase cartridge or column chromatography if needed.
• Characterize the purified sialoside using NMR spectroscopy and mass spectrometry.

Critical Notes:

• Always include a control reaction with natural substrates to verify enzyme activities.
• Store CTP at -20°C and prepare fresh solutions before use due to instability.
• Enzyme amounts may require optimization based on specific activity of enzyme preparations.
• For analogs, test modified ManNAc or mannose derivatives in small-scale reactions first to assess enzyme tolerance.

Optimization Strategies and Technical Considerations

Enzyme Engineering for Enhanced OPME Performance

The efficiency of OPME systems can be substantially improved through strategic enzyme engineering approaches:

• Thermostability Enhancement: Protein engineering techniques, including rational design and directed evolution, can significantly improve enzyme thermostability. For example, engineering sorbitol-6-phosphate dehydrogenase (EcS6PDH) through multiple mutations (EcS6PDH-M4) extended its half-life at 40°C from less than 1 minute to 375 minutes and increased melting temperature (Tₘ) by 9.1°C [60].

• Catalytic Activity Improvement: Despite challenges in enhancing catalytic efficiency, random mutagenesis and screening approaches can yield variants with improved kcat values. Error-prone PCR coupled with high-throughput screening has successfully generated enzyme variants with enhanced activities for biosynthetic applications [60].

• Substrate Promiscuity Engineering: Structure-guided mutagenesis can broaden enzyme substrate specificity, allowing incorporation of non-natural substrates. The substrate promiscuity of enzymes like Bifidobacterium infantis N-acetylhexosamine-1-kinase (BiNahK), which accepts GlcNAc, GalNAc, mannose, and their C2- or C6-modified derivatives, has been leveraged in OPME synthesis of various sugar nucleotides [56].

Computational Approaches for OPME System Design

Recent advances in computational biology facilitate the rational design of OPME systems:

• Turnover Number Optimization: The Overcoming Kinetic rate Obstacles (OKO) approach uses enzyme-constrained genome-scale metabolic models (ecGEMs) to predict modifications to enzyme turnover numbers (kcat) that enhance chemical production while maintaining cell growth. Application of OKO to Escherichia coli and Saccharomyces cerevisiae models identified strategies that could at least double the production of over 40 compounds with minimal growth penalty [61].

• Enzyme Selection and Compatibility Prediction: Bioinformatics tools can identify enzyme candidates with compatible operating parameters from diverse biological sources. Catalytic site analysis and molecular dynamics simulations help select enzymes with desired substrate flexibility and minimal product inhibition [60].

• Pathway Flux Analysis: Computational modeling of multi-enzyme cascades enables prediction of optimal enzyme ratios and identification of potential bottlenecks before experimental implementation, saving time and resources in OPME system development [61].

The Scientist's Toolkit: Essential Research Reagents

Successful implementation of OPME systems requires access to key enzymes, substrates, and cofactors. The following table details essential research reagents for establishing OPME syntheses:

Table 4: Essential Research Reagents for OPME Systems

Reagent Category	Specific Examples	Function in OPME Systems	Procurement Considerations
Sugar Nucleotide Biosynthetic Enzymes	BiNahK (N-acetylhexosamine kinase), AGX1 (sugar nucleotide pyrophosphorylase), GalK (galactokinase)	Phosphorylate monosaccharides and convert to sugar nucleotides	Recombinant forms expressed in E. coli preferred for purity and activity [56]
Glycosyltransferases	PmST1 (multifunctional sialyltransferase), CjCgtB (β1-3-galactosyltransferase), Pd2,6ST (α2,6-sialyltransferase)	Transfer sugar moieties from activated donors to acceptors	Check substrate specificity for target acceptor; bacterial sources often more flexible [59] [58]
Modifying Enzymes	Sialic acid aldolase, CMP-sialic acid synthetase, UDP-Glc dehydrogenase	Generate sugar nucleotides or modified sugar structures	Verify compatibility with downstream enzymes in cascade [58]
Energy Regeneration Enzymes	Pyrophosphatase, creatine kinase, acetate kinase	Remove inhibitory byproducts or regenerate ATP	Inorganic pyrophosphatase critical for driving sugar nucleotide formation [56]
Monosaccharide Precursors	ManNAc, GalNAc, GlcNAc, mannose, galactose, KDO	Building blocks for complex carbohydrate synthesis	Modified analogs available from specialty chemical suppliers for non-natural derivatives [58]
Nucleotide Triphosphates	ATP, UTP, GTP, CTP	Energy donors and nucleotide sugar precursors	Store at -20°C; prepare fresh solutions before use due to instability [58]
Cofactors	MgCl₂, NAD⁺, NADP⁺	Essential cofactors for kinase and dehydrogenase activities	Mg²⁺ particularly critical for kinases and nucleotidyltransferases [58]
6-Quinoxalinecarboxylic acid, 2,3-bis(bromomethyl)-	6-Quinoxalinecarboxylic acid, 2,3-bis(bromomethyl)-, MF:C11H8Br2N2O2, MW:360 g/mol	Chemical Reagent	Bench Chemicals
Tyr-(D-Dab4,Arg5,D-Trp8)-cyclo-Somatostatin-14 (4-11)	Tyr-(D-Dab4,Arg5,D-Trp8)-cyclo-Somatostatin-14 (4-11), MF:C67H85N15O11, MW:1276.5 g/mol	Chemical Reagent	Bench Chemicals

Visualization of OPME Systems

OPME Workflow for Sialoside Synthesis

Modular OPME Strategy for Glycan Assembly

One-pot multi-enzyme systems represent a paradigm shift in the synthesis of complex biomolecules, particularly carbohydrates and glycoconjugates. By harnessing the power of enzymatic catalysis in a coordinated cascade, OPME strategies overcome many limitations of traditional synthetic approaches, offering unprecedented efficiency, selectivity, and flexibility. The continued expansion of enzyme libraries, combined with advances in protein engineering and computational design, promises to further broaden the scope and efficiency of OPME systems.

Future developments in OPME technology will likely focus on several key areas: (1) integration of non-natural enzymatic reactions to expand chemical diversity; (2) development of immobilized enzyme systems for continuous flow processes and catalyst recycling; (3) implementation of machine learning algorithms for predictive enzyme selection and reaction optimization; and (4) combination of OPME with metabolic engineering for hybrid fermentation-chemoenzymatic production routes. As these advanced systems mature, they will undoubtedly accelerate drug discovery and development, particularly in the realm of glycobiology where complex carbohydrates play crucial roles in therapeutic efficacy and biological recognition.

The synthesis of complex carbohydrates represents one of the most formidable challenges in modern organic chemistry and chemical biology. These molecules, including glycoproteins, glycolipids, and various glycosylated natural products, play critical roles in virtually all biological processes, from cellular recognition and immune response to signal transduction and pathogen invasion [62] [63]. The structural complexity of glycans—encompassing diverse monosaccharide building blocks, multiple linkage possibilities, and intricate branching patterns—has traditionally rendered their chemical synthesis exceptionally laborious, requiring extensive protecting group manipulations and suffering from unpredictable stereoselectivity [63]. In response to these challenges, chemoenzymatic synthesis has emerged as a powerful interdisciplinary approach that marries the precision and mild reaction conditions of enzymatic catalysis with the flexibility and broad scope of traditional synthetic chemistry [10] [40].

This hybrid strategy leverages the unparalleled regioselectivity and stereoselectivity of enzymes to construct challenging glycosidic linkages while using chemical methods to prepare enzyme substrates, introduce non-natural modifications, or perform transformations beyond the scope of biocatalysis [64] [40]. The field has advanced dramatically in recent years, propelled by innovations in enzyme discovery and engineering, the development of sophisticated multi-enzyme cascades, and the integration of chemoenzymatic approaches with cutting-edge synthetic methodology [40] [30]. This technical guide examines the current state of chemoenzymatic glycosylation strategies, with a particular focus on their application to the synthesis of biologically significant complex carbohydrates, and places these developments within the broader context of natural product synthesis research.

Core Principles and Strategic Considerations

Fundamental Advantages of the Chemoenzymatic Approach

Chemoenzymatic strategies offer several distinct advantages over purely chemical or purely enzymatic approaches to complex carbohydrate synthesis. Firstly, enzymes catalyze glycosidic bond formation with exquisite stereocontrol, typically without requiring protecting groups on the carbohydrate hydroxyl functions [57]. This eliminates multiple synthetic steps associated with protecting group manipulation that often dominate traditional carbohydrate synthesis. For instance, the construction of β-mannosidic linkages—notoriously challenging in chemical synthesis due to the lack of neighboring group participation and the opposing anomeric effect—can be achieved efficiently using engineered β-mannosidases or mannosyltransferases [63] [30].

Secondly, enzymatic glycosylation exhibits remarkable regioselectivity, enabling selective modification of specific hydroxyl groups in complex polyol systems without the need for tedious orthogonal protection-deprotection sequences [57]. This capability is particularly valuable in the synthesis of branched oligosaccharide structures where multiple similar hydroxyl groups coexist. Thirdly, chemoenzymatic processes are generally performed in aqueous solutions under mild conditions (ambient temperature and pressure, neutral pH), making them environmentally friendly and compatible with sensitive functional groups that might not survive harsh chemical conditions [10] [40].

Key Enzymatic Tools for Glycosylation

The chemoenzymatic synthesis of complex carbohydrates relies primarily on two classes of enzymes: glycosyltransferases (GTs) and glycosidases (or their engineered variants, glycosynthases). Glycosyltransferases catalyze the transfer of activated sugar donors (typically nucleotide sugars) to specific acceptor molecules, offering excellent control over both anomeric configuration and linkage position [57]. In contrast, glycosidases, which normally hydrolyze glycosidic bonds, can be driven in reverse under appropriate conditions or engineered as glycosynthases that utilize activated sugar donors (e.g., glycosyl fluorides) for synthesis [30].

Table 1: Major Enzyme Classes Used in Chemoenzymatic Glycosylation

Enzyme Class	Typical Donor Substrates	Key Advantages	Common Applications
Glycosyltransferases	Nucleotide sugars (UDP-Glc, CMP-Neu5Ac, etc.)	High efficiency and specificity; natural biosynthesis machinery	Synthesis of mammalian glycans; terminal modifications
Glycosidases/Glycosynthases	p-Nitrophenyl glycosides; glycosyl fluorides	Low cost; broad availability; no need for expensive nucleotide sugars	Synthesis of core oligosaccharide structures; transglycosylation
Phosphorylases	Sugar-1-phosphates	Reversible reaction; simple donors	Synthesis of disaccharides and oligosaccharides with α-linkages
Sucrose Synthases	Sucrose	Cheap donor substrate; generates nucleotide sugars in situ	Regeneration of UDP-sugars for glycosyltransferase reactions

Recent advances in enzyme engineering have significantly expanded the synthetic utility of these biocatalysts. Through directed evolution, rational design, and ancestral sequence reconstruction, researchers have created enzyme variants with broadened substrate specificity, enhanced stability, improved catalytic efficiency, and novel activities [40]. For example, protein engineering of a ketoreductase from Sporidiobolus salmonicolor resulted in a variant with a 64-fold higher apparent kcat, enabling its application in the chemoenzymatic synthesis of ipatasertib, a potent protein kinase B inhibitor [40]. Similarly, engineering of the diterpene glycosyltransferase UGT76G1 yielded a variant with a 9°C increase in melting temperature and a 2.5-fold increase in product yield for the production of steviol glucosides [40].

Synthetic Strategies for Major Carbohydrate Classes

Chemoenzymatic Synthesis of N-Glycans

N-Glycans, linked to asparagine residues of proteins via a conserved chitobiose core, represent one of the most biologically significant classes of complex carbohydrates. Their structural diversity arises from variations in branching patterns and terminal modifications, which profoundly influence protein folding, stability, and function [65] [63]. The chemoenzymatic synthesis of N-glycans typically employs a modular approach wherein a chemically synthesized core oligosaccharide is enzymatically elaborated to achieve the target structure [57] [63].

A key challenge in N-glycan synthesis is the stereoselective construction of the β-mannosidic linkage between the core mannose residues. Chemical approaches to this transformation often rely on specialized methodologies such as the 4,6-O-benzylidene protecting group strategy (Crich's mannosylation), β-glycosylation-inversion sequences, or intramolecular aglycon delivery [63]. In contrast, chemoenzymatic strategies employ mannosyltransferases or engineered glycosynthases to directly install the β-mannoside with perfect stereocontrol. For instance, the β-mannosidase from Cellulomonas fimi (Cf-β-Man) has been successfully immobilized on IDA-Co²⁺-agarose, resulting in significantly improved efficiency for disaccharide synthesis (20% conversion compared to 5% for the soluble form) along with enhanced stability and reusability [30].

The terminal sialylation of N-glycans presents another significant synthetic challenge due to the poor nucleophilicity of the sialic acid hydroxyl groups and the lack of neighboring group participation. Chemoenzymatic approaches utilize sialyltransferases with cytidine monophosphate-sialic acid (CMP-Neu5Ac) donors to achieve stereoselective α-sialylation [57] [63]. Recent work has focused on expanding the scope of these enzymes to accommodate non-natural sialic acid analogs and on developing efficient systems for CMP-Neu5Ac regeneration to improve the atom economy of the process.

Diagram 1: Chemoenzymatic Assembly Workflow for Complex-Type N-Glycans

Synthesis of O-Glycans and Glycosphingolipids

O-Glycans, typically linked to serine or threonine residues via N-acetylgalactosamine (O-GalNAc) or mannose (O-Man), present distinct synthetic challenges compared to N-glycans. The chemoenzymatic modular assembly (CEMA) strategy has emerged as a powerful approach for systematically accessing diverse O-glycan structures [57]. This approach involves the enzymatic diversification of chemically synthesized core structures using carefully designed enzyme modules. For example, Li and coworkers developed a CEMA strategy incorporating 13 enzyme modules to generate a comprehensive library of O-GalNAc glycans from core structures 1-4 and 6 [57].

The synthesis of gangliosides—sialic acid-containing glycosphingolipids with crucial roles in neuronal development and signaling—exemplifies the power of chemoenzymatic approaches for complex glycolipid synthesis. A recent breakthrough described a scalable chemoenzymatic total synthesis strategy for constructing a comprehensive library of ganglio-series glycosphingolipids (ganglio-GSLs) [66]. This approach combined a chiral pool synthesis of simple glycosylsphingosines from inexpensive D-xylose with enzyme assembly synthetic map (EASyMap)-guided one-pot multienzyme (OPME) and stepwise OPME (StOPMe) glycosylation strategies. Key to this success was the engineering of mutants with improved catalytic efficiencies for two critical glycosyltransferases (CjCgtA and human ST6GALNAC5) [66]. The resulting ganglio-GSLs containing a terminal primary amino group were covalently immobilized on magnetic beads to form a comprehensive ganglio-GSL-bead library, enabling multiplex binding assays with various glycan-binding proteins.

Chemoenzymatic Approaches to Glycosylated Natural Products

Beyond structural glycobiology, chemoenzymatic strategies have revolutionized the synthesis of glycosylated natural products with pharmaceutical relevance. The sorbicillinoids, a family of fungal natural products with promising antiviral activities, exemplify this trend [64]. Their molecular architectures arise from asymmetric oxidative dearomatization of highly substituted phenols and subsequent coupling reactions—transformations that traditionally required stoichiometric chiral hypervalent iodine reagents or chiral Cu(I) salts. Independent reports from Gulder and Sib groups demonstrated that these challenging transformations could be accomplished using engineered enzymes, significantly simplifying the synthetic access to these complex molecules [64].

Another impressive example comes from the synthesis of jorunnamycin A and saframycin A, tetrahydroisoquinoline alkaloids with potent antitumor activity [64]. A collaborative effort resulted in a concise chemoenzymatic synthesis utilizing a phosphopantetheinylated SfmC, a dual Pictet–Spengler enzyme, to construct the common pentacyclic core of these molecules from a tyrosine analog. This biocatalytic key step provided the complex molecular scaffold with high efficiency, demonstrating how enzymatic transformations can streamline the synthesis of structurally complex natural products [64].

Table 2: Representative Chemoenzymatic Syntheses of Bioactive Natural Products

Natural Product	Class	Key Enzymatic Transformation	Strategic Advantage
Chrodrimanin C [10]	Terpenoid	Regio- and stereoselective enzymatic hydroxylation of 6,6,5 steroid core	Gram-scale synthesis with 67-83% yield; single methylene selectivity among 6-7 oxidizable sites
Nepetalactolone [10]	Iridoid monoterpene	Ten-enzyme cascade from geraniol	Sets three contiguous stereocenters; 93% yield; $120/g production cost
Sorbicillinoids [64]	Polyketide	Asymmetric oxidative dearomatization	Replaces stoichiometric chiral reagents; improved sustainability
Jorunnamycin A [64]	Tetrahydroisoquinoline alkaloid	Dual Pictet–Spengler cyclization	Concise access to pentacyclic core; streamlines synthetic route
Podophyllotoxin [64]	Aryltetralin lignan	Oxidative cyclization via C–C bond formation	Enantioselective synthesis; avoids racemic resolution

Experimental Methodologies and Protocols

General Considerations for Chemoenzymatic Reactions

Successful implementation of chemoenzymatic glycosylation requires careful attention to reaction conditions and component compatibility. Typical reaction buffers include 50-100 mM phosphate or Tris-HCl buffers (pH 6.0-8.0) with added magnesium chloride (5-20 mM) as a cofactor for many glycosyltransferases. To maintain enzyme stability, reactions are typically conducted at 25-37°C with mild agitation. Many enzymes benefit from the addition of bovine serum albumin (0.1-1 mg/mL) or glycerol (5-10%) to enhance stability during extended incubations [10] [57].

A critical consideration in glycosyltransferase-catalyzed reactions is the efficient regeneration of nucleotide sugar donors, which are often expensive and unstable. Regeneration systems typically employ a second enzyme to recycle the nucleotide byproduct back to the activated sugar form. For example, UDP-glucose can be regenerated from UDP using sucrose synthase with sucrose as a cheap glycosyl donor, enabling catalytic use of the expensive nucleotide [57]. Similarly, systems for regenerating CMP-sialic acid have been developed using a combination of sialic acid aldolase, pyruvate kinase, and other auxiliary enzymes.

Protocol: One-Pot Multienzyme (OPME) Synthesis of Nepetalactone

The one-pot multienzyme (OPME) synthesis of nepetalactone from geraniol exemplifies the power of multi-enzyme cascades in natural product synthesis [10]. This system employs ten enzymes—five for the biosynthetic steps and five for cofactor regeneration—in a single reaction vessel.

Procedure:

• Prepare reaction mixture containing 100 mM potassium phosphate buffer (pH 7.0), 10 mM geraniol, 2 mM NAD⁺, 5 mM ATP, and 10 mM glucose.
• Add the following enzyme cascade: geraniol hydroxylase, alcohol dehydrogenase, aldehyde reductase, iridoid synthase, and nepetalactol dehydrogenase for the biosynthetic steps.
• Include auxiliary enzymes for cofactor regeneration: glucose dehydrogenase (NAD⁺ regeneration), hexokinase, phosphoglucomutase, UDP-glucose pyrophosphorylase, and inorganic pyrophosphatase (ATP regeneration).
• Incubate at 30°C with gentle shaking for 24 hours.
• Extract products with ethyl acetate and purify by flash chromatography.

Key Features: This OPME system achieves a remarkable 93% yield of nepetalactone with excellent stereocontrol, demonstrating the possibility of performing both oxidative and reductive steps in the same pot using a shared NAD⁺/NADH recycling system [10]. The methodology highlights the potential for producing approximately 1 gram of nepetalactone per liter of reaction mixture at a reasonable cost (<$120/g).

Protocol: Chemoenzymatic Synthesis and Immobilization of Ganglio-Glycosphingolipids

The synthesis of a comprehensive ganglio-glycosphingolipid library illustrates the integration of chemical and enzymatic methods for complex glycolipid synthesis [66].

Chemical Synthesis of Glycosylsphingosine Core:

• Start with inexpensive D-xylose and employ a chiral pool approach to synthesize simple glycosylsphingosines with desired sphingosine lengths (d18:1 or d20:1).
• Protect and functionalize the intermediate to provide acceptors for enzymatic glycosylation.

Enzymatic Glycan Elaboration:

• Use EASyMap-guided OPME and StOPMe glycosylation strategies with engineered glycosyltransferases.
• Employ specifically designed CjCgtA and human ST6GALNAC5 mutants with improved catalytic efficiencies.
• Perform reactions in 50 mM HEPES buffer (pH 7.5) containing 10 mM MnClâ‚‚, 0.1% Triton X-100, and appropriate sugar nucleotides.

Chemical Acylation and Immobilization:

• Chemically acylate ganglio-GSLs containing a terminal primary amino group.
• Covalently immobilize on magnetic beads via amine coupling chemistry.
• Validate library composition using mass spectrometry and NMR spectroscopy.

This protocol enables the construction of a comprehensive ganglio-GSL-bead library encompassing 0-, a-, b-, and c-series ganglio-GSLs, including structures containing up to five sialic acid residues with different (α2-3/6/8) sialyl linkages [66]. The resulting library serves as a powerful platform for multiplex binding assays with various glycan-binding proteins.

The Scientist's Toolkit: Essential Research Reagents

Table 3: Key Research Reagent Solutions for Chemoenzymatic Glycosylation

Reagent/Resource	Function/Application	Representative Examples	Technical Notes
Engineered Glycosyltransferases	Catalyze specific glycosidic bond formation with control over linkage and stereochemistry	CjCgtA mutants; human ST6GALNAC5 variants; sialyltransferases	Often require metal cofactors (Mn²⁺, Mg²⁺); substrate promiscuity varies
Glycosynthase Mutants	Engineered glycosidases that utilize activated donors for synthesis without hydrolysis	Cf-β-Man (β-mannosidase); various endoglycosidase mutants	Use glycosyl fluorides as donors; broad substrate specificity
Nucleotide Sugars	Activated donor substrates for glycosyltransferases	UDP-Glc; UDP-Gal; CMP-Neu5Ac; GDP-Fuc	Often used with regeneration systems; commercial availability varies
Nucleotide Sugar Regeneration Systems	Enable catalytic use of expensive nucleotides	Sucrose synthase/UDP; multi-enzyme cascades	Crucial for preparative-scale synthesis; improves atom economy
Immobilized Enzyme Systems	Facilitate enzyme recovery and reuse; improve stability	IDA-Co²⁺-agarose immobilized β-mannosidase; various resin-bound GTs	Enhances operational stability; enables continuous flow processes
Specialized Glycosyl Donors	Activated substrates for chemical or enzymatic glycosylation	Glycosyl fluorides; p-nitrophenyl glycosides; trichloroacetimidates	Choice depends on enzyme specificity and reaction conditions
Pomalidomide-D5	Pomalidomide-D5, MF:C13H11N3O4, MW:278.27 g/mol	Chemical Reagent	Bench Chemicals
Guajadial C	Guajadial C	Guajadial C is a natural meroterpenoid for cancer research. It exhibits anti-proliferative and anti-estrogenic activity. For Research Use Only. Not for human consumption.	Bench Chemicals

Future Perspectives and Emerging Applications

The field of chemoenzymatic glycosylation continues to evolve rapidly, with several emerging trends likely to shape future research directions. The integration of machine learning and artificial intelligence in enzyme engineering represents a particularly promising development. For example, machine learning-aided enzyme engineering has enabled the design of smaller, more focused mutant libraries for screening, significantly accelerating the optimization process [40]. This approach was successfully applied to engineer a ketoreductase variant with 64-fold improved catalytic efficiency for the synthesis of ipatasertib intermediate [40].

Another frontier involves the development of novel chemo- and regioselective transformations inspired by biological systems. The discovery and engineering of enzymes capable of catalyzing selective C–X bond formation, selective oxidation/reduction reactions, complex multicomponent reactions, and cleavage of challenging chemical bonds continues to expand the synthetic toolbox available for complex carbohydrate synthesis [40]. For instance, the application of α-oxoamine synthases (AOSs)—a class of pyridoxal 5'-phosphate-dependent enzymes that catalyze irreversible carbon-carbon bond formation—has been expanded through structure-guided engineering to accept a greatly expanded range of amino acids and simplified N-acetylcysteamine acyl-thioester substrates [40].

The exploration of non-traditional glycosylation targets represents another exciting direction. Recent investigations into whether DNA can be glycosylated—drawing parallels with the well-documented phenomenon of RNA glycosylation—suggest that glycobiology may expand beyond its traditional boundaries [67]. If confirmed, DNA glycosylation could introduce novel functional and structural roles within the cell, including epigenetic regulation, DNA repair and stability, immune recognition, and cell-cell communication [67].

From a technological perspective, the integration of chemoenzymatic synthesis with flow chemistry and process intensification offers promising avenues for scaling up the production of complex carbohydrates for therapeutic and diagnostic applications. Continuous-flow systems with immobilized enzymes can enhance productivity, facilitate catalyst recycling, and improve process control, potentially addressing the scalability challenges that have limited the translational impact of many synthetic glycobiology methodologies [30].

Diagram 2: Emerging Research Directions in Chemoenzymatic Glycosylation

Chemoenzymatic synthesis has matured into an indispensable approach for accessing complex carbohydrates that are essential for fundamental biological research and therapeutic development. By strategically combining the precision of enzymatic catalysis with the flexibility of synthetic chemistry, this methodology enables the efficient construction of structurally defined glycans that would be exceptionally challenging to obtain through purely chemical or purely biological means. Continued advances in enzyme engineering, reaction methodology, and process development promise to further expand the scope and impact of chemoenzymatic glycosylation strategies, solidifying their role as a cornerstone technology in glycoscience and natural product synthesis.

Overcoming Practical Challenges: Enzyme Engineering, Cofactor Recycling, and Process Optimization

In the pursuit of synthesizing complex natural products for drug discovery and chemical biology, chemoenzymatic strategies have emerged as powerful tools. These strategies leverage the precision and efficiency of biological catalysts to perform transformations that are often challenging for traditional synthetic chemistry. Within this framework, enzyme engineering provides the means to tailor biocatalysts for non-natural functions and substrates, thereby expanding the synthetic chemist's toolbox. Two dominant paradigms have shaped modern enzyme engineering: directed evolution, which mimics natural selection in a laboratory setting, and computational design, which utilizes predictive models and structural insights for rational protein modification. Directed evolution, recognized by the 2018 Nobel Prize in Chemistry, enables the rapid optimization of enzyme functions without requiring extensive mechanistic knowledge [68] [69]. Conversely, computational design serves as an attractive complement, waiving some of the experimental costs by providing predictions on mutations likely to yield desired outcomes [70]. This guide provides researchers and scientists with an in-depth technical overview of these methodologies, emphasizing their application in the context of natural product synthesis.

Directed Evolution: Harnessing Darwinian Principles for Enzyme Optimization

Directed evolution (DE) is a robust protein engineering method that simulates natural evolution by imposing stringent selection pressures to identify proteins with optimized functionality [68]. Its power lies in its ability to improve enzymes without requiring prior protein structure information.

The Directed Evolution Cycle

A standard directed evolution campaign consists of three iterative steps, as illustrated in the workflow below.

Step 1: Mutagenesis - Library Generation The first step involves introducing genetic diversity into the parent gene to create a vast library of variants. The chosen mutagenesis strategy directly impacts library quality and diversity [71] [72].

• Random Mutagenesis: Methods like error-prone PCR (epPCR) introduce random point mutations throughout the entire gene. This is ideal when no structural information is available but can result in a high proportion of non-functional variants [71].
• Saturation Mutagenesis: This targeted approach randomizes specific codons to explore all possible amino acid substitutions at a chosen residue. It is particularly useful for engineering substrate specificity or enantioselectivity by focusing on active site residues [71] [72].
• Gene Recombination: Techniques such as DNA shuffling recombine sequences from several homologous parent genes, jumping into new regions of sequence space and combining beneficial mutations from different lineages [69] [72].

Step 2: Screening/Selection This critical step identifies the rare improved variants from the large mutant library. The key challenge is developing a high-throughput assay that reliably reports on the desired enzyme function [69] [72].

• Screening: Each variant is individually expressed and assayed, often using colorimetric or fluorogenic substrates. This provides quantitative data on every tested variant but typically has lower throughput than selection [69].
• Selection: This couples the desired enzyme activity directly to host survival (e.g., by enabling the synthesis of an essential metabolite or the degradation of a toxin). While offering extremely high throughput, it can be difficult to engineer and provides less detailed activity information [69].
• Display Techniques: Methods like phage display physically link the protein (phenotype) to its genetic code (genotype), allowing for efficient isolation of binding proteins [71].

Step 3: Amplification The genes of the best-performing variants are isolated and amplified, typically via PCR or by growing host cells. The resulting DNA then serves as the template for the next, iterative round of evolution, enabling stepwise improvements [68] [69].

Key Methodologies in Directed Evolution

Table 1: Common Mutagenesis Techniques in Directed Evolution [71]

Technique	Purpose	Key Advantages	Key Disadvantages
Error-prone PCR	Insertion of point mutations across the whole sequence.	Easy to perform; requires no prior structural knowledge.	Biased mutagenesis spectrum; reduced sampling of sequence space.
DNA Shuffling	Random recombination of multiple parent sequences.	Recombines beneficial mutations from different parents.	Requires high sequence homology between parents.
Saturation Mutagenesis	Focused exploration of all possible mutations at specific residues.	In-depth exploration of key positions; enables smart library design.	Libraries can become very large if multiple residues are targeted simultaneously.
RAISE	Insertion of random short insertions and deletions (indels).	Mimics a broader range of natural genetic variation.	Often introduces frameshifts, disrupting the protein.

Computational Enzyme Design: The Rational Approach

Computational design represents a complementary strategy to directed evolution, using theoretical methods to predict mutations that will confer desired properties. These approaches are particularly valuable when experimental high-throughput screening is impractical or too costly [70].

Core Strategies and Applications

Computational techniques can be deployed to engineer various enzyme properties, and often work best as part of a "semi-rational" framework.

• Enhancing Stability and Solubility: Algorithms can predict mutations that improve thermodynamic stability, such as optimizing core packing or introducing stabilizing hydrogen bonds and salt bridges, which is crucial for heterologous expression and industrial application [70].
• Altering Catalytic Activity and Specificity: By analyzing the enzyme's active site and transition state, computational tools can suggest mutations that modify substrate scope, enantioselectivity, or catalytic efficiency [70].
• Identifying Hotspots: A primary application is the analysis of protein structures and sequences to identify residues that are likely to have a high impact on function if mutated, thereby reducing the experimental screening burden by defining focused libraries for directed evolution [70].

The Computational-Experimental Workflow

The integration of computational predictions with experimental validation creates a powerful cycle for enzyme engineering, as shown in the following workflow.

Integrated and Semi-Rational Strategies

The distinction between directed evolution and computational design is increasingly blurred in modern practice. Semi-rational approaches combine the best of both worlds by using computational and bioinformatic insights to create "focused libraries" [69] [72]. This strategy concentrates diversity on regions richer in beneficial mutations, such as the active site or flexible loops, dramatically reducing the library size that must be screened experimentally while increasing the likelihood of success.

Application in Natural Product Synthesis: The Case of P450 Enzymes

Cytochrome P450 enzymes (P450s) are a quintessential example of how directed evolution and computational design can revolutionize chemoenzymatic synthesis. P450s are versatile biocatalysts capable of performing regio- and stereoselective oxidations, which are critical reactions in the diversification of natural product scaffolds [4] [73].

Success Stories and Technical Implementation

Recent advances demonstrate the power of engineering P450s for synthetic applications.

• Skeletal Editing of Natural Products: A 2025 study detailed a chemoenzymatic strategy for the skeletal editing of natural products. Researchers engineered P450 catalysts to perform site-selective oxidation of aliphatic C–H bonds. This was coupled with subsequent Baeyer-Villiger rearrangement or ketone homologation to achieve a ring expansion, effectively altering the core scaffold of the molecule. This P450-controlled "skeletal editing" provided a powerful tool to rapidly generate analogs with drastically altered biological activity for drug discovery [4].

  • Experimental Protocol Outline:
    • Library Generation: A library of P450 variants was created via random and saturation mutagenesis, targeting residues involved in substrate binding and heme coordination.
    • Screening: Variants were expressed in a suitable host (e.g., E. coli) and screened for the desired oxidative activity on the natural product substrate using a high-throughput assay (e.g., HPLC or LC-MS).
    • Biocatalytic Transformation: The best-performing variant was used to oxidize the native natural product scaffold.
    • Chemical Rearrangement: The P450-generated ketone intermediate was isolated and subjected to classical chemical steps (Baeyer-Villiger reaction) to yield the ring-expanded final product.
    • Activity Assessment: The skeletally edited analogs were evaluated for their anticancer activity.

• Overcoming Catalytic Bottlenecks: The application of P450s in synthesis often faces challenges like poor expression, limited substrate scope, and inefficient electron transfer. A 2025 review highlights engineering strategies to overcome these hurdles, including:

  • Cofactor Engineering: Optimizing the supply of the heme cofactor and engineering more efficient redox partner interactions to enhance total turnover numbers [73].
  • Substrate Tunnel Engineering: Mutating residues lining access tunnels to the active site to alter substrate specificity and enable the acceptance of bulkier natural product substrates [73].

Enzyme Databases

The foundation of any successful enzyme engineering project, especially computational and semi-rational efforts, is high-quality data. The following table summarizes key databases.

Table 2: Key Enzyme Databases for Research and Engineering [74]

Database Type	Database Name	Primary Function	Curation
Nomenclature	ExplorEnz, IntEnz	Provides official IUBMB enzyme classification (EC numbers).	Manual
Kinetics & Function	BRENDA, SABIO-RK	Comprehensive repository of functional and kinetic parameters.	Manual & Automated
Structure	Protein Data Bank (PDB), AlphaFold DB	Repository of experimentally-solved and AI-predicted protein structures.	Manual & Automated
Reactions & Pathways	Rhea, MetaCyc, KEGG	Curates biochemical reactions and metabolic pathways.	Manual
Reaction Mechanism	M-CSA (Mechanism and Catalytic Site Atlas)	Annotates catalytic residues and step-by-step reaction mechanisms.	Manual

Research Reagent Solutions

Table 3: Essential Research Reagents and Kits for Directed Evolution

Item	Function in Enzyme Engineering	Example Application
Kapa Biosystems Polymerases	Engineered DNA polymerases for PCR and library construction with high fidelity, processivity, and inhibitor resistance.	Error-prone PCR for random mutagenesis; amplification of mutant genes [68].
High-Throughput Screening Assays	Fluorogenic/Chromogenic substrates, coupled enzyme assays.	Quantitative screening of mutant library activity in microtiter plates [71] [68].
Phage Display Vectors	Vectors for displaying peptide/protein libraries on phage surfaces.	Selection of antibodies or binding proteins with enhanced affinity [71] [69].
Specialized Expression Hosts	E. coli, yeast, or cell-free systems for protein expression.	High-yield expression of mutant protein libraries for functional screening [73].

Directed evolution and computational design are synergistic pillars of modern enzyme engineering. Directed evolution excels at optimizing function without requiring mechanistic depth, while computational design provides a rational framework to navigate the vastness of protein sequence space. As the field progresses, the integration of these approaches—supported by rich enzyme databases, machine learning, and automated workflows—is poised to dramatically accelerate the development of bespoke biocatalysts. This powerful synergy is particularly transformative for chemoenzymatic strategies in natural product synthesis, enabling the efficient creation of novel, bioactive molecules and paving the way for greener manufacturing processes in the pharmaceutical and fine chemical industries.

The integration of biocatalysis into the synthesis of complex natural products represents a paradigm shift in synthetic chemistry, offering unparalleled regio-, chemo-, and enantioselectivity for challenging transformations [13]. However, the widespread application of enzymes in industrial processes, particularly within pharmaceutical development, is often constrained by their inherent limitations in thermostability, solvent tolerance, and catalytic activity under non-physiological conditions [75]. The pursuit of obtaining enzymes with high activity and stability remains a grail in enzyme evolution due to the well-documented stability-activity trade-off [76]. For practitioners of chemoenzymatic synthesis targeting complex natural products, overcoming these limitations is crucial for implementing efficient, scalable, and environmentally friendly synthetic routes [13] [77]. This technical guide examines contemporary strategies and detailed methodologies for enhancing biocatalyst performance, framed within the practical demands of natural product synthesis.

Strategic Approaches to Biocatalyst Optimization

Machine Learning-Guided Enzyme Engineering

The integration of machine learning (ML) with protein engineering has ushered in a new phase for biocatalysis, enabling the systematic improvement of enzyme properties beyond traditional directed evolution [75] [76]. ML models, particularly structure-based supervised learning, can predict enzyme function and fitness by analyzing complex sequence-structure-activity relationships, thus navigating the vast mutational space more efficiently [76]. For instance, the iCASE (isothermal compressibility-assisted dynamic squeezing index perturbation engineering) strategy employs multi-dimensional conformational dynamics to identify key regulatory residues outside the active site that influence both stability and activity [76]. This approach constructs hierarchical modular networks for enzymes of varying complexity—from simple monomeric enzymes to complex multimeric structures—allowing for targeted mutations that synergistically improve multiple performance metrics [76].

Solvent Engineering with Neat Natural Deep Eutectic Solvents

The application of Natural Deep Eutectic Solvents (NaDES) has emerged as a powerful strategy for enhancing enzyme stability and activity in non-aqueous environments [78]. Unlike conventional organic solvents, certain NaDES designs can create stabilizing interactions with enzyme structures, leading to improved activity and higher thermal stability [78]. The design of these solvent systems using computational tools like COSMO-RS allows for the rational selection of solvent components that optimize enzyme-solvent interactions, crucial for maintaining catalytic competence in media necessary for dissolving hydrophobic natural product intermediates [78].

Advanced Protein Engineering Frameworks

Traditional protein engineering approaches continue to evolve, with directed evolution remaining a cornerstone methodology for biocatalyst improvement [75]. However, the timeline for engineering suitable biocatalysts must align with the accelerated pace of pharmaceutical development, where a 10× improvement in protein engineering speed is needed to meet industry demands [75]. Current strategies often combine semi-rational design with high-throughput screening, utilizing computational tools for in silico design of smart libraries, homology modeling, and identification of hotspots for saturation mutagenesis [79]. Engineering enzymes for thermostability often focuses on enhancing hydrophobic interactions, hydrogen bonds, salt bridges, and surface charges, while activity modifications may involve channel engineering, modification of dynamic properties, and editing recognition elements such as loops [76].

Table 1: Key Strategic Approaches for Biocatalyst Optimization

Approach	Core Methodology	Primary Applications	Reported Improvements
Machine Learning (iCASE) [76]	Structure-based supervised ML predicting function/fitness; Dynamic Squeezing Index (DSI) analysis	Thermostability & activity enhancement for monomeric & multimeric enzymes	- PG Monomer: 1.82× specific activity [76]- XY TIM Barrel: 3.39× specific activity; +2.4°C Tm [76]
Solvent Engineering [78]	COSMO-RS designed Natural Deep Eutectic Solvents (NaDES)	Biocatalysis in non-aqueous media; enhanced solvent tolerance	Improved activity & thermal stability in neat NaDES [78]
Directed Evolution [75]	Iterative mutagenesis & high-throughput screening	Broad applicability for all enzyme properties; creating "new-to-nature" activity	Industry standard; enabled commercial processes (e.g., sitagliptin synthesis) [75]

Experimental Protocols for Key Methodologies

Protocol: Machine Learning-Guided Enzyme Engineering with iCASE

The iCASE strategy provides a general method for identifying mutation sites that enhance both stability and activity across enzymes of varying structural complexity [76].

Step 1: Identify High-Fluctuation Regions

• Perform molecular dynamics simulations to calculate isothermal compressibility (βT) across the enzyme structure.
• Identify secondary structures or loops with high βT fluctuations (e.g., α-helices, loops near active sites) as potential modification targets [76].

Step 2: Calculate Dynamic Squeezing Index (DSI)

• Compute DSI values for residues in the identified high-fluctuation regions.
• Selection criterion: Residues with DSI > 0.8 (representing the top 20% of scores) are considered candidate mutation sites [76].

Step 3: Predict Energetic Impacts

• Use computational tools like Rosetta 3.13 to predict changes in folding free energy (ΔΔG) upon mutation.
• Filter candidates based on predicted stabilizing mutations (negative ΔΔG) or neutral mutations [76].

Step 4: Experimental Validation

• Express and purify selected single-point mutants.
• Assess specific activity and thermal stability (e.g., Tm by DSF/CD spectroscopy).
• Combine beneficial mutations to generate multi-point mutants with synergistic effects [76].

Protocol: High-Throughput Screening for Solvent Tolerance

Step 1: Library Design

• Create mutant libraries via epPCR or site-saturation mutagenesis at identified hotspots.
• For solvent tolerance, focus on surface residues that may interact with solvent molecules [79].

Step 2: Microtiter Plate Screening

• Cultivate clones in 96- or 384-well plates with expression induction.
• Lysate cells and transfer aliquots to assay plates containing buffer with varying concentrations of target solvents (e.g., DMSO, methanol, or specific NaDES) [79].
• For hydrolases, use chromogenic substrates (e.g., p-nitrophenyl esters); for other enzymes, couple to NADH consumption/production monitored at 340 nm [79].

Step 3: Hit Validation

• Re-test positive clones in small-scale (e.g., 5-10 mL) reactions to confirm improved performance.
• Characterize kinetic parameters (kcat, KM) and thermostability (T50, Tm) in the presence of solvents [79].

Visualization of Workflows and Relationships

ML-Guided Enzyme Engineering Workflow

Solvent Tolerance Screening Pipeline

The Scientist's Toolkit: Essential Research Reagents and Solutions

Table 2: Key Research Reagents for Biocatalyst Optimization

Reagent/Solution	Function/Purpose	Application Examples
Natural Deep Eutectic Solvents (NaDES) [78]	Green solvent medium enhancing enzyme stability/activity	Biocatalysis in non-aqueous media for hydrophobic natural product substrates [78]
Rosetta Software Suite [76]	Predicts changes in protein folding free energy (ΔΔG) upon mutation	Computational filtering of mutation candidates to prioritize stabilizing variants [76]
Chromogenic Substrates (pNP-esters) [79]	Hydrolase activity detection via spectrophotometric measurement	High-throughput screening of mutant libraries in microtiter plates [79]
Cofactor Recycling Systems [75]	Regenerates expensive cofactors (NAD(P)H, ATP) for economical processes	Enabling use of ketoreductases, transaminases in synthesis [75]
Immobilization Supports [80]	Enhances enzyme reusability, stability, and facilitates continuous processing	Enzyme reuse in batch reactions; packed-bed reactors for flow chemistry [81]

The continuous improvement of biocatalysts through advanced engineering strategies is fundamental to advancing chemoenzymatic approaches for natural product synthesis. By leveraging machine learning predictions, innovative solvent systems, and high-throughput engineering methodologies, researchers can systematically overcome the traditional limitations of enzyme thermostability, solvent tolerance, and activity. The integration of these optimized biocatalysts into synthetic sequences enables more efficient, sustainable, and stereocontrolled routes to complex natural products, pushing the boundaries of what is achievable in synthetic chemistry [13] [77]. As these technologies mature and become more accessible, they promise to further expand the synthetic chemist's toolbox, accelerating drug development and the discovery of novel bioactive molecules.

The synthesis of complex natural products represents a formidable challenge in organic chemistry, driven by the need for pharmaceuticals and fine chemicals. Within this field, chemoenzymatic strategies have emerged as powerful methods that combine the precision of biological catalysts with the flexibility of synthetic organic chemistry [10] [82]. A cornerstone of these approaches is the efficient recycling of enzyme cofactors, particularly NAD(P)H, ATP, and CoA derivatives. Without regeneration, these expensive cofactors would render industrial-scale biotransformations economically unfeasible [83]. Sustainable cofactor regeneration systems therefore serve as enabling technologies that enable the practical application of oxidoreductases, kinases, and acyltransferases in multi-step synthetic sequences. This review examines contemporary cofactor recycling methodologies within the context of natural product synthesis, providing technical guidance for researchers developing chemoenzymatic routes to valuable target molecules.

NAD(P)H Regeneration Systems

Enzymatic NAD(P)+ Regeneration via NAD(P)H Oxidases

Nicotinamide adenine dinucleotide (phosphate) oxidases (NOXs) are fundamental enzymes for NAD(P)+ regeneration, catalyzing the oxidation of NAD(P)H to NAD(P)+ while reducing oxygen to either water (Hâ‚‚O-forming) or hydrogen peroxide (Hâ‚‚Oâ‚‚-forming) [83]. The Hâ‚‚O-forming NOXs are particularly valuable for industrial applications due to their superior compatibility with other enzymes in aqueous reaction systems. These enzymes enable efficient coupling with NAD(P)+-dependent dehydrogenases, facilitating redox reactions without cofactor accumulation.

The application of NOX-based regeneration is exemplified in the synthesis of rare sugars, which serve as precursors to pharmaceutical agents. The table below summarizes several successful implementations:

Table 1: NAD(P)+ Regeneration in Rare Sugar Synthesis

Product	Dehydrogenase	NOX Source	Yield	Application
L-Tagatose	Galactitol Dehydrogenase (GatDH)	SmNOX	90% (12 h)	Food additive, low-calorie sweetener [83]
L-Xylulose	Arabinitol Dehydrogenase (ArDH)	NOX	93%	Pharmaceutical precursor [83]
L-Gulose	Mannitol Dehydrogenase	NOX	5.5 g/L	Anticancer drug building block [83]
L-Sorbose	Sorbitol Dehydrogenase	NOX	92%	Intermediate for L-ascorbic acid [83]

Experimental Protocol: L-Tagatose Production with Cofactor Regeneration

• Reaction Conditions: 100 mM substrate (galactitol), 3 mM NAD+, GatDH, and Hâ‚‚O-forming NOX (SmNOX) in appropriate buffer [83].
• Procedure: Incubate the reaction mixture at optimal temperature (typically 30-37°C) with mild agitation. Monitor reaction progress via HPLC or TLC.
• Product Isolation: Terminate reaction by heat inactivation or organic solvent extraction. Purify L-tagatose using column chromatography or crystallization.
• Alternative Immobilization Approach: Prepare combined cross-linked enzyme aggregates (CLEAs) containing both GatDH and SmNOX to enhance thermal stability and reusability [83].

Cofactor-Independent Approaches: Photobiocatalysis

Recent innovations have introduced cofactor-independent reduction systems that circumvent the need for traditional nicotinamide cofactors altogether. One groundbreaking approach utilizes hybrid photobiocatalysts comprising reductive graphene quantum dots (rGQDs) and cross-linked enzymes [84].

Experimental Protocol: Cofactor-Free Photobiocatalytic Reduction

• Catalyst Preparation: Synthesize rGQDs via microwave-assisted method. Cross-link aldo-keto reductase (AKR) using bio-orthogonal chemistry. Assemble rGQDs/AKR hybrid through self-assembly via cation-Ï€, anion-Ï€, and hydrophobic interactions [84].
• Reaction Setup: Suspend rGQDs/AKR catalyst in aqueous buffer with substrate. Illuminate with infrared light (980 nm) to activate rGQDs, which split water to generate hydrogen atoms.
• Reduction Process: Hydrogen atoms transfer directly from rGQDs to enzyme-bound substrate through short-range transfer.
• Product Recovery: Filter insoluble hybrid catalyst for reuse. Extract product with organic solvent. Isolate via chromatography.
• Performance Metrics: This system achieves 82% yield for pharmaceutical intermediate (R)-1-[3,5-bis(trifluoromethyl)-phenyl] ethanol with >99.99% enantiomeric excess [84].

Figure 1: Cofactor-independent photobiocatalysis using rGQDs and enzymes. The system uses infrared light and water as a hydrogen source for enantioselective reductions [84].

ATP Regeneration Systems

Enzymatic ATP Recycling in Nucleotide Sugar Synthesis

Adenosine triphosphate (ATP) regeneration is crucial for phosphorylation reactions, particularly in the synthesis of uridine diphosphate sugars (UDP-sugars) that serve as glycosyl donors for glycosyltransferases [85]. These activated sugars are essential building blocks for oligosaccharides and glycoconjugates with various biological activities.

The general enzymatic pathway for UDP-sugar synthesis involves:

• Sugar activation to sugar-1-phosphate by a kinase (requires ATP)
• UDP transfer from UTP to sugar-1-phosphate by UDP-sugar pyrophosphorylase
• Byproduct degradation of pyrophosphate (PPi) by inorganic pyrophosphatase

Experimental Protocol: Chemoenzymatic UDP-GalNAc Synthesis

• Reaction Components: UMP, sucrose, nucleoside monophosphate kinase, sucrose synthase, galactose-1-phosphate uridyl transferase, phosphoglucomutase, glucose-6-phosphate dehydrogenase, pyruvate kinase, lactate dehydrogenase [85].
• ATP/UTP Regeneration: Pyruvate kinase regenerates ATP from ADP using phosphoenolpyruvate. UTP is regenerated through coupled enzyme systems.
• Reaction Conditions: Combine all enzymes and substrates in appropriate buffer with Mg²⁺ as cofactor. Incubate at 30-37°C with monitoring.
• Product Formation: Enzymatic steps yield 42% UDP-GalNAc, followed by chemical N-acetylation to produce final UDP-GalNAc [85].

Table 2: Key UDP-Sugars and Their Applications

UDP-Sugar	Primary Application	Synthetic Method
UDP-Glc	Glycogen, cellulose	Enzymatic from sucrose [85]
UDP-Gal	Lactose, glycoproteins	Epimerization of UDP-Glc [85]
UDP-GlcNAc	Glycosaminoglycans	Chemoenzymatic with N-acetylation [85]
UDP-GalNAc	Mucins, proteoglycans	Chemoenzymatic from UMP [85]
UDP-Xyl	Proteoglycans	Enzymatic oxidation of UDP-Glc [85]

Figure 2: ATP-dependent enzymatic pathway for UDP-sugar synthesis. Multiple enzymes work in concert with ATP regeneration to produce activated sugar nucleotides [85].

Integrated Cofactor Regeneration in Complex Synthesis

Multi-Enzyme Cascades with Cofactor Recycling

Advanced chemoenzymatic syntheses increasingly employ one-pot multi-enzyme (OPME) systems that simultaneously regenerate multiple cofactors. These cascades exemplify the power of integrated cofactor management in complex molecule construction.

Case Study: Nepetalactone Synthesis

• Enzyme System: Ten-enzyme cascade including reductases, oxidases, and cyclases [10] [77].
• Cofactor Management: NAD+/NADH system simultaneously supports oxidative and reductive steps through careful enzyme selection and reaction optimization.
• Performance: 93% yield with three contiguous stereocenters set stereoselectively [10].
• Scale Potential: System capable of producing approximately 1 g nepetalactone per liter at reasonable cost (<$120/g) [10].

Case Study: Triterpene Synthesis

• Phosphorylation Cascade: Monophosphorylation by EcTHIM, diphosphorylation by MjIPK (both requiring ATP regeneration) [77].
• ATP Regeneration: Pyruvate kinase (PK) replenishes ATP pool using phosphoenolpyruvate [77].
• Product Diversity: System produces seven sesquiterpenoid compounds and antibacterial (S)-germacrene D from simple 4- or 5-carbon starting materials [77].

The Scientist's Toolkit: Essential Research Reagents

Table 3: Key Reagents for Cofactor Regeneration Systems

Reagent/Enzyme	Function	Application Notes
Hâ‚‚O-forming NOX	NAD+ regeneration from NADH with Oâ‚‚ reduction to Hâ‚‚O	Preferred over Hâ‚‚Oâ‚‚-forming variants for enzyme compatibility [83]
rGQDs/AKR hybrid	Cofactor-free reduction using light and water	Requires IR illumination; excellent enantioselectivity [84]
Pyruvate Kinase (PK)	ATP regeneration from ADP	Uses phosphoenolpyruvate as phosphate donor [85] [77]
Sucrose Synthase	UDP-Glc generation from sucrose and UDP	Key for UDP-sugar precursor synthesis [85]
Inorganic Pyrophosphatase	PPi hydrolysis to Pi	Drives equilibrium toward product formation in nucleotide synthesis [85]
Formate Dehydrogenase (FDH)	NADH regeneration from NAD+ with formate oxidation	Clean reaction with gaseous COâ‚‚ byproduct [84]

Sustainable cofactor regeneration represents more than a mere technical necessity in chemoenzymatic synthesis—it constitutes a fundamental enabling technology that determines the economic viability and environmental impact of bio-based production routes for natural products and pharmaceuticals. The continued development of efficient NAD(P)H, ATP, and CoA recycling systems directly correlates with our capacity to access increasingly complex molecular architectures.

Future advancements will likely focus on further minimizing cofactor dependence through photobiocatalytic approaches, improving the integration of multiple regeneration systems in complex cascades, and engineering more robust enzymes capable of withstanding industrial process conditions. As these technologies mature, they will undoubtedly unlock new possibilities in the synthesis of bioactive natural products, expanding the toolbox available to researchers in pharmaceutical development and synthetic biology.

Reaction engineering, focusing on the precise optimization of solvent systems, temperature, and pH, provides the foundational control required for successful chemoenzymatic strategies in natural product synthesis. For researchers and drug development professionals, mastering these parameters is not merely about improving yields but about strategically enabling complex transformations that are essential for constructing intricate molecular architectures found in bioactive natural products. The unique synergy of chemical and enzymatic catalysis in these pathways demands a sophisticated understanding of how reaction conditions influence both biological and traditional catalytic components simultaneously [10]. This guide details the core engineering principles and practical methodologies for optimizing these critical parameters, with a specific focus on applications within natural product research.

The field has witnessed a significant expansion, with chemoenzymatic methods being adopted for the synthesis of high-value pharmaceutical agents such as sitagliptin, simvastatin, and darunavir, underscoring the industrial and research relevance of these approaches [10]. These methods integrate the twelve principles of green chemistry, leveraging the inherent benefits of enzymes as non-toxic, renewable, and highly selective catalysts that often operate under ambient conditions in aqueous or biphasic media, thereby enhancing atom economy and reducing waste [10]. The following sections provide an in-depth technical exploration of how to systematically engineer solvent, temperature, and pH environments to harness the full potential of chemoenzymatic synthesis.

Solvent System Optimization

The choice of solvent is one of the most accessible and powerful variables in reaction engineering, profoundly influencing solubility, reaction rates, selectivity, and enzyme stability.

Computational Solvent Selection and Greenness Evaluation

Modern solvent optimization has moved beyond trial-and-error approaches to sophisticated computational methods. Tools like COSMO-RS (Conductor-like Screening Model for Real Solvents) can navigate the combinatorially complex problem of selecting optimal solvent mixtures by incorporating thermodynamic parameters into a Mixed Integer Nonlinear Programming (MINLP) formulation. This allows for the identification of optimal solvent systems for objectives such as maximizing solute solubility or optimizing liquid-liquid extraction efficiency [86].

Complementing this, Linear Solvation Energy Relationships (LSERs) using Kamlet-Abboud-Taft parameters (hydrogen bond donating ability α, hydrogen bond accepting ability β, and dipolarity/polarizability π) can quantitatively correlate solvent polarity with reaction performance. For instance, the trimolecular aza-Michael addition between dimethyl itaconate and piperidine is accelerated by polar, hydrogen bond-accepting solvents, yielding the relationship: ln(k) = −12.1 + 3.1β + 4.2π [87]. This model allows researchers to predict reaction rates in untested solvents.

Solvent greenness must be evaluated alongside performance. The CHEM21 solvent selection guide provides scores for safety (S), health (H), and environment (E), typically on a scale from 1 (greenest) to 10 (most hazardous) [87]. Plotting solvent performance (e.g., ln(k)) against these greenness scores enables the identification of solvents that are both high-performing and environmentally benign, moving away from problematic solvents like DMF towards safer alternatives [87].

Table 1: Key Solvent Optimization Strategies and Tools

Strategy/Tool	Key Function	Application Example
COSMO-RS Optimization [86]	Selects optimal solvent mixtures to maximize/minimize objectives like solubility or extraction efficiency.	Formulating solvent systems for liquid-liquid extraction of natural product precursors.
Linear Solvation Energy Relationships (LSER) [87]	Correlates reaction rates with solvent polarity parameters to understand mechanism and predict performance.	Identifying that a reaction is favored by hydrogen bond-accepting solvents (positive β coefficient).
CHEM21 Solvent Guide [87]	Evaluates solvent greenness based on Safety, Health, and Environmental (SHE) profiles.	Shortlisting high-performing solvents with a combined SHE score of <10.
One-Pot Multi-Enzyme (OPME) Systems [10]	Enables cascades of reactions in a single vessel, often in aqueous media, improving efficiency.	Synthesis of nepetalactolone from geraniol using a 10-enzyme cascade in a single pot [10].

The Scientist's Toolkit: Key Reagent Solutions

Table 2: Essential Research Reagents for Chemoenzymatic Reaction Engineering

Reagent/Category	Function in Chemoenzymatic Synthesis
Terpene Cyclases [18]	Enzymes that cyclize linear isoprenoid diphosphates (e.g., FPP, GPP) to construct the core carbocyclic skeletons of terpenoids.
CYPs / P450 Enzymes [18] [4]	Catalyze site-selective oxidations, such as C-H hydroxylation; can be engineered for divergent regioselectivity.
Urease [88]	Used in reaction-diffusion systems to convert urea (Pro-A) to ammonium bicarbonate (A), generating a pH gradient (a base) in situ.
Cationic Gold Nanoparticles (GNP) [88]	Act as catalysts for base-catalyzed reactions (e.g., Kemp Elimination) and can retard the diffusion of anionic inhibitors.
Photoredox Catalysts [18]	Enable radical-based transformations via visible light activation, offering unique bond disconnections.
KitAlysis Screening Kits [89]	High-throughput screening kits for efficient identification and optimization of catalytic reaction conditions.
SYNTHIA Software [89]	Retrosynthesis software that analyzes custom pathways for known and new molecules.

Temperature and Concentration Optimization

Temperature is a critical parameter that directly influences reaction kinetics, enzyme stability, and overall process efficiency. The Arrhenius equation describes the fundamental relationship between temperature and reaction rate, making it a cornerstone of thermal optimization [90].

Advanced optimization techniques, such as the Response Surface Methodology (RSM), can be employed to identify the complex interactions between temperature and other variables like reactant concentration and diffusivity. For example, one study achieved optimal efficiency for a reaction system with a heat source set at 2.555°C, a diffusivity of 0.025, and an inner vessel diameter of 3.144 cm [90]. This demonstrates that optimal temperatures are often not intuitive and must be determined experimentally in the context of the entire system. Furthermore, research has confirmed that concentration changes significantly as reactant temperature increases, releasing more heat and creating a complex, inter-dependent relationship between these parameters [90].

The use of One-Pot Multi-Enzyme (OPME) cascades presents a particular challenge and opportunity for temperature control. These systems, as demonstrated in the synthesis of nepetalactolone, can integrate multiple enzymatic steps (e.g., allylic hydroxylation, alcohol oxidation, aldehyde reduction, cyclization) in a single vessel [10]. The temperature must be carefully chosen to maintain the activity and stability of all enzymes in the cascade. A significant advantage of these systems is their ability to perform both oxidative and reductive steps in the same pot using a shared NAD/NADH cofactor system, which is highly sensitive to temperature [10].

Table 3: Temperature and Concentration Optimization Parameters

Parameter	Optimization Method	Exemplary Optimal Value
Reaction Temperature	Response Surface Methodology (RSM) [90]	Heat source = 2.555°C [90]
Diffusivity	Finite Element Method (in software like FlexPDE) [90]	Diffusivity = 0.025 [90]
System Geometry	Design of Experiments (DoE) [90]	Diameter of inner vessel = 3.144 cm [90]
Enzyme Cascade Efficiency	One-Pot Multi-Enzyme (OPME) System [10]	10-enzyme cascade for nepetalactone synthesis at 93% yield [10]

pH Optimization and Spatial Control in Reaction-Diffusion Systems

pH is a pivotal variable in chemoenzymatic systems, affecting enzyme activity, substrate ionization, and product stability. Beyond maintaining a uniform pH, advanced reaction engineering now involves the spatial and temporal control of pH gradients using reaction-diffusion systems to mimic sophisticated biological signaling patterns.

Experimental Protocol: Establishing a Local Inhibition and Distal Activation (LIDA) System

The following methodology outlines the creation of a chemoenzymatic LIDA system, which is crucial for spatiotemporal gating of reaction activation [88].

Materials and Setup:

• Hydrogel Matrix: A 0.75 wt% agarose gel is prepared in a Petri dish, with a central 5 mm diameter vacant zone. The gel height is 3 mm.
• Embedded Components: The gel is embedded with:
  • Cationic CTAB-capped Gold Nanoparticles (GNP): Catalyst for the Kemp Elimination reaction.
  • Urease (E): Enzyme for activator generation.
  • Substrate (R): 5-Nitrobenzisoxazole (NBI), the substrate for the Kemp Elimination reaction.
• Injection Solutions:
  • Pro-Activator (ProA): Urea solution.
  • Inhibitor (IN): Adenosine triphosphate (ATP) solution.

Procedure:

• Gel Preparation: Cast the agarose gel with the embedded components (GNP, urease, NBI) around the central vacant zone.
• Solution Injection: Introduce a mixture of ProA (urea) and IN (ATP) into the central vacant zone.
• Diffusion and Reaction: Allow the components to diffuse through the gel matrix.
  • The neutral ProA (urea) diffuses rapidly through the gel without binding to GNP.
  • The anionic IN (ATP) diffuses slowly because its diffusion is restricted due to binding with the cationic GNP.
  • During diffusion, urease enzymatically converts the diffusing ProA (urea) to the Activator (A), which is ammonium bicarbonate (a base).
• Reaction Activation (Kemp Elimination): The Activator (A) initiates the base-catalyzed Kemp Elimination reaction, converting NBI (R) to 2-cyanonitrophenol (P), which is accompanied by a color change.
• Observation: The reaction (color change) is locally inhibited near the injection center due to the high concentration of the slow-diffusing IN (ATP). However, the reaction is activated distally (far from the injection zone), where the Activator (A) has arrived but the Inhibitor (IN) has not, thus creating a zone of distal activation.

This LIDA effect is a hallmark of biological signaling and can be spatiotemporally gated by modifying the ratio of injected ProA to IN [88].

Workflow Visualization: Chemoenzymatic LIDA System

The following diagram illustrates the logical relationship and workflow of the LIDA system:

Diagram Title: Workflow of a Local Inhibition and Distal Activation (LIDA) System

Integrated Case Studies in Natural Product Synthesis

Chemoenzymatic Synthesis of Artemisinin

The semi-synthetic production of the antimalarial drug artemisinin is a landmark achievement in chemoenzymatic synthesis and reaction engineering [18]. The process involves a highly engineered S. cerevisiae strain equipped with an optimized mevalonate (MVA) pathway, an amorphadiene synthase, and the P450 CYP71AV1 from A. annua. This biological system converts sugar to amorpha-4,11-diene, which is then oxidized to artemisinic acid. Through meticulous metabolic engineering to optimize precursor flux and P450 expression stoichiometry, titers of artemisinic acid exceeding 25 g L⁻¹ were achieved via fermentation [18].

The chemical conversion of artemisinic acid to artemisinin involves a critical photo-oxidation step. The acid is first functionalized to a mixed anhydride, which then undergoes a Schenck ene/rearrangement cascade with singlet oxygen (¹O₂). This step is proposed to proceed via a radical mechanism and has been scaled up using specialized photochemical reactors to ensure optimal quantum photonic yield, showcasing the importance of engineering light-based reaction parameters [18].

Chemoenzymatic Skeletal Editing via Ring Expansion

A cutting-edge application of reaction engineering is the chemoenzymatic skeletal editing of natural product scaffolds. A recent strategy combines P450-controlled site-selective oxidation with subsequent Baeyer-Villiger rearrangement or ketone homologation [4]. This synergistic approach allows for ring expansion at the level of one or more aliphatic C─H sites.

Experimental Protocol:

• Enzymatic Oxidation: An engineered P450 enzyme performs a site-selective oxidation of a specific methylene group (-CHâ‚‚-) within a complex natural product scaffold, converting it to a ketone.
• Chemical Rearrangement/Homologation: The resulting ketone is then subjected to a classical chemical transformation:
  • Baeyer-Villiger Rearrangement: An oxygen atom is inserted adjacent to the carbonyl carbon, converting the ketone to an ester and effectively expanding the ring.
  • Ketone Homologation: Alternative reactions that extend the carbon skeleton adjacent to the carbonyl group.
• Outcome: This combined chemoenzymatic process directly targets aliphatic C-H bonds with tunable selectivity, enabling the rapid generation of a panel of skeletally diverse analogs from a single natural product. This has proven powerful in drug discovery, as such skeletal modifications can drastically alter anticancer activity [4].

The strategic optimization of solvent systems, temperature, and pH is indispensable for advancing chemoenzymatic strategies in natural product synthesis. As demonstrated, this extends beyond traditional one-variable-at-a-time approaches to encompass integrated, model-guided methods like COSMO-RS and RSM, as well as sophisticated systems that exploit parameter gradients for spatiotemporal control. The continued evolution of reaction engineering—fueled by advances in enzyme engineering, computational modeling, and a steadfast commitment to green chemistry principles—will undoubtedly unlock new, efficient, and sustainable routes to complex natural products and their analogues for drug discovery and development.

The integration of enzymatic and chemical synthesis steps has emerged as a powerful paradigm for the efficient construction of complex natural products and active pharmaceutical ingredients (APIs). Within this chemoenzymatic framework, enzyme promiscuity—the ability of enzymes to catalyze reactions with non-native substrates or via non-native mechanisms—represents a critical asset for overcoming inherent substrate limitations. This capacity for versatile catalysis enables synthetic chemists to access a broader range of synthetic transformations, streamline synthetic routes, and access innovative retrosynthetic disconnections that would be challenging or impossible using traditional synthetic methods alone [91].

The strategic importance of enzyme promiscuity extends throughout modern synthetic chemistry. Recent advances have demonstrated that chemoenzymatic approaches can dramatically shorten synthetic pathways to complex molecules, as exemplified by the engineered ribosyl-1-kinase used in molnupiravir synthesis, which reduced the synthetic step count by 70% while achieving a sevenfold higher yield [92]. Similarly, the combination of biocatalytic retrosynthesis with radical-based transformations has opened doors to new strategic bond disconnections in natural product synthesis [18]. As the field continues to evolve, understanding, predicting, and harnessing enzyme promiscuity has become essential for researchers aiming to develop more efficient synthetic routes to valuable molecules.

Fundamental Concepts: Classification of Enzyme Promiscuity

Enzyme promiscuity is generally categorized into three distinct types, each with different mechanistic bases and synthetic applications [93]. A comprehensive understanding of these categories is essential for strategically selecting and engineering enzymes for synthetic applications.

Substrate Promiscuity

Substrate promiscuity refers to an enzyme's ability to catalyze the same chemical transformation across multiple structurally distinct substrates. This flexibility is largely attributed to adaptable active sites that can accommodate various molecular structures while maintaining the same fundamental catalytic mechanism. A classic example is methane monooxygenase, which can hydroxylate approximately 150 different substrates beyond its native methane [93]. In contrast, substrate-specific enzymes possess highly selective active sites that typically accommodate only one specific substrate, analogous to a key fitting precisely into a corresponding lock. The synthetic utility of substrate promiscuity is particularly valuable in diversifying natural product scaffolds and synthesizing analog libraries.

Catalytic Promiscuity

Catalytic promiscuity (also known as cross-reactivity or poly-reactivity) describes the capacity of a single enzyme to catalyze multiple chemically distinct reactions, often involving different transition states or catalytic mechanisms. This phenomenon is increasingly recognized as widespread in nature and plays a critical role in enzyme evolution [93]. According to the Yčas-Jensen theory, ancestral enzymes with dual catalytic functions existed at key evolutionary nodes, with catalytic promiscuity serving as a driving force that allowed enzymes to evolve from multifunctional ancestors into specialized catalysts [93]. Modern protein engineering efforts frequently exploit this latent promiscuity to develop new enzymatic functions.

Conditional Promiscuity

Conditional promiscuity emerges when enzymes exhibit altered substrate specificity or catalytic function under non-physiological conditions, such as in anhydrous media, extreme temperatures, or unusual pH values. For instance, lipases can catalyze ester substrates in both aqueous solutions and organic solvents, with organic solvent environments sometimes unlocking novel enzymatic functions due to enhanced substrate solubility or reversed reaction equilibria [93]. This form of promiscuity is particularly valuable for industrial biocatalysis where reaction conditions often deviate significantly from physiological norms.

Table 1: Classification and Characteristics of Enzyme Promiscuity Types

Promiscuity Type	Definition	Key Feature	Example
Substrate Promiscuity	Ability to catalyze the same transformation with multiple substrates	Spacious and adaptable active pocket	Methane monooxygenase hydroxylating ~150 substrates
Catalytic Promiscuity	Ability to catalyze multiple chemically distinct reactions	Different catalytic mechanisms or transition states	Cytochrome P450 catalysts engineered for non-native reactions
Conditional Promiscuity	Altered function under non-physiological conditions	Functionality in organic solvents, extreme pH, or temperature	Lipase catalysis in organic solvents

The following diagram illustrates the hierarchical relationship between these three types of enzyme promiscuity and their key characteristics:

Computational Approaches for Predicting and Exploiting Promiscuity

Computational tools have become indispensable for predicting enzyme promiscuity and planning chemoenzymatic synthetic routes, significantly reducing the experimental burden required to identify promising enzymatic transformations.

Machine Learning for Substrate Prediction

Support Vector Machine (SVM) classifiers trained on molecular fingerprints have demonstrated particular utility in predicting substrate-level enzyme promiscuity. These models can achieve approximately 80% accuracy in identifying novel substrates while requiring up to 33% fewer training compounds compared to approaches using all available tested compounds [94] [95]. The effectiveness of these models hinges on chemical diversity in training datasets; models trained on structurally diverse compounds demonstrate significantly better generalization to novel substrate scaffolds.

Active learning approaches further enhance the efficiency of promiscuity characterization by strategically selecting the most informative compounds for experimental testing. These methods prioritize substrates that resolve classification uncertainties, thereby maximizing the information gain from each experimental cycle. Implementation typically involves iterating through prediction, uncertainty sampling, experimental testing, and model retraining phases [94] [95].

Synthesis Planning Tools

Recent advances in computer-aided synthesis planning have produced specialized tools for designing hybrid chemoenzymatic routes:

• Synthetic Potential Score (SPScore): This approach uses a multilayer perceptron trained on reaction databases (USPTO for organic reactions, ECREACT for enzymatic reactions) to evaluate the potential of enzymatic or organic reactions for synthesizing a given molecule. The model generates two continuous values (S~Chem~ and S~Bio~) that reflect how favorable each reaction type is for a target molecule, guiding retrosynthetic planning [92].

• ACERetro: An asynchronous search algorithm guided by SPScore that demonstrated the ability to find hybrid synthesis routes for 46% more molecules compared to previous state-of-the-art tools when tested on a dataset of 1001 molecules [92].

• minChemBio: A computational tool that designs synthetic routes minimizing transitions between biological and chemical reaction steps, thereby reducing purification requirements. The tool employs a curated dataset of 1,808,938 chemical reactions from USPTO and 57,541 biological reactions from MetaNetX [6].

Table 2: Computational Tools for Chemoenzymatic Synthesis Planning

Tool Name	Core Methodology	Data Sources	Key Advantage
SPScore/ACERetro	Multilayer perceptron with asynchronous search	USPTO (484,706 reactions), ECREACT (62,222 reactions)	Finds hybrid routes for 46% more molecules
minChemBio	Transition minimization algorithm	USPTO (1.8M reactions), MetaNetX (57,541 reactions)	Reduces costly transitions between reaction types
SVM with Active Learning	Support vector machine with strategic sampling	BRENDA, ZINC, literature data	80% accuracy with 33% fewer training compounds

Experimental Methods for Characterizing Enzyme Promiscuity

Substrate Multiplexed Screening (SUMS)

Substrate Multiplexed Screening (SUMS) represents a powerful approach for simultaneously evaluating enzyme activity across multiple substrates in a single reaction mixture. Traditional single-substrate screening often inadvertently selects enzymes with high activity but narrow substrate scopes, whereas SUMS directly assesses catalyst promiscuity by measuring activity on competing substrates [96].

The experimental workflow for SUMS involves:

• Substrate Cocktail Design: Selecting structurally diverse substrates that represent the chemical space of interest
• Reaction Setup: Incubating enzyme variants with the substrate mixture
• Product Analysis: Using chromatographic (e.g., GC-MS, LC-MS) or spectroscopic methods to quantify multiple products simultaneously
• Data Interpretation: Analyzing product ratios to determine substrate preferences and identify variants with altered scope

A critical consideration in SUMS is that under initial velocity conditions with equimolar substrates, product abundances are proportional to the catalytic efficiencies (k~cat~/K~M~) of the individual reactions. However, when reactions proceed to higher conversion, the product profile becomes a heuristic readout of reactivity that incorporates effects of enzyme stability and inhibition [96].

The following diagram illustrates the SUMS workflow and its advantages over traditional screening methods:

Detailed SUMS Protocol for Promiscuity Assessment

Materials Required:

• Enzyme variants (e.g., site-saturation mutagenesis library)
• Substrate cocktail (3-5 structurally diverse compounds at equimolar concentrations)
• Appropriate reaction buffer
• Analytical standards for all potential products
• GC-MS or LC-MS system for analysis

Procedure:

• Prepare substrate cocktail in appropriate reaction buffer, ensuring all substrates are soluble and at equimolar concentrations (typically 0.1-1 mM each).
• Initiate reactions by adding enzyme variants to substrate cocktail.
• Incubate at optimal temperature for a predetermined time (consider both initial velocity and higher conversion timepoints).
• Quench reactions by heat inactivation or organic solvent addition.
• Analyze reaction mixtures using GC-MS or LC-MS with appropriate calibration curves for each potential product.
• Calculate product ratios and compare across enzyme variants to identify those with altered substrate specificity.

Data Interpretation:

• Under initial velocity conditions, product ratios directly reflect catalytic efficiency (k~cat~/K~M~) ratios
• At higher conversions, product profiles incorporate effects of enzyme stability, substrate inhibition, and differential depletion
• Variants showing increased activity toward multiple poor substrates indicate enhanced promiscuity
• Variants with dramatically altered product ratios suggest mutations that impact substrate specificity

Engineering Promiscuous Enzymes for Synthetic Applications

Protein engineering provides powerful tools to enhance or alter the inherent promiscuity of enzymes for synthetic applications. Both structure-based and directed evolution approaches have proven successful.

Engineering Strategies

Directed Evolution: This approach involves iterative rounds of mutagenesis and screening to enhance promiscuous activities without requiring detailed structural knowledge. The method is particularly valuable when the structural basis for promiscuity is poorly understood [93].

Rational Design: Based on structural information, this approach targets specific active site residues to modulate substrate scope. For example, structure-based modeling of RgnTDC suggested that active site residue W349 forms preclusive steric interactions with 5-substituted Trp analogs, guiding library design for altered specificity [96].

Semi-Rational Approaches: Combining elements of both methods, semi-rational design uses evolutionary information and structural insights to identify "hotspot" residues for randomization, creating focused libraries with higher probabilities of containing beneficial mutations [93].

Engineering Catalytic Promiscuity

Recent advances have demonstrated remarkable success in engineering catalytic promiscuity for synthetic applications. Notable examples include:

• Cytochrome P450 enzymes engineered to catalyze non-native reactions including C-H amination, cyclopropanation, and other carbene transfer reactions [93]
• Lipase variants engineered to catalyze aldol additions, representing a dramatic shift from their native hydrolytic function [93]

Engineering catalytic promiscuity often requires extensive remodeling of active sites and can be facilitated by computational design tools that identify promising mutation sites or even generate entirely new catalytic motifs.

Applications in Natural Product and Pharmaceutical Synthesis

The strategic application of promiscuous enzymes has enabled innovative approaches to natural product and active pharmaceutical ingredient synthesis, demonstrating the power of chemoenzymatic strategies.

Chemoenzymatic Synthesis of Complex Natural Products

Terpenoid Synthesis: The combination of terpene cyclases with radical-based functionalization has enabled efficient syntheses of complex terpenoids. For instance, Liu, Christmann and coworkers developed a concise synthesis of englerin A by employing heterologous production of guaia-6,10(14)-diene in S. cerevisiae using a promiscuous sesquiterpene cyclase, followed by chemical manipulations including hydrogen atom transfer-based olefin isomerization [18].

Alkaloid Synthesis: Pictet-Spenglerases have been employed for the convergent synthesis of isoquinoline scaffolds that can be elaborated to protoberberine alkaloids. Similarly, P450 enzymes have catalyzed asymmetric dimerization of diketopiperazines in the synthesis of naseseazine alkaloids [91].

Pharmaceutical Synthesis

Molnupiravir Synthesis: A chemo-enzymatic cascade was developed for the synthesis of the antiviral molnupiravir, featuring a five-enzyme cascade for 1-phosphorylation and nucleobase installation with an engineered MTR kinase and an engineered uridine phosphorylase [91].

Artemisinin Production: Semi-synthetic production combines microbial production of artemisinic acid in engineered yeast followed by chemical conversion to artemisinin, including a key Schenck ene/rearrangement cascade with ^1^O~2~ proposed to proceed via a radical mechanism [18].

The Scientist's Toolkit: Essential Research Reagents and Materials

Table 3: Essential Research Reagents for Studying Enzyme Promiscuity

Reagent/Material	Function/Application	Example Sources/References
Substrate Cocktails	SUMS assays for parallel activity assessment	Structurally diverse compounds representing target chemical space [96]
Molecular Fingerprints	Machine learning feature generation	ECFP4, MAP4 for SVM training [92]
Site-Saturation Mutagenesis Kits	Library generation for directed evolution	Commercial kits (NEB) or custom protocols [96]
Analytical Standards	Product identification and quantification	Commercial suppliers or synthetic preparation [96]
BRENDA Database	Source of enzyme substrate specificity data	https://www.brenda-enzymes.org/ [95]
Metabolic Intermediates	Testing native-like promiscuous activities	ZINC database, commercial suppliers [94]
Engineered Host Strains	Heterologous enzyme production	MVA-pathway engineered S. cerevisiae for terpene production [18]

Enzyme promiscuity represents a fundamental resource for overcoming substrate limitations in chemoenzymatic synthesis. As computational prediction methods continue to advance and high-throughput experimental characterization becomes more accessible, the systematic exploration and engineering of enzyme promiscuity will play an increasingly central role in synthetic chemistry. The integration of machine learning, automated laboratory workflows, and structure-guided engineering promises to accelerate our ability to harness nature's catalytic diversity for synthetic applications. For researchers in natural product synthesis and pharmaceutical development, embracing these tools and methodologies will be essential for designing next-generation synthetic routes that combine the precision of enzymatic catalysis with the versatility of synthetic chemistry.

The transition from milligram-scale synthesis in a research laboratory to industrial production is a pivotal, high-stakes endeavor in the development of chemoenzymatic processes for natural products. This scale-up process requires significant time and investment, often exceeding the resources spent on initial microbe and process development [97]. When approached properly, scale-up can be executed successfully, but omissions, oversights, and errors can prove costly—even fatal to the entire program [97]. For chemoenzymatic synthesis, which combines traditional chemical methods with enzymatic catalysis, scale-up presents unique challenges and opportunities. The field has gained substantial attention due to the exceptional benefits enzymes offer, including mild reaction conditions, remarkable chemo-, regio-, and stereoselectivity, and superior atom economy with minimal waste generation [40]. These advantages make chemoenzymatic approaches particularly valuable for synthesizing complex natural products, which often feature intricate structures with multiple stereocenters that are challenging to produce using conventional synthetic methods alone [10].

The financial implications of scale-up are substantial, with investments typically ranging from US $100 million to $1 billion for transitioning from laboratory to manufacturing scale, including intermediate process validation and plant construction [97]. The timeline for this transition generally spans 3-10 years, during which any deterioration in process performance can severely impact financial returns and stakeholder confidence [97]. Within this context, this technical guide examines core principles, methodologies, and practical considerations for successfully scaling chemoenzymatic processes for natural product synthesis, providing researchers and drug development professionals with a framework for navigating this critical development phase.

Guiding Principles for Successful Process Scale-Up

Foundational Scale-Up Philosophies

Based on experiences from commercializing various industrial microbial processes, three guiding principles emerge as critical for successful scale-up of chemoenzymatic processes [97]:

• Begin with the end in mind: A skilled project team should prepare a detailed conceptual design of the envisioned manufacturing process and plant before conducting initial laboratory experiments. This design, based on realistic biology, chemistry, and engineering assumptions, should include process flow diagrams, material and energy balances, unit operation designs, and techno-economic models. This initial investment is negligible compared to the total project cost and provides essential guidance to the experimental R&D program on process viability and key scale parameters [97].

• Be diligent in the details: Close attention to critical details enables scaling with minimal surprises, ultimately yielding a safe, reliable manufacturing plant that meets or exceeds financial objectives. Common oversights include failing to pilot first-of-a-kind processes, not validating industrial-grade raw materials ahead of scale-up, inadequate training of operations teams, and skipping sterility validation of fermentation systems [97].

• Prepare for the unexpected: Regardless of preparation, issues will arise during scale-up. Common examples include utility interruptions, microbial contamination, variable raw material quality, equipment fouling, equipment failure, and unexpected poor process performance at scale. Formal risk assessment and mitigation planning are essential, including brainstorming conceivable risks, rating probability and severity, and preparing detailed mitigation strategies [97].

Scale-Up Stages and Strategic Framework

Scale-up of industrial processes typically occurs in stages, particularly when there is a high degree of novelty in the process or commercial product. The first stage usually involves a pilot plant (pilot scale) with 100–10,000 L fermentors and matched downstream equipment. This stage translates the lab-scale process into a realistic scaled-down version of the manufacturing process. The second stage is a demonstration plant (demo scale) with 10,000–100,000 L fermentors and matched downstream processing, which serves to minimize risk before large capital investment in the full-scale manufacturing plant [97]. If the degree of novelty is low, the demonstration plant stage may be skipped to accelerate commercialization.

Table 1: Scale-Up Stages and Their Characteristics

Scale Stage	Typical Volume Range	Primary Purpose	Process Integration Level
Laboratory Scale	0.5–10 L	Microbe and process development	Individual unit operations
Pilot Scale	100–10,000 L	Process translation and validation	Batch-wise operations
Demonstration Scale	10,000–100,000 L	Risk minimization before full investment	Continuous with recycle streams
Manufacturing Scale	20,000–2,000,000 L	Commercial production	Fully integrated continuous process

Critical Parameters in Bioreactor and Fermentation Scale-Up

Scale-Dependent and Scale-Independent Parameters

Fermentation scale-up requires careful consideration of both scale-independent and scale-dependent parameters. Scale-independent parameters—including pH, temperature, dissolved oxygen (DO) concentration, and media composition and osmolality—are typically tested and optimized in small-scale bioreactors and then kept constant during scale-up [98]. Scale-dependent parameters, affected by bioreactor geometric configuration and operating parameters, require particular attention as they change with increasing scale [98].

The table below outlines key scale-dependent parameters that significantly impact fermentation performance during scale-up:

Table 2: Scale-Dependent Parameters in Fermentation Scale-Up

Parameter	Typical Deviation at Scale	Potential Impact on Process
Raw Material Grade	Industrial vs. reagent grade, purity variability	Accumulation of inhibitors; impacts fermentation, DSP, and WWT
Mixing Time	Increase in magnitude	Gradients in temperature, pH, substrate concentration
Mass Transfer Coefficient (kLa)	Gradient due to power dissipation	Limitations in oxygen transfer affecting cell growth and productivity
Broth Hydrostatic Pressure	Increase with gradient along vertical axis	Elevated gas partial pressures impacting cell physiology
Shear Stress	Increase in magnitude	Potential cell damage affecting fermentation and DSP performance
Sterilization Method	Batch vs. continuous	Component degradation and/or inhibitor formation

Bioreactor Geometric Considerations and Scaling Criteria

Geometric similarity—maintaining similar height-to-tank diameter (H/T) and impeller diameter-to-tank diameter (D/T) ratios across bioreactor sizes—is often a prerequisite for scale-up [98]. Laboratory-scale bioreactors frequently have an H/T ratio of 2:1, while large-scale bioreactors may range from 2:1 to 4:1. D/T ratios are generally maintained between 1:3 and 1:2 [98]. A significant consequence of maintaining constant H/T ratios during scale-up is a dramatic reduction in the surface area to volume (SA/V) ratio, which creates challenges for heat removal in large-scale microbial fermenters and CO₂ removal in animal-cell-culture bioreactors [98].

Several traditional scale-up criteria are used in microbial and animal-cell culture scale-up, each with distinct implications for the physical environment experienced by the cells [98]:

• Constant impeller-tip speed: Maintains similar shear conditions but reduces power input
• Constant power per unit volume (P/V): Maintains similar energy dissipation but increases tip speed and mixing time
• Constant oxygen mass-transfer coefficient (kLa): Ensures similar oxygen transfer capabilities
• Constant mixing time: Maintains similar homogenization but requires substantial power increase
• Constant Reynolds number (Re): Maintains similar flow regimes but significantly reduces P/V

The objective of scale-up is not to keep all scale-dependent parameters constant, but rather to define operating ranges for scale-sensitive parameters such that cellular physiological states—and thus productivity and product-quality profiles—can be maintained across scales [98].

Scale-Up Parameter Relationships

Chemoenzymatic Methodologies and Experimental Protocols

Enzyme Discovery and Engineering for Scale-Up

Implementing biocatalytic transformations at industrial scale depends heavily on enzyme performance characteristics necessary to achieve required productivity levels [40]. Several advanced approaches facilitate the development of enzymes suitable for large-scale applications:

Protein Engineering for Enhanced Performance: Through mutational scanning and structure-guided rational design, significant improvements in enzyme activity and robustness can be achieved. For example, engineering a ketoreductase (KR) from Sporidiobolus salmonicolor for the chemoenzymatic synthesis of ipatasertib—a potent protein kinase B inhibitor—yielded a variant with ten amino acid substitutions that exhibited a 64-fold higher apparent kₐₜ and improved robustness under process conditions compared to the wild-type enzyme [40].

Computational Design for Thermostability: Computational strategies can simultaneously improve thermostability and enzymatic activity. For instance, computational design applied to the diterpene glycosyltransferase UGT76G1—critical for industrial production of steviol glucosides—yielded a variant with a 9°C increase in apparent Tₘ, a 2.5-fold increase in product yield, and significant reduction in by-product formation [40].

Ancestral Sequence Reconstruction (ASR): This sequence-based protein design method predicts ancestral sequences from multiple sequence alignments and phylogenetic trees. Ancestral enzymes often exhibit improved properties such as enhanced substrate selectivity, increased thermostability, and better soluble expression. For example, ASR was used to design a novel L-amino acid oxidase (HTAncLAAO2) with high thermostability and long-term stability [40].

Chemoenzymatic Reaction Optimization Strategies

One-Pot Multi-Enzyme (OPME) Systems: These systems combine multiple enzymes in a single reaction vessel to perform sequential transformations without intermediate isolation. In the synthesis of nepetalactolone—the active molecule in catnip—a ten-enzyme cascade was employed, performing allylic hydroxylation, alcohol oxidation, aldehyde reduction, cyclization, and hemiacetal oxidation in one pot [10]. The system maintained the ability to perform both oxidative and reductive steps simultaneously using the same NAD/NADH system, achieving excellent yields (93%) with potential to produce approximately 1 g nepetalactone per liter of solution [10].

Cofactor Regeneration Systems: Efficient cofactor regeneration is essential for economical large-scale biocatalysis. In the enzymatic Baeyer-Villiger oxidation of cyclobutanone, incorporating an NADPH regeneration system increased product concentration to 9.3 g/L [99]. Switching to a phosphite dehydrogenase system (Opt-13) enabled complete conversion of cyclobutanone at concentrations of 40 mM and 83 mM, allowing preparation of over 100 g of lactone product with 95% enantiomeric excess [99].

Reaction Engineering with Non-Conventional Media: The choice of reaction medium can dramatically influence enzyme activity and stability. In the synthesis of prostaglandins, using DMSO as a co-solvent with chloroform reversed the diastereoselectivity of bromohydrin formation, significantly improving yield and desired product ratio [99].

Detailed Experimental Protocol: Chemoenzymatic Synthesis of Prostaglandins

The following protocol outlines a concise chemoenzymatic synthesis of prostaglandins achieved in 5 to 7 steps, demonstrating key scale-up considerations [99]:

Step 1: Preparation of Chiral Lactone via Enzymatic Baeyer-Villiger Oxidation

• Substrate: Racemic cyclobutanone (commercially available at ~$2.3 per gram)
• Enzyme System: Cyclohexanone monooxygenase (CHMO) co-expressed with phosphite dehydrogenase (Opt-13) for NADPH regeneration
• Reaction Conditions: 83 mM substrate concentration in aqueous buffer with sodium phosphite as co-substrate
• Scale-up Parameters: Reaction run at 83 mM with full conversion, enabling preparation of >100 g lactone product
• Quality Control: Enantiomeric excess maintained at 95% ee across scales

Step 2: Bromohydrin Formation with Diastereocontrol

• Substrate: Chiral lactone from Step 1
• Reagents: N-Bromosuccinimide (NBS) in water with DMSO/chloroform co-solvent system
• Key Optimization: DMSO as Lewis base to reverse bromonium ion formation direction
• Result: Significant improvement in desired diastereomer ratio and overall yield

Step 3: Nickel-Catalyzed Radical Coupling for Sidechain Installation

• Catalyst System: Nickel-based catalyst with bidentate ligands
• Challenge Prevention: Addition of 1.1 equivalents N-(Trimethylsilyl)imidazole to protect hydroxyl groups in situ and prevent epoxide formation
• Yield: Coupling product obtained in 52% yield with 37% recovery of starting material

This protocol demonstrates several scale-up advantages: utilization of cost-effective starting materials, minimization of protection/deprotection steps, and implementation of efficient catalytic reactions with high atom economy.

Process Analytical Technology and Manufacturing Metrics

Essential Manufacturing KPIs for Process Assessment

Manufacturing Key Performance Indicators (KPIs) provide critical measurements for evaluating production processes against specific business objectives [100]. For chemoenzymatic processes, these metrics help identify bottlenecks, optimize resource allocation, and align manufacturing operations with broader goals [100]. The table below summarizes essential manufacturing metrics relevant to chemoenzymatic process scale-up:

Table 3: Essential Manufacturing KPIs for Chemoenzymatic Process Monitoring

KPI Category	Specific Metric	Calculation Formula	Application in Chemoenzymatic Processes
Production Efficiency	Overall Equipment Effectiveness (OEE)	Availability × Performance × Quality	Benchmark for comparing similar production assets
	Throughput	# of Units Produced / Time	Measures production capabilities of equipment
	Cycle Time	Process End Time – Process Start Time	Identifies inefficiencies at macro and micro scales
Quality Control	First Time Right (FTR)	Total # of Good Units / Total Units in Process	Indicates precision of production process
	Defect Density	# of Defective Units / Total Units Produced	Tracks quality issues for prompt correction
	Rate of Return (ROR)	(Current Value – Initial Value) / Initial Value	Measures financial performance of investment
Cost Management	Production Costs	Direct Labor + Direct Materials + Overhead	Tracks all financial expenditures in manufacturing
	Maintenance Cost per Unit	Total Maintenance Costs / # of Produced Units	Optimizes equipment availability at minimal cost
	Unit Cost	(Variable Costs + Fixed Costs) / Total Units	Determines production efficiency
Resource Utilization	Capacity Utilization	(Total Capacity Used / Total Available Capacity) × 100	Assesses efficiency and growth opportunities
	Inventory Turns	Cost of Goods Sold (COGS) / Average Inventory	Indicates resource effectiveness
	Asset Turnover	Net Sales / Average Total Asset Value	Measures efficiency of asset use for revenue generation

The Scientist's Toolkit: Essential Research Reagent Solutions

Successful scale-up of chemoenzymatic processes requires specific reagents and materials optimized for large-scale applications. The following table details key research reagent solutions and their functions in scale-up experiments:

Table 4: Essential Research Reagent Solutions for Chemoenzymatic Scale-Up

Reagent/Material	Function in Scale-Up	Scale Considerations
Engineered Ketoreductases (KRs)	Stereoselective reduction of ketones	64-fold higher kₐₜ achieved through protein engineering [40]
Cyclohexanone Monooxygenases (CHMOs)	Baeyer-Villiger oxidations	Co-expression with phosphite dehydrogenase enables >100 g scale [99]
Imine Reductases (IREDs)	Asymmetric synthesis of chiral amines	Engineered variants with expanded substrate range for bulky amines [40]
Glycosynthases	Glycoengineering of therapeutic proteins	Prevents product re-hydrolysis in aqueous environments [12]
Phosphite Dehydrogenase (Opt-13)	NADPH regeneration	Enables complete substrate conversion at high concentrations (83 mM) [99]
Nickel-Based Catalysts	Radical cross-couplings	Installs sidechains with minimal protection/deprotection [99]
N-(Trimethylsilyl)imidazole	In situ hydroxyl protection	Prevents epoxide formation during nickel-catalyzed coupling [99]

Industrial Case Studies and Applications

Large-Scale Chemoenzymatic Glycoengineering

The industrial-scale application of chemoenzymatic methods faces both challenges and opportunities, particularly in the production of therapeutic monoclonal antibodies (mAbs). mAbs possess a conserved N-glycosylation site at Asparagine 297, with the carbohydrate identity dictating therapeutic activity and stability [12]. Traditional mammalian production systems yield highly heterogeneous glycoforms, with over 70 N-glycoforms identified in eight commercial therapeutic mAb formulations [12].

Chemoenzymatic glycoengineering addresses this heterogeneity through a two-step process: (1) trimming native heterogeneous glycans to a single GlcNAc unit using wild-type endo-N-acetylglucosaminidases (ENGases), and (2) biocatalytic en bloc homogeneous glycosylation using glycosynthases [12]. This approach affords homogeneous glycoforms in high yields with excellent chemo-, regio-, and stereo-specificity—all crucial attributes for large-scale therapeutic production [12].

The major challenges for industrial-scale implementation include the need for activated sugar donors (which can participate in undesired side reactions) and the economic cost of additional enzymatic steps and purification stages [12]. Recent developments in enzyme engineering and process optimization continue to address these limitations, making large-scale chemoenzymatic glycoengineering increasingly feasible.

Skeletal Editing of Natural Product Scaffolds

Recent advances in chemoenzymatic synthesis enable sophisticated structural modifications known as "skeletal editing"—introducing subtle modifications at the level of single atoms or bonds to fine-tune structure and biological activity [4]. A particularly powerful approach combines P450-mediated site-selective oxidation with subsequent Baeyer-Villiger rearrangement or ketone homologation to achieve ring expansion at aliphatic C–H sites [4].

This strategy, when combined with engineered P450 catalysts exhibiting divergent regioselectivity, enables expeditious synthesis of ring-expanded analogs of various complex natural products [4]. Importantly, these skeletal modifications can drastically alter biological activity, as demonstrated by enhanced anticancer activity in some natural product analogs [4]. This approach provides a powerful tool for rapidly accessing skeletally edited derivatives of natural products for drug discovery applications.

Scale-Up Process Workflow

The successful scale-up of chemoenzymatic processes from milligram to industrial production requires meticulous planning, attention to critical parameters, and strategic implementation of appropriate scale-up criteria. By beginning with the end in mind, maintaining diligence in details, and preparing for unexpected challenges, researchers and process developers can navigate the complex transition from laboratory discovery to commercial manufacturing.

Future advancements in chemoenzymatic scale-up will likely focus on several key areas: further development of enzyme engineering methodologies to enhance stability and activity under process conditions, innovation in cofactor regeneration systems to improve economic viability, and integration of continuous processing approaches to maximize efficiency. As these technologies mature, chemoenzymatic strategies will play an increasingly important role in the sustainable and efficient production of natural products and therapeutic compounds at commercial scales.

The convergence of biocatalysis with traditional chemical synthesis—embodied in chemoenzymatic approaches—represents a powerful paradigm for addressing the complex challenges of industrial-scale synthesis of structurally sophisticated natural products. By leveraging the complementary strengths of enzymatic and chemical methods, this approach enables efficient, scalable, and environmentally responsible manufacturing processes for high-value compounds.

Immobilization Techniques for Enzyme Reuse and Stability

The integration of enzymatic and chemical synthesis steps, known as chemoenzymatic synthesis, has emerged as a powerful strategy for the efficient production of high-value natural products and pharmaceutical precursors. This approach leverages the mild reaction conditions and exceptional selectivity of enzymes to complement traditional organic synthesis, often eliminating the need for protecting groups and reducing environmental impact [9]. However, a significant challenge in deploying enzymes on an industrial scale is their limited operational stability, difficulty in recovery, and sensitivity to process conditions, which can drastically increase costs [101] [102]. Enzyme immobilization provides a robust solution to these limitations, enhancing the economic viability of biocatalytic processes.

Immobilization, defined as the confinement of an enzyme to a solid phase distinct from the substrate and product stream, is a critical tool for engineering biocatalysts [103]. For chemoenzymatic synthesis, this technology is indispensable. It enables the easy separation of the biocatalyst from the reaction mixture, allows for reuse over multiple cycles, and significantly improves the enzyme's stability against temperature, pH, and organic solvents [101] [104]. By transforming soluble enzymes into heterogeneous catalysts, immobilization facilitates the design of continuous flow processes and complex multi-step cascades, making sophisticated chemoenzymatic routes for natural product synthesis more practical and efficient [9]. This technical guide provides an in-depth analysis of immobilization techniques, their applications, and detailed protocols, framed within the context of modern chemoenzymatic strategies.

Core Immobilization Techniques: Mechanisms and Trade-offs

The selection of an immobilization method is a critical decision that depends on the enzyme's characteristics, the nature of the support, and the intended application. The following sections detail the primary techniques, their mechanisms, advantages, and disadvantages.

Physical Adsorption

Mechanism: This simplest and oldest method relies on weak, non-covalent physical or electrostatic interactions—such as hydrophobic, van der Waals, hydrogen bonds, or ionic forces—between functional groups on the enzyme's surface and the support material [101] [102].

Advantages: The procedure is straightforward, inexpensive, and reversible, allowing for support regeneration. As it avoids harsh chemicals, it typically results in high retention of catalytic activity because the enzyme's native conformation is largely preserved [105] [102] [103].

Disadvantages: The primary drawback is the potential for enzyme leakage (desorption) due to changes in pH, ionic strength, or substrate exposure. This can lead to product contamination and loss of catalytic activity over time [102] [103].

Table 1: Common Support Materials for Physical Adsorption

Support Type	Specific Examples	Key Characteristics
Inorganic	Silicas, Titania, Hydroxyapatite, Zeolites	High surface area, mechanical stability [102]
Natural Organic Polymers	Chitin, Chitosan, Alginate, Cellulose	Biocompatible, biodegradable, cost-effective [102]
Synthetic Polymers	Polyacrylamide, Polypropylene-based granules (e.g., Accurel EP-100)	Tunable hydrophobicity and porosity [103]
Novel/Eco-friendly	Coconut fibers, Kaolin, Mesoporous Silica Nanoparticles (MSNs)	High cation exchange, good water-holding capacity, long-term durability [102] [103]

Covalent Binding

Mechanism: This technique involves forming strong, irreversible covalent bonds between functional groups on the enzyme (e.g., amino groups from lysine, carboxylic groups from aspartic/glutamic acids, thiol groups from cysteine) and reactive groups on a functionalized support [104] [102]. Activation of the support is often achieved using linkers like glutaraldehyde or carbodiimide [102].

Advantages: The covalent linkage prevents enzyme leakage, ensuring no contamination of the product and enabling long-term use. Multipoint covalent attachment (where the enzyme is bound to the support via several residues) can dramatically enhance the enzyme's thermal and operational stability by rigidifying its structure and preventing denaturation [106] [102].

Disadvantages: The method is more complex and expensive. There is a risk of activity loss if the covalent modification involves amino acid residues critical for catalysis or if the enzyme's active site becomes sterically blocked due to unfavorable orientation [101] [104] [102].

Entrapment and Encapsulation

Mechanism: These methods involve physically enclosing enzymes within a porous polymer matrix, membrane, or fiber network [101] [103]. The pore size is designed to be large enough to allow the free diffusion of substrates and products but small enough to retain the enzyme.

Advantages: Enzymes do not chemically interact with the polymer, minimizing the risk of denaturation. These techniques allow for high enzyme loading and can effectively shield the biocatalyst from harsh environmental conditions, such as proteolysis or exposure to interfaces [101] [103].

Disadvantages: A major limitation is mass transfer resistance, as the substrate must diffuse through the matrix to reach the enzyme, which can reduce the apparent reaction rate. There is also a risk of enzyme leakage if the pore sizes are not optimally controlled [101].

Cross-Linked Enzyme Aggregates (CLEAs)

Mechanism: CLEAs are a carrier-free immobilization technique. Enzymes are first precipitated from an aqueous solution using salts, organic solvents, or non-ionic polymers to form aggregates. These aggregates are then cross-linked with bifunctional agents like glutaraldehyde to form insoluble, stable particles [104] [103].

Advantages: This method results in a high catalyst concentration (no inert support) and generally exhibits excellent stability and reusability. It is particularly effective for stabilizing multimeric enzymes, preventing subunit dissociation [106] [104].

Disadvantages: The use of precipitating agents and cross-linkers can sometimes lead to significant activity loss. The resulting particles may have poor mechanical properties and can cause high pressure drops in packed-bed reactors [104].

The logical relationship between the objectives of immobilization and the techniques used to achieve them is summarized in the following workflow:

Advanced and Site-Specific Strategies

Moving beyond classical methods, advanced strategies offer greater control over enzyme orientation and interaction, which can lead to superior catalytic performance.

Site-Specific Immobilization

Classical non-specific immobilization can lead to random orientation, where a significant portion of enzymes may have their active sites blocked or be attached in a conformation that reduces activity [101]. Site-specific immobilization addresses this by targeting a unique tag or residue on the enzyme. One powerful example is the aldehyde-tag system. A specific cysteine residue within a consensus sequence in the enzyme is converted to a unique C-formylglycine (an aldehyde group) using a formylglycine-generating enzyme (FGE). This exposed aldehyde can then be specifically and covalently linked to amine-functionalized beads, ensuring a uniform and optimal orientation [104]. This method provides stable bonds and minimizes structural distortion compared to non-specific covalent binding.

Combined Engineering and Immobilization

The most robust biocatalysts are often created by combining protein engineering with immobilization. Protein engineering techniques, such as site-directed mutagenesis, can be used to:

• Introduce stabilizing mutations that enhance intrinsic enzyme stability before immobilization [101].
• Create unique attachment points (like the aldehyde-tag) for site-specific immobilization [104].
• Improve enzyme properties like solvent tolerance or substrate range, which are then further enhanced by the immobilization step [9]. This synergistic approach allows for the creation of tailor-made biocatalysts for specific challenging applications in chemoenzymatic synthesis.

Experimental Protocols and Performance Data

Detailed Protocol: Covalent Immobilization on Glutaraldehyde-Activated Amine Beads

This protocol is adapted from studies on transaminase immobilization and is a representative method for achieving a stable, multi-point covalent attachment [104] [102].

• Support Activation:

  • Weigh 1 gram of amine-functionalized beads (e.g., Amine-Sepabeads).
  • Suspend the beads in 10 mL of a 2.5% (v/v) glutaraldehyde solution in 0.1 M potassium phosphate buffer, pH 7.0.
  • Incubate the mixture with gentle agitation for 2 hours at room temperature.
  • Recover the activated beads by filtration and wash extensively with the same buffer (e.g., 5 x 20 mL) to remove any unreacted glutaraldehyde.

• Enzyme Immobilization:

  • Dissolve the target enzyme (e.g., a transaminase) in 0.1 M potassium phosphate buffer, pH 7.0, to a final concentration of 5-10 mg/mL.
  • Add the glutaraldehyde-activated beads to the enzyme solution. A typical ratio is 100 mg of support per 10 mg of enzyme.
  • Incubate the mixture with gentle shaking for 16-24 hours at 4°C to allow for covalent coupling.
  • Recover the immobilized enzyme by filtration and wash thoroughly with buffer to remove any physically adsorbed enzyme.

• Blocking and Storage:

  • To block any remaining reactive aldehyde groups, incubate the immobilized enzyme with 1 M glycine or ethanolamine solution (pH 8.0) for 1-2 hours.
  • Wash again with buffer and store the final preparation at 4°C in a suitable storage buffer until use.

Detailed Protocol: Preparation of Cross-Linked Enzyme Aggregates (CLEAs)

This carrier-free protocol is widely applicable for creating highly concentrated and stable biocatalysts [104].

• Enzyme Precipitation:

  • Place 1 mL of a purified enzyme solution (e.g., 20 mg/mL in a suitable buffer) in a centrifuge tube.
  • While stirring vigorously, slowly add 9 mL of cold, anhydrous acetone (or ammonium sulfate solution to 80% saturation) to precipitate the enzyme.
  • Continue stirring for 30 minutes to allow aggregate formation.
  • Recover the protein aggregates by centrifugation (10,000 x g, 10 min, 4°C) and carefully decant the supernatant.

• Cross-Linking:

  • Re-suspend the wet enzyme aggregate pellet in 10 mL of 0.1 M potassium phosphate buffer, pH 7.5.
  • Add glutaraldehyde to a final concentration of 10-50 mM.
  • Stir the mixture gently for 2-4 hours at 4°C to form the cross-links.
  • Recover the CLEAs by centrifugation or filtration and wash extensively with buffer to stop the cross-linking reaction.

• Post-Treatment and Storage:

  • (Optional) To enhance stability, the CLEAs can be post-treated with a stabilizing agent like bovine serum albumin (BSA) followed by a second, mild cross-linking step.
  • Store the final CLEAs as a suspension in buffer at 4°C.

Comparative Performance of Immobilized Enzymes

The effect of immobilization is highly dependent on the enzyme, the method, and the application conditions. The following table summarizes performance data from comparative studies.

Table 2: Performance Comparison of Different Immobilization Techniques

Enzyme Class	Immobilization Technique	Key Performance Outcomes	Reference
Transaminases (ATAs)	Site-specific (Aldehyde-tag on HA-beads)	High activities up to 62 U/g beads; enabled reusability for ≥10 cycles with high activity retention.	[104]
Transaminases (ATAs)	Covalent (HAGA-beads)	Often resulted in the highest activities among tested methods; performance varied with enzyme quaternary structure.	[104]
Lipase (C. rugosa)	Physical Adsorption (on biodegradable polymer)	94% residual activity after 4h at 50°C; reusability for 12 cycles.	[103]
Lipase (Y. lipolytica)	Physical Adsorption (octyl-agarose)	Tenfold greater stability than free lipase; high yields.	[103]
Oxidoreductases (Laccase)	Entrapment (Alginate beads)	Effective for dye removal from water, demonstrating application in environmental remediation.	[101]
Polyphenol Oxidases	Adsorption (MWCNT-ZnO-Nafion electrode)	Improved biosensor sensitivity, stability, and lower detection limit (30 nM) for phenolic compounds.	[106]

The Scientist's Toolkit: Essential Reagents and Materials

Successful immobilization requires careful selection of both the enzyme and the support matrix. The following table lists key reagents and their functions in developing immobilized biocatalysts.

Table 3: Key Research Reagent Solutions for Enzyme Immobilization

Reagent / Material	Function / Role in Immobilization	Example Use Cases
Glutaraldehyde	Bifunctional cross-linker; activates amine-bearing supports and covalently links to enzyme amino groups.	Covalent binding to amine-beads; preparation of CLEAs.
Amine-Functionalized Supports	Solid carriers (e.g., Sepabeads, Amine-Sepharose) providing primary amino groups for covalent attachment.	Used with glutaraldehyde activation or for site-specific coupling to aldehyde-tagged enzymes.
Epoxy-Functionalized Supports	Supports with epoxy groups that can form multi-point covalent attachments with nucleophilic enzyme residues.	Direct covalent immobilization without a pre-activation step.
Mesoporous Silica Nanoparticles (MSNs)	Inorganic support with high surface area and tunable pore size for physical adsorption or covalent binding.	Provides a biocompatible, durable matrix for biocatalysis, especially in energy applications.
Formylglycine-Generating Enzyme (FGE)	Biocatalyst that creates a unique aldehyde handle (C-formylglycine) on a target enzyme for site-specific immobilization.	Used in the aldehyde-tagging technique to ensure controlled enzyme orientation.
Sodium Alginate	Natural polymer used for entrapment via ionotropic gelation with divalent cations like Ca²⁺.	Encapsulation of enzymes and whole cells for applications in dairy processing and bioremediation.
Chitosan	Natural, cationic biopolymer with functional groups for both adsorption and covalent binding.	A cost-effective, biodegradable support for a wide range of enzymes.

Application in Chemoenzymatic Synthesis: A Workflow for Natural Products

The power of immobilized enzymes in chemoenzymatic synthesis is exemplified by multi-enzyme cascades. A classic example is the one-pot synthesis of sialosides, important carbohydrate motifs in natural products and pharmaceuticals, using a three-enzyme system [58]. The workflow involves a sialic acid aldolase, a CMP-sialic acid synthetase, and a sialyltransferase. Employing immobilized enzymes in such a system allows for the facile recovery and reuse of each biocatalyst, simplifies product purification, and enhances overall process efficiency.

This chemoenzymatic approach, powered by immobilized and reusable biocatalysts, allows for the incorporation of both natural and non-natural sialic acid forms into complex molecules, showcasing a key strategy in modern natural product synthesis [58]. The integration of computational tools like minChemBio, which helps plan synthetic routes to minimize costly transitions between chemical and biological steps, further optimizes these processes [6].

Evaluating Success: Comparative Analysis, SAR Studies, and Real-World Impact

The pursuit of sustainable and efficient synthetic methodologies represents a cornerstone of modern chemical research, particularly in the realm of natural product and pharmaceutical synthesis. Chemoenzymatic strategies, which strategically integrate enzymatic transformations with synthetic organic chemistry, have emerged as powerful approaches that leverage the complementary strengths of both biological and chemical catalysis [107]. Enzymatic reactions typically provide exceptional selectivity under mild, environmentally benign conditions, while chemical steps offer well-established versatility for diverse structural transformations [18]. This paradigm is particularly valuable for synthesizing complex natural products, where traditional synthetic approaches often involve lengthy sequences with protecting group manipulations and purification challenges.

The integration of radical-based transformations with enzymatic catalysis has recently created new possibilities for unconventional bond disconnections, enabling more direct synthetic routes to complex molecular architectures [18]. Similarly, the incorporation of non-canonical amino acids and synthetic cofactors has expanded the catalytic repertoire of enzymes, moving beyond the limitations of nature's palette [108]. As the field advances, rigorous benchmarking of these hybrid approaches becomes essential for guiding strategic decisions in research and process development. This technical review provides a comprehensive framework for evaluating chemoenzymatic routes through quantitative metrics of step-count, yield, and sustainability, with specific case studies from contemporary literature.

Quantitative Benchmarking of Representative Chemoenzymatic Routes

Comparative Performance Metrics

Table 1: Benchmarking metrics for representative chemoenzymatic syntheses

Target Compound	Route Description	Key Enzymes/Reagents	Overall Yield	Step Count	Notable Sustainability Features
m1ΨTP (mRNA vaccine component)	Chemoenzymatic from uridine	Biocatalytic cascade, UMPK, Acetate kinase	68% (from uridine)	3 main steps	ATP regeneration from acetyl phosphate; reduced hazardous waste [109]
Englerin A	Terpene cyclase + radical functionalization	FgJ02895 cyclase, HAT isomerization	Not specified	Streamlined approach	Metabolic engineering for precursor supply; atom-economic cyclization [18]
Optically active promethazine/ethopropazine	Lipase-mediated kinetic resolution	Novozym 435, Lipozyme TL IM	High enantiopurity (84-98% ee)	4 steps	Mild conditions; superb enantioselectivity (E = 844) [110]
Indican for denim dyeing	Glycosyltransferase catalysis	Engineered PtUGT1, sucrose synthase	65% (100 mM scale)	1 enzymatic step	UDP-glucose recycling; replacement of reducing agents [111]
Tartaric acid	Chemoenzymatic from glucose	Engineered glucose oxidase, bimetallic AuPt/TiOâ‚‚	100% conversion of glucose to gluconic acid	2 steps	Renewable feedstock; durable catalyst system [112]

Sustainability and Economic Assessment

Table 2: Sustainability and economic metrics for chemoenzymatic processes

Process	Environmental Impact Reduction	Economic Viability	Social Sustainability Aspects
Indican production	Elimination of dithionite reducing agent; reduced water pollution	Raw material cost: 9.9-15 USD/kg (competitive with synthetic indigo)	Neutral-to-positive social impact; reduced occupational hazards [111]
m1ΨTP synthesis	Atom-economic route; reduced solvent waste	Major cost reduction for mRNA vaccine manufacturing	Improved access to therapeutic mRNA technologies [109]
Artemisinin semi-synthesis	Combined fermentation/chemical synthesis	High titer production (>40 g L⁻¹) enables affordable malaria treatment	Improved global access to essential antimalarial medication [18]

Experimental Protocols for Key Chemoenzymatic Methodologies

Integrated Synthesis of m1ΨTP from Uridine

Background: Pseudouridine-5′-triphosphate (ΨTP) and its N1-methylated derivative (m1ΨTP) are critical monomer building blocks for mRNA therapeutics, with m1ΨTP representing a major cost factor in COVID-19 vaccine production [109]. The following integrated protocol demonstrates a highly efficient chemoenzymatic route.

Experimental Protocol:

• Biocatalytic Cascade Rearrangement:

  • Reaction Setup: Charge a reaction vessel with uridine (∼1 mol L⁻¹) in appropriate aqueous buffer. Add the three-enzyme cascade system (specific enzymes not named in source) and maintain at optimal temperature with agitation.
  • Monitoring: Follow reaction progression by HPLC until complete consumption of uridine is observed.
  • Workup: Filter off the enzymes through a 10 kDa molecular weight cutoff membrane. The resulting ΨMP solution can be used directly in the next step without further purification. Typical yield: 95% at up to ∼1.6 g scale [109].

• Chemical Methylation:

  • Protection: Protect the ΨMP with acetonide protecting groups to direct methylation selectivity.
  • Methylation: Treat protected ΨMP with dimethyl sulfate for selective N1-methylation under controlled conditions.
  • Deprotection: Remove acetonide protecting groups under mild acidic conditions to yield m1ΨMP [109].

• Enzymatic Phosphorylation Cascade:

  • Reaction Setup: Combine m1ΨMP with Saccharomyces cerevisiae UMP kinase (UMPK, ∼100 units mg⁻¹ with ΨMP, 0.3 units mg⁻¹ with m1ΨMP) and Escherichia coli acetate kinase (AcK, 200 units mg⁻¹ with m1ΨDP) in buffer containing acetyl phosphate (AcP) for ATP regeneration.
  • Optimization: Maintain Mg²⁺ concentration at 10-20 mM and adjust pH to 7.5 for optimal activity. Use an ATP regeneration system with 2-5 mM initial ATP.
  • Scale-up: The reaction has been demonstrated at ∼50 mg mL⁻¹ concentration with isolated product yield of ∼200 mg. Overall yield from uridine: 68% [109].

Critical Parameters: The UMPK shows excellent activity with ΨMP but reduced activity with the methylated derivative m1ΨMP, necessitating appropriate enzyme loading adjustments. The AcP-driven ATP regeneration system is crucial for economic viability.

Chemoenzymatic Synthesis of Optically Active Pharmaceuticals via Kinetic Resolution

Background: This protocol describes the synthesis of enantioenriched promethazine and ethopropazine through lipase-mediated kinetic resolution, demonstrating the power of biocatalysis for introducing stereochemistry in pharmaceutical synthesis [110].

Experimental Protocol:

• Synthesis of Racemic Intermediate:

  • Reaction: Add phenothiazine (1) to a solution of n-butyllithium in anhydrous tetrahydrofuran at ambient temperature under inert atmosphere. Slowly add propylene oxide (2) and stir until complete consumption of starting material.
  • Workup: Isolate racemic 1-(10H-phenothiazin-10-yl)propan-2-ol (±)-3 by vacuum distillation. Yield: 64-77% (higher yields obtained at larger scales with distillation vs. column chromatography) [110].

• Lipase-Catalyzed Kinetic Resolution:

  • Biocatalyst Selection: Screen lipases (Novozym 435 and Lipozyme TL IM identified as optimal) for enantioselective acylation of racemic alcohol (±)-3.
  • Reaction Setup: Suspend lipase in organic solvent (e.g., vinyl acetate as both acyl donor and solvent) and add racemic alcohol. Agitate at room temperature.
  • Monitoring: Track enantiomeric excess by chiral HPLC. Reactions typically achieve >99% ee for both remaining alcohol and formed ester.
  • Enantioselectivity: The process demonstrates superb enantioselectivity (E = 844) [110].

• Stereodivergent Transformation to Active Pharmaceuticals:

  • Bromination: Treat resolved alcohol (S)-(+)-5 or (R)-(−)-7 with PBr₃ in dichloromethane to yield corresponding bromides.
  • Amination: React bromide with appropriate amine in toluene (mainly product of single inversion) or methanol (exclusively product of net retention) to achieve stereodivergent synthesis.
  • Purification: Isulate final pharmaceuticals (R)- and (S)-promethazine and ethopropazine with enantiomeric purity of 84-98% ee [110].

Critical Parameters: The choice of base for the initial epoxide opening is critical - sodium amide or sodium hydride led to significant byproduct formation, while n-butyllithium provided clean regioselective ring opening.

The Scientist's Toolkit: Essential Research Reagents and Materials

Table 3: Key research reagents for developing chemoenzymatic processes

Reagent/Enzyme	Function in Chemoenzymatic Synthesis	Application Notes
S. cerevisiae UMP kinase	Phosphorylation of ΨMP and m1ΨMP to diphosphate forms	Shows exceptional activity with ΨMP (∼100 units mg⁻¹) and usable activity with m1ΨMP (0.3 units mg⁻¹) [109]
E. coli acetate kinase	Final phosphorylation to triphosphate and ATP regeneration from acetyl phosphate	Displays promiscuous activity for phosphorylation of both ΨDP (40 units mg⁻¹) and m1ΨDP (200 units mg⁻¹) [109]
Engineered PtUGT1 glycosyltransferase	Glycosylation of indoxyl to form indican	Rational engineering (decatuple variant) improved stability (ΔTₘ +13.1°C) and resistance to substrate inactivation [111]
Sucrose synthase (SuSy)	UDP-glucose recycling from sucrose	Enables cost-effective glycosylation by regenerating expensive nucleotide sugar donors [111]
Novozym 435 & Lipozyme TL IM	Kinetic resolution of racemic alcohols via enantioselective acylation	Provide exceptional enantioselectivity (E = 844) for pharmaceutical intermediates [110]
Acetyl phosphate	ATP regeneration co-substrate	Enables economical phosphorylation cascades by regenerating ATP in situ [109]
Bimetallic AuPt/TiOâ‚‚ catalyst	Chemical decarboxylation of gluconic acid to tartaric acid	Durable catalyst for chemical step in chemoenzymatic cascade; performance affected by impurities in enzymatically-produced stream [112]

Workflow Visualization of Chemoenzymatic Routes

Integrated m1ΨTP Synthesis Workflow

Integrated m1ΨTP Synthesis Workflow

Strategic Planning for Chemoenzymatic Synthesis

Strategic Chemoenzymatic Planning

The benchmarking data and methodologies presented in this review demonstrate that strategic integration of enzymatic and chemical transformations can deliver substantial improvements in synthetic efficiency, sustainability, and cost-effectiveness for complex molecule synthesis. The development of computational tools like minChemBio, which minimizes transitions between chemical and biological reaction environments, represents an important advancement for planning efficient chemoenzymatic routes [6].

Future directions in the field will likely focus on expanding the palette of enzymatic reactivity through incorporation of non-canonical amino acids and synthetic cofactors [108], as well as the continued strategic combination of biocatalytic with radical-based transformations [18]. As the toolkit of stabilized and engineered enzymes grows, and methodologies for seamless integration of reaction types improve, chemoenzymatic approaches will play an increasingly central role in sustainable synthesis of natural products and pharmaceuticals.

Artemisinin, a sesquiterpene lactone containing a crucial endoperoxide bridge, is the cornerstone of modern malaria treatment and represents a prime candidate for examining chemoenzymatic synthesis strategies [113]. The global demand for artemisinin continues to grow, driven not only by its established role in Artemisinin-based Combination Therapies (ACTs) but also by its emerging potential in anticancer, anti-inflammatory, and antiviral applications [113] [114]. This escalating demand highlights the critical need for efficient, scalable, and sustainable production methods. The inherent limitations of traditional plant extraction—specifically low artemisinin content in Artemisia annua L. (0.1-1.0% of dry weight)—coupled with the challenges of complex chemical synthesis, have catalyzed innovation across multiple scientific disciplines [113] [114] [115]. This case study provides a comparative analysis of established and emerging artemisinin synthesis routes, with a particular focus on advanced chemoenzymatic strategies that combine the precision of biological catalysis with the flexibility of synthetic chemistry. By framing this analysis within the broader context of natural product synthesis, we aim to illuminate the evolving paradigm of hybrid biosynthetic-chemical approaches for producing complex therapeutic molecules.

Established Artemisinin Biosynthesis Pathway inArtemisia annua

The native biosynthesis of artemisinin in Artemisia annua provides the foundational blueprint for all heterologous and semi-synthetic production efforts. This specialized metabolic pathway occurs primarily in the glandular trichomes of the plant's aerial parts and involves a series of enzymatic steps that convert primary metabolic precursors into the bioactive sesquiterpene lactone [116] [115].

The pathway begins with the universal terpenoid precursors, isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP), which are derived from both the cytosolic mevalonate (MVA) pathway and the plastidial methylerythritol phosphate (MEP) pathway [113] [115]. The core enzymatic steps are as follows:

• Farnesyl Diphosphate Synthesis: Farnesyl diphosphate synthase (FPPS) condenses two molecules of IPP with one molecule of DMAPP to form the 15-carbon farnesyl diphosphate (FPP) [115].
• Cyclization: Amorpha-4,11-diene synthase (ADS) catalyzes the cyclization of FPP to form amorpha-4,11-diene, creating the characteristic sesquiterpene skeleton [117] [115].
• Oxidation: The cytochrome P450 monooxygenase CYP71AV1 (also known as AMO), in conjunction with its redox partner cytochrome P450 reductase (CPR), performs a three-step oxidation of amorpha-4,11-diene. This yields artemisinic alcohol, then artemisinic aldehyde, and finally artemisinic acid (AA) as the major product [117] [115].
• Reduction Branch: Artemisinic aldehyde can also enter an alternative branch where artemisinic aldehyde Δ11(13) reductase (DBR2) reduces its double bond to form dihydroartemisinic aldehyde (DHAld) [114] [115]. This is subsequently oxidized to dihydroartemisinic acid (DHAA) by aldehyde dehydrogenase 1 (ALDH1) [115].
• Final Conversion: The pathway concludes with non-enzymatic, light-dependent photo-oxidation that spontaneously converts DHAA into artemisinin. Artemisinic acid can also undergo a similar conversion to artemisinin B, but the route through DHAA is significantly more efficient [114] [115].

Recent evolutionary studies reveal that this specialized pathway likely evolved from the ancestral costunolide biosynthetic pathway common to the Asteraceae family, through gene duplication and neofunctionalization of germacrene A oxidase (GAO) into the more specialized CYP71AV1/AMO [117].

The following diagram illustrates the complete native biosynthesis pathway of artemisinin in Artemisia annua:

Artemisinin Biosynthesis Pathway in A. annua

Comparative Analysis of Synthesis Routes

A multi-faceted approach has been developed to address the global supply challenge for artemisinin. The following table provides a quantitative and qualitative comparison of the four primary production routes.

Table 1: Comparative Analysis of Artemisinin Production Methods

Production Method	Maximum Reported Yield	Key Advantages	Key Limitations	Technology Readiness Level
Plant Extraction	0.1-1.0% of dry weight [114] [115]	Well-established process; Direct access to natural product	Low yield; Land and resource intensive; Seasonal and geographic variability; Supply volatility	Commercial (Mature)
Total Chemical Synthesis	Achieved in 1983 [113] [115]	Full control over synthesis; No biological constraints	>10 steps; High cost; Low overall yield; Not commercially viable	Pilot (Not Commercialized)
Microbial Fermentation (Semi-Synthesis)	25 g/L Artemisinic Acid [114] [115]	High yield and scalability; Fermentation-based; Independent of agricultural constraints	Requires subsequent chemical conversion; High initial capital investment	Commercial (Implemented by Sanofi)
Chemoenzymatic Route	3.97 g/L Dihydroartemisinic Acid (DHAA) [114]	Streamlined pathway; Avoids costly chemical reduction; More "natural" synthesis	Emerging technology; Requires further optimization in microbial chassis	Pilot/Demonstration

Analysis of Route Viability

The plant extraction method, while historically critical, faces significant challenges in meeting growing global demand due to its inherently low yield and susceptibility to agricultural and market fluctuations [113]. Total chemical synthesis, though a landmark scientific achievement, is characterized by its complexity, numerous steps, and consequently low yield and high cost, rendering it economically non-viable for large-scale production [113] [115].

The microbial fermentation approach pioneered by the Keasling lab represents a paradigm shift. By engineering the yeast Saccharomyces cerevisiae to produce high titers of artemisinic acid (AA), it provides a reliable and scalable source of a key precursor [115]. However, this route remains a semi-synthetic process, as the AA must be chemically reduced to dihydroartemisinic acid (DHAA) before the final spontaneous oxidation to artemisinin can occur. This chemical reduction step introduces complexity, adds cost, and can lead to significant yield loss due to by-product formation [114].

The emerging chemoenzymatic route, enabled by the recent discovery of the enzyme dihydroartemisinic acid dehydrogenase (AaDHAADH), offers a compelling alternative. This enzyme catalyzes the direct bidirectional conversion between AA and DHAA in vivo [114]. Integrating this enzyme into an engineered microbial host can create a more direct and efficient biosynthetic pathway. This strategy shortens the synthetic route by bypassing the need for a separate chemical reduction step, potentially leading to a higher overall yield and a more sustainable production process [114].

Advanced Chemoenzymatic Strategies and Experimental Protocols

Discovery and Engineering of a Key Enzyme: AaDHAADH

A landmark 2025 study identified a previously unknown enzyme, dihydroartemisinic acid dehydrogenase (AaDHAADH), which provides a critical shortcut in the artemisinin biosynthetic pathway [114]. The experimental workflow for its discovery and application is summarized below:

AaDHAADH Discovery and Engineering Workflow

Key Experimental Protocol:

• Enzyme Discovery and Purification: The crude enzyme was extracted from the leaves of Artemisia annua. Catalytic activity-guided purification was performed using 80% ammonium sulfate precipitation, followed by sequential chromatography using dextran G50 gel, dextran G25 gel, and DEAE columns [114].
• Proteomic Identification: The active protein fraction (DEAE-2) was analyzed by mass spectrometry, identifying 1261 proteins. Bioinformatics filtering for oxidoreductases narrowed the candidates to 61 proteins. Evolutionary tree analysis alongside known artemisinin pathway enzymes highlighted three strong candidates, including A0A2U1QC71 (later named AaDHAADH) [114].
• Functional Validation: The candidate genes were cloned and expressed in both E. coli and Nicotiana benthamiana. In vivo and in vitro assays using artemisinic acid (AA) and dihydroartemisinic acid (DHAA) as substrates confirmed that only AaDHAADH catalyzed the bidirectional conversion between AA and DHAA [114].
• Enzyme Optimization: Site-directed mutagenesis was employed to improve the enzyme's catalytic efficiency. A mutant variant, AaDHAADH (P26L), was identified, which exhibited a 2.82-fold increase in activity toward AA compared to the wild-type enzyme [114].
• Pathway Implementation: The optimized gene, AaDHAADH (P26L), was integrated into an engineered strain of S. cerevisiae. Fed-batch fermentation in a 5 L bioreactor demonstrated the viability of this approach, achieving a de novo production of 3.97 g/L of DHAA [114].

The Scientist's Toolkit: Key Research Reagent Solutions

Table 2: Essential Research Reagents for Chemoenzymatic Artemisinin Research

Reagent / Material	Function in Research	Specific Example from Literature
Engineered S. cerevisiae Strains	Chassis for heterologous production of artemisinin precursors (e.g., AA, DHAA).	Strains engineered with optimized MVA pathway and artemisinin genes [114] [115].
Heterologous Expression Systems	Functional characterization of putative enzymes from the artemisinin pathway.	E. coli and N. benthamiana used to express and validate AaDHAADH function [114].
Site-Directed Mutagenesis Kits	Engineering enzymes for improved catalytic activity, stability, or specificity.	Used to create the high-activity AaDHAADH (P26L) mutant [114].
Chromatography Media	Purification of enzymes and metabolites during discovery and analysis.	Dextran G50/G25 and DEAE used for activity-guided purification of AaDHAADH [114].
LC-MS / GC-MS Systems	Quantitative and qualitative analysis of metabolic products in complex mixtures.	Used to identify and quantify amorpha-4,11-diene, AA, and DHAA in engineered strains [114] [115].

Broader Chemoenzymatic Applications

The strategy of combining enzymatic precision with synthetic flexibility is a powerful trend in natural product synthesis. Beyond artemisinin, chemoenzymatic methods are being applied for:

• Skeletal Editing: Cytochrome P450 enzymes can be engineered to perform site-selective oxidations on complex natural product scaffolds. Subsequent chemical steps, like Baeyer-Villiger rearrangement, enable "skeletal editing" through ring expansion, creating novel analogs with potentially altered bioactivity [4].
• Peptide Macrocyclization: Non-ribosomal peptide cyclases are utilized to achieve precise macrocyclization of linear peptide precursors, which are often synthesized chemically. This facilitates the production of complex lariat lipopeptides with antibiotic and anticancer potential [118].
• Computational Pathway Design: New computational tools like minChemBio are being developed to plan optimal chemoenzymatic synthesis routes by minimizing costly transitions between chemical and biological reaction environments, thereby improving overall efficiency [6].

The comparative analysis of artemisinin synthesis routes clearly demonstrates the pharmaceutical industry's strategic pivot from traditional extraction and purely chemical methods toward integrated bio-based solutions. The semi-synthetic production via engineered yeast has already proven its commercial viability. However, the recent discovery of the AaDHAADH enzyme and the development of a more direct chemoenzymatic route signifies the next evolutionary step [114]. This approach elegantly bypasses a key chemical bottleneck, leveraging biological catalysis to create a more streamlined and potentially more economical process.

Future research will likely focus on further optimizing this chemoenzymatic pipeline through systems and synthetic biology approaches. This includes refining multigene engineering strategies in microbial hosts, employing CRISPR/Cas9 for precise genome editing in Artemisia annua, and utilizing systems biology and computational models to identify and overcome remaining regulatory and metabolic bottlenecks [113]. The successful implementation of these advanced chemoenzymatic strategies for artemisinin production provides a robust blueprint for the synthesis of other complex natural products, heralding a new era of sustainable and efficient drug discovery and development.

Structure-Activity Relationship (SAR) studies represent a fundamental approach in medicinal chemistry and drug discovery, aiming to understand how chemical modifications influence the biological activity of a compound. In natural product research, SAR studies have gained substantial attention as they enable scientists to optimize naturally occurring lead compounds for enhanced potency, improved selectivity, and reduced toxicity [119]. Natural products (NPs) are particularly valuable starting points for drug discovery because they have been "fine-tuned over the ages to bind to specific classes of drug targets" through evolutionary processes [119]. The primary challenge, however, lies in efficiently generating diverse analogues of these often complex molecular structures to systematically explore their chemical space and biological potential.

The interest in NP-based SAR is evidenced by the significant scientific literature on the topic, with searches for "natural product" and "structure-activity-relationships" in PubMed yielding approximately 675,000 and 210,000 hits, respectively [119]. This review focuses specifically on chemoenzymatic strategies—the synergistic combination of chemical synthesis and enzymatic transformations—as powerful tools for accessing natural product analogues to enable robust SAR studies. These approaches leverage the selectivity and efficiency of enzymes to perform complex transformations that are challenging to achieve using traditional synthetic methods alone.

Chemoenzymatic Strategies for Natural Product Analogue Generation

Skeletal Editing via Ring Expansion

A cutting-edge chemoenzymatic approach for natural product analogue generation involves skeletal editing—modifying the core framework of natural products at the level of single atoms or bonds. A recent groundbreaking method enables ring expansion at aliphatic C─H sites through the synergistic combination of P450-mediated site-selective oxidation with subsequent Baeyer-Villiger rearrangement or ketone homologation [4].

This strategy begins with engineered P450 cytochrome enzymes that perform highly selective oxidation of specific methylene (C─H) groups within complex natural product scaffolds, converting them to ketone functionalities. The resulting ketone intermediates then undergo one of two divergent pathways:

• Baeyer-Villiger Rearrangement: This transformation inserts an oxygen atom adjacent to the carbonyl, converting cyclic ketones into esters or lactones, thereby expanding the ring size by one atom.
• Ketone Homologation: This process extends the carbon skeleton adjacent to the carbonyl group, providing alternative ring-expanded analogues.

The power of this methodology lies in combining engineered P450 catalysts exhibiting divergent regioselectivity with subsequent chemical transformations, enabling the expeditious synthesis of a panel of ring-expanded analogs from a single natural product precursor. This approach was successfully applied to generate skeletally diverse derivatives of various complex natural products, with biological evaluation revealing that these subtle skeletal modifications "drastically altered the anticancer activity of some of these compounds" [4]. This highlights the profound impact that minimal atomic-level changes can have on biological function, providing valuable insights for drug optimization.

Chemoenzymatic Glycopeptide Synthesis

Another significant chemoenzymatic strategy focuses on the synthesis of complex glycopeptides, which are crucial for understanding SAR in glycosylated natural products. An integrated chemoenzymatic approach streamlines the preparation of complex glycopeptides by combining hydrophobic tag-supported chemical peptide synthesis with enzymatic glycosylation [120].

This methodology employs a hydrophobic tag to facilitate liquid-phase peptide chain elongation and expeditious product separation via centrifugation. After tag removal, diverse glycan structures are installed on the peptide backbone using highly specific glycosyltransferase-catalyzed reactions. This approach demonstrates remarkable versatility, enabling the efficient preparation of numerous well-defined glycopeptides, including 16 SARS-CoV-2 O-glycopeptides, 4 complex MUC1 glycopeptides, and a 31-mer glycosylated glucagon-like peptide-1 [120].

The enzymatic glycosylation step leverages various glycosyltransferases—including β1,3-galactosyltransferase 1 (C1GalT1), α-2,6-sialyltransferases (ST6GalNAc1, ST6Gal1, and Pd2,6ST), α2,3-sialyltransferases (ST3Gal1 and ST3Gal4), β-1,6-GlcNAc-transferase 1 (GCNT1), and β1,4-galactosyltransferase 1 (B4GalT1)—to achieve precise and diverse glycan patterning [120]. This methodology provides unprecedented access to structurally defined glycopeptide analogues for comprehensive SAR studies, particularly in exploring how glycan structure and positioning influence biological activity.

Experimental Protocols for Key Chemoenzymatic Methods

Protocol: P450-Controlled Site-Selective Ring Expansion

Objective: To perform skeletal editing of natural product scaffolds via P450-catalyzed oxidation followed by ring expansion.

Materials:

• Natural product substrate
• Engineered P450 enzyme (appropriate variant for target C─H site)
• Cofactor system (NADPH or regeneration system)
• Baeyer-Villiger reagent (e.g., mCPBA) or homologation reagents
• Appropriate buffers and solvents
• Analytical standards

Procedure:

• P450-Mediated Oxidation:

  • Prepare a reaction mixture containing natural product substrate (0.1-1.0 mM) and engineered P450 enzyme (1-5 mol%) in appropriate buffer (e.g., potassium phosphate, pH 7.4).
  • Add necessary cofactors (NADPH, 1-2 mM) to initiate oxidation.
  • Incubate at optimized temperature (typically 25-37°C) with shaking for 2-24 hours.
  • Monitor reaction progress by LC-MS or TLC until complete consumption of starting material.
  • Extract and purify the ketone intermediate using standard techniques (e.g., solvent extraction, chromatography).

• Ring Expansion Pathways:

  • Option A: Baeyer-Villiger Rearrangement:

    • Dissolve ketone intermediate (1.0 equiv) in anhydrous dichloromethane or chloroform.
    • Add meta-chloroperbenzoic acid (mCPBA, 1.2-2.0 equiv) at 0°C.
    • Warm reaction mixture to room temperature and stir for 2-12 hours.
    • Quench with saturated sodium sulfite solution.
    • Extract with organic solvent, dry over anhydrous sodium sulfate, and concentrate.
    • Purify ring-expanded product via flash chromatography.

  • Option B: Ketone Homologation:

    • Employ appropriate homologation conditions (e.g., diazomethane treatment, Seyferth-Gilbert homologation) specific to the ketone functionality.
    • Standardize reaction conditions based on the specific natural product scaffold.
    • Purify homologated product using appropriate chromatographic methods.

• Product Characterization:

  • Confirm structure of ring-expanded analogues using NMR (^1H, ^13C), HRMS, and IR spectroscopy.
  • Evaluate purity by analytical HPLC or UPLC.

Protocol: Hydrophobic Tag-Assisted Glycopeptide Synthesis

Objective: To synthesize complex glycopeptides using hydrophobic tag-assisted liquid-phase synthesis followed by enzymatic glycosylation.

Materials:

• Fmoc-protected amino acids
• Hydrophobic tag (e.g., lipid-based tag)
• Coupling reagents (HATU, DIC, etc.)
• Glycosyltransferases (selected based on target glycan structure)
• Sugar nucleotide donors (UDP-Gal, CMP-Neu5Ac, etc.)
• Appropriate buffers (e.g., HEPES, Tris-HCl)
• C18 solid-phase extraction cartridges

Procedure:

• Liquid-Phase Peptide Synthesis:

  • Couple first Fmoc-protected amino acid to hydrophobic tag using DIC/DMAP in dichloromethane.
  • Precipitate tag-modified product by dilution with acetonitrile; separate by centrifugation.
  • Remove Fmoc protecting group using 20% piperidine in DMF.
  • Continue iterative coupling and deprotection steps using Fmoc chemistry (1.2 equiv of amino acid building blocks per coupling).
  • Precipitate and separate intermediate products after each coupling via centrifugation.
  • After final deprotection, cleave tag and side-chain protecting groups using TFA/TIS/H`2O (95:2.5:2.5).
  • Remove acetyl protecting groups from sugar residues using 10% hydrazine in water.
  • Purify core glycopeptide using reversed-phase C18 chromatography.

• Enzymatic Glycan Elongation:

  • Prepare reaction mixture containing core glycopeptide (0.1-0.5 mM) and appropriate glycosyltransferases (0.1-1.0 mg/mL) in suitable buffer.
  • Add required sugar nucleotide donors (1.5-3.0 equiv).
  • Incubate at optimal temperature and pH for each specific glycosyltransferase (typically 4-24 hours).
  • Monitor reaction progress by ESI-MS.
  • If starting material remains, add additional enzymes and sugar nucleotides to drive reaction to completion.
  • Purify final glycopeptide using C18 solid-phase extraction.

• Quality Control:

  • Confirm glycopeptide structure by mass spectrometry and NMR.
  • Assess homogeneity by analytical HPLC.

Analytical and Computational Tools for SAR Studies

Computational Methods for SAR Analysis

Modern SAR studies extensively integrate computational approaches to rationalize experimental findings and guide analogue design:

• Molecular Docking: Virtual screening of natural product analogues against target protein structures to predict binding modes and affinities [119]. For example, docking simulations of mono- and bis-indole alkaloids against a homology model of Onchocerca ochengi thioredoxin reductase helped explain their anti-filarial activities [119].
• Pharmacophore Modeling: Identification of essential steric and electronic features necessary for biological activity [119] [121].
• Molecular Dynamics Simulations: Investigation of the dynamic behavior of protein-ligand complexes over time to assess binding stability and mechanism [119].
• Binding Free Energy Calculations: Quantitative estimation of binding affinities using methods such as MM-PBSA or MM-GBSA to correlate structural modifications with biological activity [119].

Experimental Biological Evaluation

Comprehensive SAR studies require rigorous biological assessment of synthesized analogues through a combination of in vitro, in silico, and in vivo experiments [119]. The biological profiling should include:

• Potency Assays: Determination of IC_50 or EC_50 values against molecular targets or cellular models.
• Selectivity Profiling: Evaluation against related targets to assess specificity.
• Cytotoxicity Assessment: Testing against relevant cell lines (e.g., H460 lung cancer cells) to establish therapeutic windows [119].
• Mechanistic Studies: Investigation of molecular mechanisms of action, such as the study of Genistein's anti-anaphylactoid activity mediated by GPCRs [119].

Table 1: Key Biological Assays for SAR Studies of Natural Product Analogues

Assay Type	Specific Examples	Application in SAR	Key Parameters
Anticancer	Cytotoxicity against H460 cells [119]	Optimization of anticancer natural products	IC_50 values, selectivity indices
Antibacterial	Activity against Bacillus subtilis [119]	Improvement of antibiotic potency	MIC values, spectrum of activity
Anti-filarial	Motility inhibition of Onchocerca ochengi [119]	Identification of anti-parasitic leads	IC_50 for microfilariae and adult worms
Enzyme Inhibition	DYRK1A kinase inhibition [119]	Selectivity optimization	IC_50, kinase selectivity profiling
Viral Inhibition	Influenza A virus ion channel blockade [119]	Antiviral activity enhancement	EC_50, viral titer reduction

Visualization of Chemoenzymatic Workflows

Skeletal Editing via Ring Expansion

Glycopeptide Synthesis Workflow

Research Reagent Solutions

Table 2: Essential Research Reagents for Chemoenzymatic Natural Product SAR Studies

Reagent Category	Specific Examples	Function in SAR Studies
Engineered Biocatalysts	P450 variants with divergent regioselectivity [4]	Site-selective oxidation of natural product scaffolds for subsequent diversification
Glycosyltransferases	C1GalT1, ST6GalNAc1, ST3Gal1, B4GalT1 [120]	Precise enzymatic glycosylation for generating glycopeptide analogues
Sugar Nucleotide Donors	UDP-Galactose, CMP-Neu5Ac, UDP-GlcNAc [120]	Glycosyl donors for enzymatic glycan assembly
Coupling Reagents	DIC (N,N'-diisopropylcarbodiimide), HATU, DMAP [120]	Peptide bond formation in liquid-phase peptide synthesis
Specialized Tags	Hydrophobic separation tags [120]	Facilitate liquid-phase synthesis and purification of peptide intermediates
Oxidation Reagents	mCPBA (meta-chloroperbenzoic acid) [4]	Baeyer-Villiger rearrangement for ring expansion
Cofactor Systems	NADPH regeneration systems [4]	Support P450-mediated oxidation reactions

Chemoenzymatic strategies provide powerful and efficient methods for accessing natural product analogues to enable comprehensive SAR studies. The approaches described herein—including P450-controlled skeletal editing and hydrophobic tag-assisted glycopeptide synthesis—represent significant advances over traditional synthetic methods, offering improved selectivity, efficiency, and access to diverse chemical space. By integrating these synthetic methodologies with robust computational and biological evaluation platforms, researchers can systematically explore the SAR of complex natural products, accelerating the discovery and optimization of novel therapeutic agents. As these chemoenzymatic methods continue to evolve, they will undoubtedly play an increasingly important role in bridging the gap between natural product discovery and drug development.

The process of drug discovery is notoriously challenging, requiring an average of $1.3-$4 billion and a decade from discovery to regulatory approval, with approximately 90% of candidates failing in pre-clinical and clinical stages [122] [123]. In this high-risk landscape, natural products (NPs) derived from traditional medicinal systems offer a promising alternative, with nearly 60% of small-molecule drugs approved since 1981 being NPs or NP-derived synthetics [124]. These compounds provide unique advantages, including evolutionary optimization for biological function, structural rigidity ensuring robust target binding, and higher similarity to active biological metabolites compared to synthetic compounds [124]. However, applying traditional natural product knowledge to modern disease targets presents significant challenges, particularly for diseases not historically described in traditional medicine systems [124].

Chemoenzymatic synthesis has emerged as a powerful strategy to bridge this gap, combining the precision of enzymatic transformations with the flexibility of synthetic chemistry to efficiently optimize natural product scaffolds for drug development [10] [40]. This approach leverages the exceptional chemo-, regio-, and stereoselectivity of enzymes under mild reaction conditions (ambient temperature, neutral pH, aqueous media) while enabling structural modifications that enhance drug-like properties [40]. The integration of chemoenzymatic methods with modern computational planning and artificial intelligence represents a transformative advancement in streamlining the path from natural product discovery to clinical candidate identification [6].

Foundational Concepts: Natural Products and Chemoenzymatic Strategies

The NaCTR Pipeline: Integrating Traditional Knowledge with Modern Discovery

The Natural product-derived Compound-based drug discovery pipeline from Traditional oriental medicine by search space Reduction (NaCTR) exemplifies the modern approach to NP-based discovery. This integrated pipeline addresses critical bottlenecks in conventional drug discovery by systematically combining phenotypic evidence from traditional medicine with contemporary compound-gene interaction data [124]. The pipeline operates through four key stages:

• Target and phenotype identification: Translation of modern disease terminology into traditional medicine phenotypes
• TOM-based NP selection: Using traditional knowledge to reduce compound-gene search space
• Toxicity prediction: In silico assessment of compound safety profiles
• Pharmacokinetic analyses: Evaluation of drug-like properties and bioavailability

In a case study applied to Parkinson's disease, researchers identified 19 disease-related phenotypes through literature survey, of which 17 were successfully mapped to Traditional Oriental Medicine terminology using the COCONUT database [124]. This phenotype-based approach, combined with therapeutic target identification from databases including DisGeNET, OMIM, and TTD, enabled a dramatic reduction of the search space from 2,288,893 natural products to just 7 promising candidates containing compounds with potential therapeutic effects for Parkinson's disease [124].

Advanced Chemoenzymatic Approaches for Natural Product Optimization

Chemoenzymatic synthesis has evolved beyond simple biocatalytic transformations to encompass sophisticated strategies for natural product modification and optimization:

• Skeletal Editing: Recent advances enable precise modifications at the level of single atoms/bonds through strategies like P450-controlled site-selective ring expansion at aliphatic C─H sites. This approach combines P450-mediated oxidation with Baeyer-Villiger rearrangement or ketone homologation to systematically alter natural product scaffolds while preserving their core bioactive structures [4].

• Multi-Enzyme Cascades: One-pot multi-enzyme (OPME) systems integrate multiple enzymatic transformations in a single reaction vessel, dramatically improving synthetic efficiency. For example, the synthesis of nepetalactolone from geraniol employs a ten-enzyme cascade that achieves 93% yield while setting three contiguous stereocenters with precision [10].

• Engineered Biocatalysts: Protein engineering through computational design or ancestral sequence reconstruction produces enzymes with enhanced properties. For instance, engineering of a ketoreductase from Sporidiobolus salmonicolor resulted in a variant with a 64-fold higher apparent kcat and improved robustness under process conditions for the synthesis of ipatasertib, a potent protein kinase B inhibitor [40].

Table 1: Key Advantages of Chemoenzymatic Synthesis in Drug Discovery

Advantage	Impact on Drug Discovery	Example
Excellent Stereoselectivity	Prevents formation of inactive or toxic stereoisomers	Synthesis of alcohol intermediate for ipatasertib with 99.7% diastereomeric excess [40]
Mild Reaction Conditions	Enables functionalization of sensitive natural product scaffolds	Ambient temperature, neutral pH, aqueous media [40]
Tunable Selectivity	Allows precise modification of complex molecules	P450-controlled site-selective oxidation for skeletal editing [4]
Atom Economy	Reduces waste generation and improves sustainability	Alignment with green chemistry principles [10]

Integrated Methodologies: Experimental Protocols and Workflows

Target Identification and Natural Product Selection Protocol

The initial phase of the drug discovery pipeline requires systematic identification of disease-relevant targets and natural products with potential therapeutic effects:

Step 1: Disease Phenotype Identification

• Conduct comprehensive literature survey to identify symptoms and phenotypes associated with the target disease
• For Parkinson's disease, this resulted in 19 phenotypes including tremor, bradykinesia, muscle rigidity, and postural instability [124]

Step 2: Traditional Medicine Terminology Mapping

• Map modern medical phenotypes to traditional medicine terminology using specialized databases
• Utilize COCONUT database (Compound Combination-Oriented Natural Products Database with Unified Terminology) to filter phenotypes associated with natural products in Traditional Oriental Medicine
• For Parkinson's disease, this process reduced 19 modern phenotypes to 17 TOM-applicable terms [124]

Step 3: Therapeutic Gene Identification

• Query disease-gene databases including OMIM, TTD, and DisGeNET using disease name or UMLS CUI (e.g., 'C0030567' for Parkinson's disease)
• Cross-reference with ClinicalTrials.gov to identify genes targeted in clinical trials
• Select intersection of database-derived genes and clinically targeted genes for higher confidence
• For Parkinson's disease, this identified 17 potential therapeutic target genes [124]

Step 4: Compound-Natural Product Mapping

• Use COCONUT database to identify compounds that influence therapeutic target genes, considering only relations with experimental or clinical support
• Map these compounds to natural products that contain them, again using experimentally validated relationships
• Select natural products based on both phenotype targeting (TOM records) and compound-gene interactions [124]

Diagram 1: Workflow for target identification and natural product selection, illustrating the integration of traditional knowledge and modern bioinformatics.

Chemoenzymatic Skeletal Editing Protocol

The following protocol details the skeletal editing of natural product scaffolds via P450-controlled site-selective ring expansion, enabling precise modification of core structures:

Step 1: P450 Enzyme Selection and Engineering

• Select P450 enzymes based on substrate compatibility and desired oxidation site
• Engineer P450 variants for divergent regioselectivity using structure-guided mutagenesis or directed evolution
• Express and purify P450 enzymes using standard protein expression systems

Step 2: Site-Selective Oxidation

• Prepare natural product substrate solution in appropriate buffer (typically 50-100 mM potassium phosphate, pH 7.4)
• Set up reaction mixture containing: natural product substrate (0.1-1 mM), P450 enzyme (0.5-5 μM), NADPH regeneration system (e.g., glucose-6-phosphate/glucose-6-phosphate dehydrogenase)
• Incubate at 25-30°C with shaking for 2-24 hours
• Monitor reaction progress by LC-MS or TLC
• Extract oxidation product using organic solvents (ethyl acetate or dichloromethane)
• Purify via flash chromatography or preparative HPLC

Step 3: Baeyer-Villiger Rearrangement or Ketone Homologation

• For Baeyer-Villiger rearrangement: Dissolve oxidized product in appropriate solvent and treat with peracid (e.g., mCPBA) or use enzymatic BV reaction with Baeyer-Villiger monooxygenases
• For ketone homologation: Employ established homologation conditions (e.g., diazomethane or alternative carbene insertion methodology)
• Purify ring-expanded products using standard chromatographic techniques

Step 4: Structural Validation and Biological Assessment

• Characterize skeletally edited derivatives using NMR, HRMS, and other analytical methods
• Evaluate effects of skeletal modification on biological activity through relevant assays
• For the P450-controlled ring expansion, this approach has successfully generated panels of ring-expanded analogs with drastically altered anticancer activity [4]

Computational Planning for Chemoenzymatic Synthesis

The minChemBio computational tool enables efficient planning of chemoenzymatic syntheses by minimizing costly transitions between chemical and biological reactions:

Algorithm Implementation:

• Curate datasets of 1,808,938 chemical reactions from USPTO and 57,541 biological reactions from MetaNetX
• Remove duplicate and incorrectly annotated reactions
• Define each reaction as transformation of most structurally similar molecules (main reactant and product)
• Assign reaction IDs and chemical IDs to navigate reaction pathway search space
• Implement filtering algorithm to minimize biological-chemical and chemical-biological transitions
• Integrate dGpredictor tool to assess thermodynamic favorability of reactions [6]

Application Workflow:

• Input target molecule and available starting materials
• Run minChemBio algorithm to identify synthetic pathways with minimal reaction type transitions
• Filter pathways based on thermodynamic feasibility and precursor cost
• Select optimal route for experimental implementation
• This approach has demonstrated practical utility in guiding the chemoenzymatic synthesis of bioplastic precursor 2,5-furandicarboxylic acid from inexpensive glucose [6]

The Scientist's Toolkit: Essential Research Reagents and Solutions

Successful implementation of chemoenzymatic natural product drug discovery requires specialized reagents and resources. The following table details key solutions and their applications:

Table 2: Essential Research Reagent Solutions for Chemoenzymatic Natural Product Discovery

Reagent/Resource	Function	Application Example
COCONUT Database	Provides herb-phenotype relationships and natural product-compound associations	Mapping disease phenotypes to traditional medicine natural products [124]
Engineered P450 Enzymes	Catalyze site-selective oxidation of natural product scaffolds	Skeletal editing via ring expansion at aliphatic C-H sites [4]
NADPH Regeneration System	Maintains cofactor supply for oxidase enzymes	Supporting P450-mediated oxidation during chemoenzymatic synthesis [4]
Imine Reductases (IREDs)	Catalyze asymmetric synthesis of chiral amines	Production of amine-containing natural product analogs [40]
Ketoreductases (KREDs)	Enable stereoselective reduction of ketones	Synthesis of alcohol intermediates with high diastereomeric excess [40]
One-Pot Multi-Enzyme Systems	Combine multiple enzymatic transformations in single reaction	Efficient synthesis of nepetalactolone from geraniol [10]
minChemBio Software	Computational planning of chemoenzymatic synthetic routes	Minimizing transitions between chemical and biological reactions [6]

Data Integration and Analysis Frameworks

Quantitative Models for Predictive Drug Discovery

The integration of Large Quantitative Models (LQMs) represents a transformative advancement in natural product-based drug discovery. Unlike large language models trained on textual data, LQMs are grounded in first principles of physics, chemistry, and biology, enabling them to simulate fundamental molecular interactions and predict behavior of novel drug candidates without relying on existing literature patterns [122]. These models leverage quantum mechanics to understand and predict molecular behavior, exploring expanded chemical space to identify compounds meeting specific pharmacological criteria that may not exist in known databases [122].

The power of LQMs is magnified by access to specialized structural databases containing over one million protein-ligand complexes and 5.2 million 3D structures with annotated experimental potency data. This structural information enables rapid in silico evaluation of potential drug molecules, focusing development efforts on compounds with higher likelihood of success [122]. For natural product discovery, LQMs can predict how structural modifications through chemoenzymatic synthesis will affect target binding, toxicity, and pharmacokinetic properties, dramatically accelerating the optimization process.

Experimental Data Integration Challenges and Solutions

Effective data management remains a critical challenge in modern drug discovery, with implications for natural product-based approaches:

Key Challenges:

• Data Silos: Traditional organizational structures in pharmaceutical companies create isolated data repositories that impede information sharing [125]
• Quality Variability: Inconsistent data quality from public and proprietary sources affects AI model performance and prediction accuracy [125]
• Standardization Gaps: Lack of universal data standards limits interoperability between different software platforms and research groups [125]

Strategic Solutions:

• Implement robust data foundations and knowledge graphs to enable creation of unique chemical entities [125]
• Adopt flexible data governance frameworks ensuring data integrity and accessibility [125]
• Increase cross-organizational collaboration to establish best practices for data standardization [125]
• Deploy AI-based data curation and cleanup tools to manage anomalies and integration challenges [125]

Diagram 2: Data integration and analysis framework for natural product-based drug discovery, highlighting challenges and AI-enhanced solutions.

The integration of traditional natural product knowledge with modern chemoenzymatic synthesis and computational approaches represents a paradigm shift in drug discovery. The NaCTR pipeline demonstrates how search space reduction through traditional medicine evidence can dramatically improve efficiency in identifying promising candidates [124]. Meanwhile, advanced chemoenzymatic strategies enable precise skeletal editing of natural product scaffolds [4], and computational tools like minChemBio optimize synthetic routes to minimize costly transitions between reaction types [6].

The future of natural product-based drug discovery will be increasingly driven by Large Quantitative Models that simulate molecular interactions from first principles [122], moving beyond pattern recognition in existing data to create novel knowledge through billions of in silico simulations. This approach is particularly valuable for rare diseases and challenging targets like neurodegenerative disorders, where traditional methods have struggled to deliver effective treatments.

As these technologies mature, the drug discovery pipeline will continue to accelerate, potentially reducing development timelines from decades to years while improving success rates. The integration of physicochemical principles with biological knowledge through LQMs will enable more accurate prediction of clinical outcomes earlier in the development process, ultimately delivering better therapies to patients faster and at lower cost [122]. Through the strategic combination of traditional wisdom, synthetic biology, and computational power, the future of natural product-based drug discovery appears increasingly promising.

The field of natural product synthesis, a cornerstone in the development of therapeutic agents, continuously evolves to incorporate more sustainable and efficient methodologies. Green chemistry, defined by the twelve principles established by Anastas and Warner, provides a framework for designing chemical products and processes that reduce or eliminate the use and generation of hazardous substances [126]. Within the specific context of chemoenzymatic strategies for natural product synthesis, green chemistry transcends mere environmental responsibility to become a driver of economic and technical innovation. Chemoenzymatic synthesis, which integrates traditional chemical synthesis with enzymatic transformations, inherently aligns with green chemistry goals by leveraging the high selectivity, efficiency, and benign nature of biological catalysts [10]. This whitepaper provides a technical assessment of the demonstrable economic and environmental advantages afforded by adopting green and chemoenzymatic principles, equipping researchers and drug development professionals with the metrics and methodologies to quantify these benefits in their own workflows.

Quantifying the Advantages: Core Green Metrics

A fundamental challenge in green chemistry is the objective evaluation of the "greenness" of a process. Moving from qualitative statements to quantitative assessment requires a set of standardized metrics. These metrics allow for the direct comparison of different synthetic routes and provide tangible data to gauge improvements in sustainability and efficiency.

Key Green Chemistry Metrics and Calculations

The following table summarizes the principal metrics used for quantitative assessments in green chemistry.

Table 1: Key Green Chemistry Metrics for Process Assessment

Metric	Calculation Formula	Interpretation & Ideal Value	Primary Advantage Measured
Atom Economy (AE) [127]	(Molecular Weight of Desired Product / Molecular Weight of All Reactants) × 100%	Measures efficiency by incorporating reactant atoms into the final product. Ideal: 100%.	Resource Efficiency, Waste Prevention
E-Factor [127]	Total Mass of Waste (kg) / Mass of Product (kg)	Quantifies total waste generated per unit of product. Ideal: 0.	Waste Reduction, Environmental Impact
Reaction Mass Efficiency (RME) [128]	(Mass of Product / Total Mass of All Reactants) × 100%	Measures what proportion of the mass of reactants is converted to product. Ideal: 100%.	Resource Efficiency, Cost Reduction
Process Mass Intensity (PMI) [127]	Total Mass of Materials Used in Process (kg) / Mass of Product (kg)	Accounts for all materials input, including water, solvents, etc. Ideal: As low as possible.	Overall Material Efficiency

These metrics can be applied to evaluate and compare synthetic routes. For instance, case studies in fine chemical production have demonstrated the power of this approach. The synthesis of dihydrocarvone from limonene-1,2-epoxide showcased excellent green characteristics with an Atom Economy of 1.0 and a Reaction Mass Efficiency of 0.63, whereas the synthesis of florol via isoprenol cyclization, while having a perfect AE of 1.0, had a lower RME of 0.233, indicating a greater mass of inputs required per unit of product [128].

Experimental Protocol: Measuring Green Metrics for a Synthetic Process

To standardize the evaluation of a chemical process, the following procedural protocol is recommended:

• Define System Boundaries: Clearly delineate the synthetic steps to be included in the assessment (e.g., from starting materials to isolated, purified product).
• Material Inventory: Accurately record the masses (in kg) of all input materials, including reactants, solvents, catalysts, and all purification agents. Simultaneously, record the mass of the final isolated product.
• Waste Calculation: The total waste is calculated as the difference between the total mass of input materials and the mass of the isolated product. Alternatively, it can be summed from the masses of identified waste streams.
• Metric Computation:
  • Atom Economy (AE): Use the balanced chemical equation for the key synthetic step to calculate the theoretical AE.
  • E-Factor: E-Factor = (Total Mass of Inputs - Mass of Product) / Mass of Product. Note that PMI = E-Factor + 1 [127].
  • Reaction Mass Efficiency (RME): RME = (Mass of Product / Total Mass of Reactants) × 100%. This can be calculated for individual steps or the entire sequence.
• Comparative Analysis: Use the calculated metrics to benchmark the process against industry standards or alternative synthetic routes to identify areas for improvement.

Industry data reveals a stark contrast in E-Factors across sectors, underscoring the need for improvement in fine chemical and pharmaceutical manufacturing: oil refining (<0.1), bulk chemicals ( <1 to 5), fine chemicals (5 to >50), and pharmaceuticals (25 to >100) [127].

Green Chemistry and Chemoenzymatic Synthesis

Chemoenzymatic synthesis, the combined use of chemical and enzymatic transformations, is a powerful manifestation of green chemistry principles in natural product research. Enzymes are inherently natural, non-toxic catalysts that typically operate in water under mild conditions, aligning with multiple principles of green chemistry [10].

Experimental Workflow for Chemoenzymatic Synthesis

The following diagram illustrates a generalized workflow for developing and optimizing a chemoenzymatic synthesis, highlighting the integration of traditional and enzymatic steps with green metric evaluation.

Diagram 1: Chemoenzymatic synthesis workflow.

This workflow demonstrates the iterative process of designing a synthetic route that leverages the strengths of both chemical and enzymatic methods, with continuous feedback from green metric assessment to guide optimization toward a more sustainable and economical process.

Case Study: Chemoenzymatic Synthesis of Natural Products

Recent literature provides compelling examples of this approach. The synthesis of the terpenoid nepetalactolone features a one-pot multienzyme (OPME) system that sets three contiguous stereocenters from geraniol [10]. This ten-enzyme cascade performs allylic hydroxylation, alcohol oxidation, aldehyde reduction, cyclization, and hemiacetal oxidation in a single pot, achieving a 93% yield. The system elegantly manages to perform both oxidative and reductive steps concurrently using a shared NAD/NADH cofactor regeneration system, demonstrating high atom and reaction mass efficiency [10].

In another example, the synthesis of chrodrimanin C utilized a key enzymatic hydroxylation of a complex steroid core on a gram scale [10]. The enzyme provided regioselective oxidation of a single methylene group with 83% yield and high enantioselectivity, despite the presence of numerous other oxidizable sites. This showcases a key green advantage of biocatalysis: avoiding the need for protecting groups and hazardous oxidants, thereby reducing synthetic steps (derivatization) and waste [10].

The Researcher's Toolkit for Green Chemoenzymatic Synthesis

Implementing green chemoenzymatic strategies requires a specific set of reagents and tools. The following table details essential items for a research laboratory engaged in this field.

Table 2: Research Reagent Solutions for Green Chemoenzymatic Synthesis

Item Category	Specific Examples	Function & Green Chemistry Rationale
Biocatalysts	Ketoreductases (e.g., T4HNR, ARti-2), Cytochrome P450s, Transaminases, Engineered enzymes for cascades (e.g., OPME systems)	Provide high stereoselectivity and regioselectivity under mild conditions; enable cascade reactions reducing intermediate isolation; often replace heavy metal catalysts and stoichiometric oxidants/reductants. [10]
Green Solvents	Water, Ethanol, Cyclopentyl methyl ether (CPME), 2-Methyltetrahydrofuran (2-MeTHF)	Safer alternatives to hazardous solvents like hexane or chlorinated solvents; water is a non-toxic and renewable medium for enzymatic reactions. [126]
Renewable Feedstocks	Carbohydrates, Geraniol, Isoprenol, Plant Oils	Serve as starting materials derived from biomass, reducing reliance on depleting petroleum-based feedstocks. [10] [126]
Catalysts	Immobilized enzymes, Heterogeneous catalysts (e.g., Sn-zeolites), Metal complexes for cooperative catalysis	Enhance reaction efficiency and selectivity; can be recovered and reused multiple times, minimizing waste versus stoichiometric reagents. [128] [126]
Analytical & Monitoring Tools	In-line IR spectroscopy, HPLC, Chemical substitution software (e.g., EcoOnline)	Enable real-time analysis for pollution prevention and rapid evaluation of chemical hazards to facilitate substitution with safer alternatives. [126]

Integrated Economic and Environmental Impact Analysis

The adoption of green chemistry and chemoenzymatic strategies delivers a compelling dual benefit: it reduces environmental footprint while simultaneously improving economic performance.

Environmental Benefits

The environmental advantages are wide-ranging and directly measurable using the metrics in Section 2.

• Waste Reduction: The most direct impact is a significant reduction in waste generation, as captured by a lower E-Factor. This minimizes the burden on hazardous waste landfills and reduces the environmental damage from chemical disposal [129] [127].
• Safer Materials: The use of less hazardous solvents and renewable feedstocks leads to cleaner air and water by reducing the release of persistent, bioaccumulative, and toxic substances [129] [126]. Designing chemicals for degradation, as seen with compostable polymers, prevents long-term environmental persistence [126].
• Energy Efficiency: Conducting reactions at ambient temperature and pressure, facilitated by enzymatic catalysis and improved reactor design, significantly lowers energy consumption [10] [126].

Economic Benefits

Green chemistry is not an environmental expense but a competitive economic advantage.

• Cost Savings from Efficiency: Higher atom economy and reaction mass efficiency directly translate to lower consumption of often-expensive feedstock. Reduced waste also leads to substantial cost savings in waste treatment and disposal [129] [128].
• Operational and Capital Cost Reduction: Fewer synthetic steps, faster reaction times (e.g., using microwave irradiation), and reduced solvent usage increase plant throughput and can reduce the required plant size or footprint for the same output [129]. This increases capacity without major capital investment.
• Reduced Risk and Liability: The use of safer chemicals and processes minimizes the potential for accidents (fires, explosions) and occupational exposures, leading to lower insurance premiums, regulatory burdens, and potential liability [129] [126]. Furthermore, designing for regulatory compliance ahead of stringent laws (e.g., REACH, TSCA) mitigates the risk of process obsolescence [126].

Table 3: Synthesis of Economic and Environmental Advantages

Green Chemistry Principle	Economic Impact	Environmental Impact
Atom Economy & E-Factor Reduction [127]	Lower raw material costs; reduced waste disposal costs.	Less depletion of resources; less waste for treatment and landfill.
Safer Solvents & Auxiliaries [126]	Reduced costs for personal protective equipment and ventilation; lower liability.	Cleaner air and water; safer working conditions.
Use of Catalysts [126]	Higher throughput and lower energy use per unit product; catalyst reuse.	Less energy consumption; avoidance of stoichiometric waste.
Design for Degradation [126]	Avoided future remediation and liability costs.	Prevention of persistent environmental pollutants.

The integration of green chemistry principles, particularly through chemoenzymatic strategies, represents a paradigm shift in natural product synthesis and drug development. It moves sustainability from a peripheral concern to a central driver of innovation. As demonstrated by the quantitative metrics, experimental protocols, and case studies herein, this approach offers a clear and actionable pathway to simultaneously achieve superior environmental performance and enhanced economic competitiveness. For researchers and scientists, the adoption of these methodologies is not merely an ethical choice but a practical imperative for developing the efficient, safe, and sustainable chemical processes of the future.

The pharmaceutical industry faces a perpetual challenge: accelerating the delivery of new therapeutics while managing escalating development costs and high attrition rates. Successful drug development necessitates strategic innovation not only in identifying new chemical entities but also in optimizing development methodologies and formulation technologies. This whitepaper examines the industrial adoption of two landmark pharmaceutical compounds—sitagliptin and simvastatin—through detailed technical case studies. Framed within the context of modern chemoenzymatic strategies for natural product synthesis, these case studies provide critical insights into the experimental protocols, quantitative modeling, and advanced formulation techniques that have defined successful drug development campaigns. For researchers and drug development professionals, understanding these paradigms is essential for leveraging contemporary synthetic biology and process optimization tools, such as computational synthesis planning with tools like minChemBio which minimizes costly transitions between chemical and biological reactions [6], to advance future therapeutic candidates.

The case studies herein explore distinct facets of pharmaceutical innovation: the use of biomarkers to accelerate clinical development for sitagliptin, and the application of advanced formulation and societal benefit analysis for simvastatin. Furthermore, we explore how emerging chemoenzymatic skeletal editing techniques—enabling precise ring expansion at aliphatic C─H sites of natural product scaffolds [4]—represent the next frontier in pharmaceutical innovation, allowing medicinal chemists to fine-tune the structure and biological activity of complex molecules efficiently.

Case Study 1: Sitagliptin - Biomarker-Driven Development

Background and Therapeutic Target

Sitagliptin, a novel dipeptidyl-peptidase IV (DPP4) inhibitor for type 2 diabetes, exemplifies a biomarker-accelerated development pathway. Type 2 diabetes pathogenesis involves three key defects: insulin resistance, loss of insulin secretion, and hepatic glucose overproduction [130]. DPP4 inhibitors address the incretin defect by inhibiting the degradation of glucagon-like peptide-1 (GLP-1), thereby enhancing glucose-dependent insulin secretion and suppressing inappropriately elevated glucagon levels. The strategic use of proximal and distal biomarkers in the sitagliptin development program significantly reduced the overall cycle time to filing compared to industry averages [131] [130].

Experimental Protocols: Biomarker Validation and Application

The sitagliptin development program implemented a comprehensive biomarker strategy grounded in pharmacokinetic/pharmacodynamic (PK/PD) modeling. The experimental framework involved:

• Target Engagement Biomarker (Proximal): Plasma DPP4 activity was measured as a direct indicator of enzyme inhibition. This biomarker confirmed that sitagliptin effectively engaged its intended target at selected dose levels [130].
• Disease-Related Biomarkers (Distal): Serum glucose, insulin (reflecting β-cell response), and glucagon (reflecting α-cell response) were monitored as indicators of pharmacological efficacy on diabetes pathophysiology [130].
• PK/PD Modeling Integration: Exposure/response relationships were characterized to define the relationship between drug concentration, DPP4 inhibition (proximal biomarker), and changes in glucose regulation (distal biomarkers). This quantitative modeling facilitated optimal dose selection and clinical trial design [131].

Table 1: Key Biomarkers in Sitagliptin Development

Biomarker Category	Specific Marker	Measurement Purpose	Application in Development
Proximal	Plasma DPP4 activity	Target engagement	Dose confirmation and optimization
Distal	Serum glucose	Disease impact	Proof-of-concept evaluation
Distal	Insulin secretion	β-cell function	Mechanism of action confirmation
Distal	Glucagon levels	α-cell function	Comprehensive pathway analysis

Development Workflow and Decision Pathways

The interplay between proximal and distal biomarkers created a efficient decision-making framework throughout the development process. The following diagram illustrates the biomarker-driven development workflow and decision pathways for sitagliptin:

Case Study 2: Simvastatin - Formulation Innovation and Societal Impact

Background and Therapeutic Profile

Simvastatin, a HMG-CoA reductase inhibitor, has demonstrated significant societal benefits through cholesterol management and cardiovascular risk reduction. Beyond its established therapeutic applications, recent research has explored simvastatin's potential in combination cancer therapy, particularly for colorectal cancer (CRC) [132]. This expanded investigation required advanced formulation strategies to overcome challenges associated with conventional drug administration, such as differing biodistribution profiles of combined active substances and cumulative toxicity issues.

Experimental Protocols: Quality by Design (QbD) in Liposomal Co-Formulation

The development of liposomal formulations co-encapsulating simvastatin with doxorubicin (DOX) implemented the Quality by Design (QbD) concept to optimize critical quality attributes (CQAs) [132]. The methodological approach included:

• Quality Target Product Profile (QTPP) Definition: Established target ranges for liposome CQAs, including drug entrapped concentration, encapsulation efficiency, size, zeta potential, and drug release profile [132].
• Risk Assessment: Identified critical formulation factors (phospholipids, DOX, and SIM concentrations) and process parameters (incubation time and pH of ammonium sulphate solution) with highest potential impact on CQAs [132].
• Design of Experiments (DoE) Implementation: A screening experimental design was employed to systematically analyze the relationship between independent variables and CQAs, followed by statistical analysis to identify critical factors [132].
• In Vitro Performance Evaluation: Cytotoxic profiles were assessed at different drug ratios on C26 murine colon cancer cells in co-culture with macrophages, confirming the importance of delivering optimal drug ratios to the target site [132].

Table 2: QbD Application in Simvastatin-Doxorubicin Liposomal Formulation

QbD Element	Application in Simvastatin-DOX Liposomes	Impact on Product Quality
QTPP	Target ranges for encapsulation efficiency, size, drug release	Defined optimal therapeutic performance parameters
Critical Material Attributes	Phospholipid concentration, Drug concentrations	Directly influenced CQAs based on statistical analysis
Critical Process Parameters	Incubation time, pH of AS solution	Affected drug loading efficiency and stability
Design Space	Established relationships between factors and CQAs	Enabled robust formulation optimization
Control Strategy	Monitoring and controlling critical factors	Ensured consistent batch-to-batch quality

Quantitative Societal Benefits Analysis

Beyond formulation science, simvastatin's development offers insights into the broad societal impact of pharmaceutical innovation. A comprehensive analysis of simvastatin's benefits in Canada from 1990-2009 revealed cumulative monetary benefits of $4.8 billion (2010 CA$) distributed across multiple sectors [133] [134]. The distribution of benefits included:

• Developing and generic manufacturers: 32%
• Healthcare sector: 32% (through cost avoidance from prevented cardiovascular events)
• Generic manufacturers: 27%
• Employment sector: 9% (through reduced productivity loss from disability and premature death) [133]

Sensitivity analysis demonstrated that higher patient compliance and drug efficacy significantly increased benefits to healthcare and employment sectors, while manufacturer benefits remained unchanged [133]. This analysis highlights the vital role of patents, compliance, and efficacy in maximizing the societal value of pharmaceutical innovation.

The Chemoenzymatic Synthesis Connection

Modern Skeletal Editing Approaches for Natural Product Diversification

The case studies above demonstrate established industrial adoption patterns, but contemporary research in chemoenzymatic synthesis offers transformative potential for future drug development. Recent advances enable skeletal editing of natural product scaffolds via P450-controlled site-selective ring expansion at aliphatic C─H sites [4]. This methodology combines P450-mediated site-selective oxidation with subsequent Baeyer-Villiger rearrangement or ketone homologation, allowing direct modification of molecular frameworks at the level of single atoms or bonds.

For pharmaceutical scientists, this approach provides a powerful tool to rapidly generate structural diversity from natural product starting materials, fine-tuning biological activity and optimizing drug properties. The technology has demonstrated potential to drastically alter anticancer activity in natural product derivatives [4], suggesting applications in optimizing statin-based compounds or creating novel DPP4 inhibitors with improved therapeutic profiles.

Computational Tools for Chemoenzymatic Synthesis Planning

The integration of computational tools further enhances the potential of chemoenzymatic approaches. The minChemBio synthesis planning tool addresses a critical challenge in chemoenzymatic methods: the costly transitions between chemical and biological reaction systems [6]. By curating datasets of over 1.8 million chemical reactions and 57,000 biological reactions, this tool identifies synthetic pathways that minimize transitions between reaction types, enabling more efficient synthesis of target molecules from cheap and abundant starting materials [6].

Essential Research Reagent Solutions

The following table details key research reagents and materials critical for the experimental protocols described in the featured case studies and emerging chemoenzymatic approaches:

Table 3: Essential Research Reagents and Materials

Reagent/Material	Function/Application	Technical Considerations
DPP4 Enzyme Assay	Quantification of target engagement for sitagliptin	Critical proximal biomarker validation
Ammonium Sulphate (AS) Solution	Active loading of doxorubicin into liposomes	pH critical process parameter for encapsulation
Phospholipids	Structural components of liposomal formulations	Concentration significantly impacts critical quality attributes
Engineered P450 Catalysts	Site-selective oxidation for skeletal editing	Enables divergent regioselectivity for natural product diversification
C26 Murine Colon Cancer Cell Line	In vitro evaluation of combination therapy	Used in co-culture with macrophages to simulate tumor microenvironment
Baeyer-Villiger Reagents	Ring expansion via skeletal editing	Applied following P450 oxidation to achieve molecular restructuring

The industrial adoption of pharmaceutical innovations, as exemplified by sitagliptin and simvastatin, demonstrates the critical importance of strategic development approaches. The leveraged use of biomarkers in sitagliptin development provided a framework for accelerating clinical proof-of-concept and streamlining dose optimization [131] [130]. Meanwhile, the application of QbD principles in simvastatin-DOX liposomal formulation enabled systematic optimization of critical quality attributes for enhanced therapeutic performance [132].

For today's researchers and drug development professionals, these case studies provide validated methodologies while pointing toward future opportunities through chemoenzymatic synthesis strategies. The emerging capabilities in skeletal editing of natural product scaffolds [4] and computational synthesis planning [6] represent the next frontier in pharmaceutical innovation, potentially accelerating the development of future therapeutics with optimized properties and enhanced clinical benefits. As the field advances, integrating these sophisticated approaches with the proven strategies documented in successful drug development campaigns will be essential for addressing ongoing challenges in pharmaceutical R&D.

Conclusion

Chemoenzymatic synthesis has unequivocally emerged as a powerful and indispensable paradigm in natural product chemistry, successfully bridging the gap between traditional organic synthesis and biosynthesis. By strategically integrating the precision of enzymatic catalysis with the flexibility of synthetic methodology, this approach enables more efficient, sustainable, and innovative routes to complex bioactive molecules. The key takeaways underscore its capacity to address long-standing synthetic challenges, simplify access to stereochemically dense architectures, and generate diverse analogues for drug discovery. Looking forward, the convergence of continued enzyme discovery, advances in protein engineering, and the development of novel chemoenzymatic cascades promises to further expand the boundaries of accessible chemical space. For biomedical and clinical research, these advancements translate directly into an accelerated pipeline for developing natural product-inspired therapeutics, particularly against pressing global threats such as antimicrobial resistance and cancer. The future of chemoenzymatic synthesis lies in the deeper integration of computational design, artificial intelligence, and systems biocatalysis, paving the way for next-generation strategies that will continue to revolutionize the synthesis and optimization of life-saving medicines.

References

• 1. Recent Advances in the Chemoenzymatic Synthesis of ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7237303/]
• 2. Recent advances in the chemoenzymatic synthesis of ... [https://www.sciencedirect.com/science/article/abs/pii/S1367593120300065]
• 3. Biocatalytic stereocontrolled head-to-tail cyclizations of ... [https://www.nature.com/articles/s41467-024-48993-9]
• 4. Chemoenzymatic Skeletal Editing of Natural Product Scaffolds ... [https://pubmed.ncbi.nlm.nih.gov/40757801/]
• 5. Grand challenges in Chemical Biology from the ... [https://www.frontiersin.org/journals/chemical-biology/articles/10.3389/fchbi.2025.1731631/full]
• 6. Guiding chemoenzymatic synthesis [https://www.nature.com/articles/s41589-025-01876-6]
• 7. Chemoenzymatic Synthesis of siRNA and sgRNA Using ... [https://www.hongene.com/resources/blogs/chemoenzymatic-synthesis-of-sirna-and-sgrna-using-ligation-technology/]
• 8. Organocatalytic kinetic resolution of sulfinamides by N/O ... [https://www.nature.com/articles/s41467-025-61429-2]
• 9. Chemoenzymatic synthesis - PMC - PubMed Central - NIH [https://pmc.ncbi.nlm.nih.gov/articles/PMC11906607/]
• 10. Current Progress in the Chemoenzymatic Synthesis of ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9571504/]
• 11. Non-ribosomal peptide cyclase-directed chemoenzymatic ... [https://www.nature.com/articles/s41557-025-01979-6]
• 12. Challenges and Opportunities for the Large-Scale ... [https://www.frontiersin.org/journals/catalysis/articles/10.3389/fctls.2021.810779/full]
• 13. Charting the Evolution of Chemoenzymatic in the... Strategies [https://pmc.ncbi.nlm.nih.gov/articles/PMC11107883/]
• 14. Merging enzymatic and synthetic chemistry with ... [https://www.nature.com/articles/s41467-022-35422-y]
• 15. Protein Flexibility and Stiffness Enable Efficient Enzymatic ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC6396832/]
• 16. Chemoenzymatic Synthesis, Characterization, and Scale- ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC4613946/]
• 17. Structural dynamics and computational design of synthetic ... [https://www.sciencedirect.com/science/article/pii/S2667109321002748]
• 18. Combining biocatalytic and radical retrosynthesis for ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12282579/]
• 19. Compartmentalization of multi-enzymes within designable ... [https://www.sciencedirect.com/science/article/abs/pii/S0141813025078742]
• 20. Recent Advances in the Strategies of Simultaneous ... [https://www.mdpi.com/2076-3417/14/9/3702]
• 21. Extremophilic Oxidoreductases for the Industry [https://pmc.ncbi.nlm.nih.gov/articles/PMC8387880/]
• 22. Connecting chemical and protein sequence space to ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12488478/]
• 23. Transferase [https://en.wikipedia.org/wiki/Transferase]
• 24. Methyltransferases: Functions and Applications - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC9539859/]
• 25. Transferase - an overview [https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/transferase]
• 26. New reaction pathways by integrating chemo [https://www.sciencedirect.com/science/article/abs/pii/S2589597422000703]
• 27. Connecting chemical and protein sequence space to ... [https://www.nature.com/articles/s41586-025-09519-5]
• 28. Combining chemistry and protein engineering for new-to ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC8995090/]
• 29. Automated in vivo enzyme engineering accelerates ... [https://www.nature.com/articles/s41467-024-46574-4]
• 30. New Advances in Chemoenzymatic Synthesis [https://www.mdpi.com/2073-4344/15/3/232]
• 31. Advances in Terpenoid Biosynthesis: Chemical Diversity ... [https://etflin.com/article/310]
• 32. Biotechnological production of terpenoids using cell factories [https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1621406/full]
• 33. Advances in the Biosynthesis of Plant Terpenoids [https://pmc.ncbi.nlm.nih.gov/articles/PMC12114759/]
• 34. Strategies for terpenoid overproduction and new ... [https://www.sciencedirect.com/science/article/abs/pii/S0958166917300459]
• 35. Cryo-EM Structure of the Cyclase Domain and Evaluation ... [https://pubmed.ncbi.nlm.nih.gov/41106812/]
• 36. Structure and Function of Terpene Cyclase - Scholars@UK [https://scholars.uky.edu/en/projects/structure-and-function-of-terpene-cyclase/]
• 37. Construction and analysis of a cell factory for terpenoid ... [https://www.sciencedirect.com/science/article/pii/S2405805X25001401]
• 38. Structure and Mechanisms of Assembly-Line Polyketide ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11907408/]
• 39. Developing tools for engineering hybrid polyketide ... [https://www.sciencedirect.com/science/article/abs/pii/S0958166906001431]
• 40. Chemoenzymatic synthesis | Communications Chemistry [https://www.nature.com/articles/s42004-025-01451-z]
• 41. Assessing and harnessing updated polyketide synthase ... [https://www.nature.com/articles/s41467-024-50844-6]
• 42. Directed Evolution of a Modular Polyketide Synthase ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12083843/]
• 43. Chemoenzymatic Synthesis of 13-Oxoverruculogen - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC12581595/]
• 44. The Pictet-Spengler Reaction Updates Its Habits [https://www.mdpi.com/1420-3049/25/2/414]
• 45. Pictet Spengler Reaction - an overview [https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/pictet-spengler-reaction]
• 46. Chemoenzymatic synthesis [https://www.nature.com/collections/afjacdgebd]
• 47. Enzymatic cascade reactions for the efficient synthesis of ... [https://www.sciencedirect.com/science/article/abs/pii/S0040402022005737]
• 48. Structural Biology of Non-Ribosomal Peptide Synthetases - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC4760355/]
• 49. Nonribosomal peptide [https://en.wikipedia.org/wiki/Nonribosomal_peptide]
• 50. Structures of a non-ribosomal peptide synthetase ... [https://www.nature.com/articles/s41467-021-22623-0]
• 51. An emerging family of non-ribosomal peptide cyclases with ... [https://www.sciencedirect.com/science/article/pii/S1367593124000413]
• 52. Merging Chemoenzymatic and Radical-Based ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7250629/]
• 53. Radical retrosynthesis for terpenoid synthesis: a review [https://www.linkedin.com/posts/kukreja3_offering-a-one-electron-logic-that-complements-activity-7382040077054644224-pxeY]
• 54. Bridging biocatalysis and chemical catalysis: Innovative ... [https://www.sciencedirect.com/science/article/abs/pii/S2452223625000343]
• 55. Cooperative chemoenzymatic and biocatalytic cascades to ... [https://www.nature.com/articles/s41467-024-52608-8]
• 56. One-pot multienzyme (OPME) systems for chemoenzymatic ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC4795158/]
• 57. Recent advances in enzymatic and chemoenzymatic ... [https://www.sciencedirect.com/science/article/abs/pii/S1367593123001552]
• 58. One-pot three-enzyme chemoenzymatic approach to the ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC2586341/]
• 59. One-pot multi-enzyme (OPME) chemoenzymatic synthesis ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC3722252/]
• 60. Development of an in vitro multi-enzyme system for efficient ... [https://bioresourcesbioprocessing.springeropen.com/articles/10.1186/s40643-025-00943-z]
• 61. Harnessing the optimization of enzyme catalytic rates in ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11563432/]
• 62. Glycosylation in neuroinflammation: mechanisms, implications ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12452027/]
• 63. Recent Chemical and Chemoenzymatic Strategies to ... [https://www.frontiersin.org/journals/chemistry/articles/10.3389/fchem.2022.880128/full]
• 64. Recent advances in the chemoenzymatic synthesis of ... [https://www.sciencedirect.com/science/article/pii/S1367593120300065]
• 65. Structural basis of regulated N-glycosylation at ... [https://www.nature.com/articles/s41586-025-09756-8]
• 66. Advancing Chemoenzymatic Synthesis and Covalent ... [https://pubmed.ncbi.nlm.nih.gov/41017468/]
• 67. Exploring the untapped potential of DNA glycosylation [https://www.news-medical.net/news/20250829/Exploring-the-untapped-potential-of-DNA-glycosylation.aspx]
• 68. Directed Evolution [https://www.sigmaaldrich.com/US/en/technical-documents/technical-article/protein-biology/protein-expression/directed-evolution]
• 69. Directed evolution - Wikipedia [https://en.wikipedia.org/wiki/Directed_evolution]
• 70. Computational design of enzymes for biotechnological ... [https://pubmed.ncbi.nlm.nih.gov/33513434/]
• 71. A primer to directed evolution: current methodologies and future directions - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC10074555/]
• 72. A roadmap to directed enzyme evolution and screening systems for biotechnological applications [https://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-97602013000400011]
• 73. Recent Advances in P450 Enzyme Engineering for the ... [https://pubmed.ncbi.nlm.nih.gov/40931706/]
• 74. Enzyme Databases in the Era of Omics and Artificial Intelligence [https://pmc.ncbi.nlm.nih.gov/articles/PMC10707154/]
• 75. Biocatalysis in the Pharmaceutical Industry: The Need for Speed [https://pmc.ncbi.nlm.nih.gov/articles/PMC5430392/]
• 76. Tailoring industrial enzymes for thermostability and activity ... [https://www.nature.com/articles/s41467-025-55944-5]
• 77. Current Progress in the Chemoenzymatic Synthesis of ... [https://www.mdpi.com/1420-3049/27/19/6373]
• 78. Improved activity and thermostability of glycosylating ... [https://www.sciencedirect.com/science/article/pii/S0141813025055655]
• 79. Biocatalysis: a Competitive Innovation for the Industry - SEQENS [https://www.seqens.com/service/biocatalysis/]
• 80. Enzymes as Catalysts in Industrial Biocatalysis: Advances ... [https://www.mdpi.com/2073-4344/15/9/891]
• 81. Integrating biocatalysis with continuous flow: current status, ... [https://www.sciencedirect.com/science/article/pii/S2090123225005089]
• 82. Chemoenzymatic total synthesis of natural products - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC8210581/]
• 83. Regeneration of cofactor NAD(P)+ with NAD(P)H oxidase ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12433975/]
• 84. Cofactor-independent photo-enzymatic reductions with ... [https://www.nature.com/articles/s41467-025-61908-6]
• 85. Methods for the synthesis of natural UDP-sugars and ... [https://www.sciencedirect.com/science/article/abs/pii/S0008621525002770]
• 86. Solvent Optimization — COSMO-RS 2025.1 documentation [https://www.scm.com/doc/COSMO-RS/Solvent_Optimization.html]
• 87. Reaction Optimization for Greener Chemistry with a ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9738638/]
• 88. A chemoenzymatic reaction-diffusion system with local ... [https://www.nature.com/articles/s41467-025-65605-2]
• 89. Reaction Design & Optimization [https://www.sigmaaldrich.com/US/en/applications/chemistry-and-synthesis/reaction-design-and-optimization?srsltid=AfmBOoovmsOzxhq-voVGQHNhBlKLugnrw5WqG2J2F8cRu5wfdhLp_lun]
• 90. Optimizing the amount of concentration and temperature ... [https://www.sciencedirect.com/science/article/pii/S2666202722001331]
• 91. Chemo-enzymatic synthesis of natural products and their ... [https://www.sciencedirect.com/science/article/abs/pii/S0958166922000933]
• 92. Chemoenzymatic synthesis planning guided by synthetic ... [https://pubs.rsc.org/en/content/articlehtml/2025/dd/d5dd00008d]
• 93. Engineering catalytically promiscuous enzymes to serve ... [https://www.sciencedirect.com/science/article/abs/pii/S0734975025000874]
• 94. Predicting novel substrates for enzymes with minimal ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7055960/]
• 95. Predicting novel substrates for enzymes with minimal ... [https://www.sciencedirect.com/science/article/abs/pii/S1096717617300708]
• 96. Substrate multiplexed protein engineering facilitates ... [https://www.nature.com/articles/s41467-022-32789-w]
• 97. Scale-up of industrial microbial processes - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC5995164/]
• 98. Exploring Principles of Bioreactor Scale-Up [https://www.bioprocessintl.com/bioreactors/lessons-in-bioreactor-scale-up-part-1-mdash-exploring-introductory-principles]
• 99. A concise and scalable chemoenzymatic synthesis of ... [https://www.nature.com/articles/s41467-024-46960-y]
• 100. 78 Essential Manufacturing Metrics and KPIs to Guide Your ... [https://www.netsuite.com/portal/resource/articles/erp/manufacturing-kpis-metrics.shtml]
• 101. A Comprehensive Guide to Enzyme Immobilization: All You ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11857967/]
• 102. Review of research progress in immobilization and chemical ... [https://microbialcellfactories.biomedcentral.com/articles/10.1186/s12934-025-02791-0]
• 103. Enzyme immobilization: an overview on techniques and ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC3563746/]
• 104. Comparison of Four Immobilization Methods for Different ... [https://www.mdpi.com/2073-4344/13/2/300]
• 105. Enhancing Lipase Immobilization via Physical Adsorption [https://pmc.ncbi.nlm.nih.gov/articles/PMC11603209/]
• 106. Immobilization as a Strategy for Improving Enzyme ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC6271243/]
• 107. Chemoenzymatic Semisynthesis of Proteins - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC7101271/]
• 108. Designing Enzymatic Reactivity with an Expanded Palette [https://pmc.ncbi.nlm.nih.gov/articles/PMC12135140/]
• 109. Integrated Chemoenzymatic Synthesis of the mRNA ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12363647/]
• 110. First chemoenzymatic stereodivergent synthesis of both ... [https://www.beilstein-journals.org/bjoc/articles/10/322]
• 111. Chemoenzymatic indican for light-driven denim dyeing [https://www.nature.com/articles/s41467-024-45749-3]
• 112. Chemoenzymatic two-step synthesis of tartaric acid ... [https://www.sciencedirect.com/science/article/pii/S2666554925000274]
• 113. Artemisinin production strategies for industrial scale [https://www.sciencedirect.com/science/article/abs/pii/S0926669024009142]
• 114. Dihydroartemisinic acid dehydrogenase-mediated ... [https://www.nature.com/articles/s41467-025-59312-1]
• 115. From Plant to Yeast—Advances in Biosynthesis of ... [https://www.mdpi.com/1420-3049/27/20/6888]
• 116. The evolutionary advantage of artemisinin production by ... [https://www.sciencedirect.com/science/article/abs/pii/S1360138524002395]
• 117. Functional analysis of CYP71AV1 reveals the evolutionary ... [https://www.frontiersin.org/journals/plant-science/articles/10.3389/fpls.2024.1361959/full]
• 118. Chemoenzymatic Synthesis of Lariat Lipopeptides ... [https://bioengineer.org/chemoenzymatic-synthesis-of-lariat-lipopeptides-revolutionized/]
• 119. Editorial to Special Issue—“Structure-Activity Relationships ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7825126/]
• 120. Integrated Chemoenzymatic Approach to Streamline the ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9590255/]
• 121. Structure–Activity Relationships (SAR) of Natural Products [https://www.mdpi.com/journal/molecules/special_issues/Molecules_Structure_Activity_Relationships]
• 122. How Large Quantitative Models Are Shaping the Future Of ... [https://www.sandboxaq.com/post/how-large-quantitative-models-are-shaping-the-future-of-drug-discovery]
• 123. The Role of AI in Drug Discovery: Challenges, Opportunities ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10302890/]
• 124. NaCTR: Natural product-derived compound-based drug ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11564001/]
• 125. Challenges and opportunities in data for drug discovery [https://www.cas.org/ja/resources/cas-insights/challenges-opportunities-prioritizing-data-drug-discovery]
• 126. Green Chemistry: Principles & Benefits [https://www.ecoonline.com/en-us/blog/green-chemistry-driving-sustainable-innovation/]
• 127. Green Chemistry Metrics with Special Reference to ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC6272361/]
• 128. Green chemistry metrics: Insights from case studies in fine ... [https://www.sciencedirect.com/science/article/pii/S2352554125001603]
• 129. Benefits of Green Chemistry [https://www.epa.gov/greenchemistry/benefits-green-chemistry]
• 130. Accelerating Drug Development Using Biomarkers [https://pmc.ncbi.nlm.nih.gov/articles/PMC2751391/]
• 131. A Case Study With Sitagliptin, a Novel DPP4 Inhibitor for ... [https://pubmed.ncbi.nlm.nih.gov/18686043/]
• 132. A Screening Study for the Development of Simvastatin ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC8537800/]
• 133. the case of simvastatin in Canada [https://pubmed.ncbi.nlm.nih.gov/22989373/]
• 134. BENEFITS OF PHARMACEUTICAL INNOVATION [https://www.cambridge.org/core/journals/international-journal-of-technology-assessment-in-health-care/article/benefits-of-pharmaceutical-innovation-the-case-of-simvastatin-in-canada/9D88BA638DBB38EE86FEEE1D52994253]